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ABSTRACT OF THE DISSERTATION 
Transcriptional Signatures of Host Susceptibility in Urinary Tract Infections  
by 
Lu Yu 
Doctor of Philosophy in Biology and Biomedical Sciences 
Biochemistry, Biophysics & Structural Biology  
Washington University in St. Louis, 2018 
Professor Scott Hultgren, Chair 
Urinary tract infections (UTI) caused by uropathogenic Escherichia coli (UPEC) are common and 
highly recurrent. Two important non-behavioral risk factors for UTI in women are genetics and 
history of two or more episodes of previous UTI. However, specific mechanisms of how these two 
factors modulate host susceptibility to UTI remain unclear. Concordantly, inbred mice of various 
genotypes and with different infection histories exhibit different susceptibilities to acute and 
chronic bladder infection (cystitis), which recapitulates a range of clinical UTI outcomes observed 
in women. Early host-pathogen interactions have been shown to determine UTI outcomes in mouse 
models. Here, we used two strains of Juvenile Naive mice (no UTI history; C57BL/6J & 
C3H/HeOuJ), as well as previously infected C3H/HeN mice to identify shared patterns of gene 
expression that correlate with susceptibility to recurrent and chronic UTI.  
Compared to adult C3H/HeN mice that had no prior UTI (“Adult Naïve” mice), the disease 
outcomes of a prior infection in C3H/HeN mice: spontaneously resolved (“Resolved” mice) or 
develop chronic cystitis (“Sensitized” mice), dramatically separated their susceptibilities to 
subsequent infection: resistant or susceptible, respectively. Altered cell morphology, 
differentiation state, membrane proteomes, etc. have been revealed, suggesting remodeling of the 
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urothelium by prior infections. This thesis investigates the transcriptomic profiles of C3H/HeN 
mice with different disease histories and corresponding susceptibility. Adult Naïve and Resolved 
mice shared similar transcriptomes, while Sensitized mice displayed a distinct transcriptomic 
profile from Adult Naïve (very) and Resolved (intermediate) mice. The differences in gene 
expression are mostly correlated with immune responses, cell morphology, and cell growth 
pathways. The results suggest that prior infections left persisting imprints at a transcriptional level 
that vary in susceptibility to subsequent challenge.  
The transcriptomic profiles of mice were also investigated upon bladder infection. Juvenile Naïve 
C57BL/6J mice and C3H/HeN Resolved were highly resistant to UPEC infection, whereas 
Juvenile Naïve C3H/HeOuJ mice and C3H/HeN Sensitized were highly susceptible. Microscopic 
and cytokine analyses of infected bladders revealed differing kinetics of inflammation among mice 
with different genotypes and disease histories. Resistant mice (C57BL/6J) initiated a robust, early-
onset (peaked at 6 hours post inoculation, but short-lasting inflammatory response, while the 
susceptible mice (C3H/HeOuJ) had an inverse pattern: robust, late-onset (peaked at 24 hpi), but 
persisting. Transcriptomic profiling of whole bladders revealed a specific dynamic pattern of 
TNFɑ signaling that mirrored the degree and kinetics of this bladder inflammation. In convalescent 
C3H/HeN mice, prior infection resulted in an acquired capacity for robust to severe bladder 
inflammatory responses with a robust, early-onset TNFɑ. In contrast, age-matched C3H/HeN mice 
with no prior infection history had muted responses. Depletion of TNFɑ in an rUTI model revealed 
that early TNFɑ signaling promoted colonization resistance via exfoliation of infected bladder 
cells, but prolonged TNFɑ signaling exacerbated inflammation, thereby worsening infection. 
In summary, host susceptibility to severe and chronic cystitis are greatly impacted by the degree 




Chapter 1: Introduction 
1.1 Urinary tract infection: pathogenesis and host response 
1.1.1 Urinary tract infection: clinical symptoms and disease course 
Urinary tract infections (UTI) are one of the most common bacterial infections (Foxman, 2003; 
Hooton and Stamm, 1997), resulting in over $2 billion direct and indirect cost in 2010 in the 
United States alone (Foxman, 2010). Women endure greater risk than men: over 50% women 
will experience at least one episode of UTI, and over 30-40% suffer recurrent urinary tract 
infections (rUTI) within three to four months (Foxman, 2002). Pathogenesis and host responses 
to UTI have been extensively studied to understand the mechanisms and to develop therapeutic 
strategies.  
Clinically, symptomatic UTI are defined as having urinary tract symptoms in the presence of 
bacteria in the urine, i.e. bacteriuria. Bladder infection is known as cystitis and kidney infection 
is known as pyelonephritis. For lower tract UTI, the urethra and bladder are affected, and clinical 
symptoms often include frequent urination, pain and burning sensation during urination 
(dysuria), cloudy or bloody urine, foul-smelling urine, and discomfort of lower abdomen. For 
upper tract UTI, the kidney and ureters are affected, and clinical symptoms often include cloudy 
urine and fever. This thesis is focused on the lower tract UTI.  
Interestingly, UTI can also be asymptomatic. A high level of bacteriuria without typical signs 
such as dysuria and abdominal pain are present in patients with asymptomatic bacteriuria (ASB). 
ASB is common in young women but rarely persists (Hooton et al., 2000). On the one hand, it is 




the other hand, some other researches have suggested a protective role of ASB in preventing 
symptomatic recurrences and suggested no treatment (Cai et al., 2012).  
After infection, the outcome of the disease in women can be one of the following: self-limiting 
acute cystitis, recurrent or chronic cystitis, or asymptomatic bacteriuria as mentioned above 
(Foxman, 2002). In placebo-controlled studies, about half of the women displayed persistent 
high bacteriuria for weeks after an acute episode of cystitis if left untreated (Ferry et al., 2009; 
Mabeck, 1972).  Even with antibiotic treatment, some women are subjected to recurrent chronic 
cystitis (Conway et al., 2007; Foxman, 2002, 2010; Raz et al., 2000).  
1.1.2 Host risk factors of UTI 
UTI in premenopausal women are affected by a variety of risk factors, such as the frequency of 
sexual activity, new sexual partner, exposure to spermicides and antimicrobials, urogenital and 
intestinal microbiota, anatomic and functional problems of the urinary tract, a maternal history of 
UTI, and a childhood history of UTI, etc. (Scholes et al., 2000; Stapleton, 2014). Clinical studies 
of women before and after sexual intercourse revealed that intercourse raises the risk of 
bacteriuria, especially in women using spermicides (Hooton et al., 1991). Frequent intercourse 
and a new sexual partner within the last year are also correlated with increased incidence of UTI 
(Hooton et al., 1996; Scholes et al., 2000).  
The intestinal microbiota is thought to be the ultimate source of uropathogens, while the vagina 
is a key anatomical niche that serves as a potential “way station” reservoir for uropathogens 
before colonizing the lower urinary tract, thus both play an important part in (recurrent) UTI 
pathogenesis (Czaja et al., 2009; Pfau and Sacks, 1981; Stamey and Sexton, 1975). Increased 
vaginal colonization of E. coli is accompanied by loss of protective vaginal lactobacilli and 




has also been shown to increase risk of UTI, whether the treatment was given for UTI or not 
(Smith et al., 1997). It is possible that upon antibiotic treatment, the normal microbiota is 
disturbed, rendering the host vulnerable to uropathogen colonization. In addition, usage of 
antimicrobials for UTI may increase pathogen resistance, which in turn increases the risk to UTI 
(Beerepoot et al., 2011; Costelloe et al., 2010). 
A history of maternal and childhood UTI could indicate the presence of inheritable factors or 
shared environmental factors that contribute to host susceptibility (Scholes et al., 2000). The 
former factor has been investigated and revealed that polymorphisms/mutations in certain genes, 
such as Toll-Like-Receptors and CXCRs (Lundstedt et al., 2007; Ragnarsdottir et al., 2010; 
Ragnarsdottir et al., 2007), could predispose host to recurrent UTI, putting them and their 
offspring at greater risk of infection. In addition, anatomic and functional abnormalities of the 
urinary tract, diabetes, post menopause hormonal changes (lack of estrogen), catheterization, etc. 
are also associated with increased risk of UTI through various mechanisms (Foxman, 2002; 
Patterson and Andriole, 1997; Sedor and Mulholland, 1999) 
1.1.3 Uropathogens and murine models 
UTI can be caused by a diverse range of pathogens, including both Gram-positive and Gram-
negative bacteria. Gram-positive bacteria, such as Streptococcus and Enterococcus species, are 
also among the top strains that cause community-acquired UTI (Foxman, 2010).  Gram-negative 
bacteria, in particular uropathogenic E. coli (UPEC), account for 80% or more of community-
acquired and 25% of hospital-acquired infections (Ronald, 2003). Therefore, UPEC is employed 
as a model organism for studying UTI. In my thesis, clinical isolate UTI89 strain (Mulvey et al., 




Murine models of UTI have been developed utilizing various mouse strains and bacterial 
species/strains to study UTI disease progression and host-pathogen interactions (Hung et al., 
2009). These models have been shown to recapitulate phenotypes that are observed in women in 
the clinics, such as intracellular bacterial communities formation and filamentation of pathogen 
in the urine (Rosen et al., 2007). In the case of UPEC, bacteria are cultured to induce type 1 pilus 
expression and introduced to mouse bladder transurethrally by catheters made out of 
polyethylene tubing covered by 30-G hypodermic needles. Bacterial burdens in tissue can be 
determined by plating tissue homogenates on appropriate agar plates. Other signs of disease 
progress and host response can be obtained via multiple methods, such as various kinds of 
microscopy, immunohistochemistry, biochemical (e.g., ELISA), and biophysical (flow 
cytometry) techniques. 
1.1.4 Pathogenesis of UTI  
From entering the bladder until establishment of colonization, pathogens must subvert multiple 
stages of immune defense developed by the host. During each stage, the diversity of bacteria is 
reduced (Bergstrom et al., 1999). After ascending the urethra against the flow of urine, pathogens 
need to establish colonization in the bladder, which require adherence to the mucosa in order to 
resist shear forces (Thomas et al., 2002). The mucosa is a strong barrier with layers of superficial 
umbrella (facet) cell, basal, and intermediate cells (Wu et al., 2009). The urothelium is coated 
with uroplakin proteins (Hu et al., 2002; Wu et al., 1994) and a purported glycosaminoglycan 
(GAG) mucin layer (Parsons et al., 1990; Thomas D. Geppert, 1994 ) that form a permeable 
barrier against pathogen adherence factors. UPEC is able to circumvent such protection by 
adhering and entering the superficial cells in a type-1-pili-dependent manner (Martinez and 




the tip of type 1 pili binds to mannose on uroplakin UPIa (Xie et al., 2006; Zhou et al., 2001) to 
mediate bacterial attachment. Following this event, a subpopulation of type 1-piliated pathogen 
is internalized by urothelial cells. Host actin polymerization, protein tyrosine phosphorylation, 
and PI 3-kinase activation are required to reorganize host cytoskeleton during internalization 
(Martinez et al., 2000; Mulvey et al., 1998).  
After internalization, UPEC may escape into the cytoplasm of the superficial umbrella cells and 
rapidly replicate and aggregate into intracellular bacterial communities (IBCs) that can protect 
the bacteria from host immune defense and antibiotic treatment (Blango and Mulvey, 2010; 
Gregory G. Anderson, 2003; Justice et al., 2004; Nicholson et al., 2009). Intracellular replication 
is rapid with a doubling time of 30-35 minutes, thus explaining how IBCs are clonal, originating 
from a single invasive bacterium (Schwartz et al., 2011).. Aggregation of UPEC into IBCs also 
requires type 1 pili expression (Wright et al., 2007). Certain non-mannose-binding pocket amino 
acid residues are under positive selection and mutation of these residues lead to defects in IBC 
formation (Chen et al., 2009). Within 12 to 16 hours post inoculation (hpi), the first round of 
IBCs mature, resulting in bacteria emerging from dying urothelial cells, often in filamentous 
form (increases their resistance to neutrophilic attacks), into the lumen where they can proceed to 
colonize and invade neighboring cells (Justice et al., 2004; Justice et al., 2006a). Multiple rounds 
of IBC formation and dispersal takes place during early acute cystitis and both steps are critical 
for persistence of pathogen. Multiple clinical isolates of UPEC, even other type 1 pili expressing 
gram-negative uropathogens such as Klebsiella pneumonia, are able to form IBCs in murine 
models (Garofalo et al., 2007; Rosen et al., 2008).  
The internalization of bacteria not only promotes colonization of the bladder during acute 




positive vesicles and remain for months within superficial facet and underlying transitional cells 
in a non-replicating state, inducing no measurable inflammatory response of the murine host and 
forming quiescent intracellular reservoirs (QIR) (Blango et al., 2014; Mysorekar and Hultgren, 
2006). Upon epithelial turnover, either naturally or due to damage, dormant bacteria in QIR are 
capable of emerging and seeding a new acute cystitis, causing recurrence. Unlike IBCs, which 
are transient and cytosol-residing to facilitate bacterial spread during acute infection stage, QIR 
are latent and confined within endosomal vesicles. 
1.1.5 Host defense against UTI 
Host innate immunity plays an important role in defending against UTI. Many antimicrobial 
peptides, such as cathelicidin (LL-37) and beta defensin-1 (BD1), are constitutively expressed in 
the urinary tract (Chromek et al., 2006; Morrison et al., 2002), serving as part of mucosal 
immune defense. Humoral factors, such as the complement cascade and PTX3, are inducible and 
contribute to bacterial clearance in the bladder and kidney (Jaillon et al., 2014).  
Multiple species of leukocytes are recruited and stimulated through various cytokines and are 
involved in host immune responses. Mast cells, macrophages and dendritic cells reside in healthy 
bladders and are activated upon bacterial infection (Hirose et al., 1992). Neutrophils are a critical 
player in host innate immunity against infection. Under the effect of CXCL chemokines and 
other cytokines such G-CSF, neutrophils are recruited to the bladder and transmigrate across the 
epithelial barrier into the lumen, causing pyuria (neutrophils in the urine) and killing bacteria by 
producing reactive oxygen species (ROS) and phagocytosis (Babior, 1984; Haraoka et al., 1999; 
Ingersoll et al., 2008). However, excessive neutrophilic attack is associated with severe mucosal 




reduces neutrophil transmigration and protects the host against chronic and recurrent cystitis 
(Hannan et al., 2014).  
Before bacterial adherence, continuous low shear force flow of urine and intermittent high shear 
force flow of urine create barriers for bacteria to ascend, adhere, and colonize the bladder 
epithelium. After internalization, UPEC reside within vesicles that can be expelled through a 
Toll-Like-Receptor (TLR) 4-initiated, cAMP, Rab27b, and Caveolin-1-dependent mechanism 
that constitutes a transmission bottleneck (Song J, 2009). Exfoliation is another important 
defense against pathogen invasion. Infected urothelial cells undergo cell death and are shed into 
the urine stream (Matthew A. Mulvey, 2000; Mulvey et al., 1998). Underlying urothelial cells 
are stimulated to be hyper-proliferative to compensate for the loss during infection (Mysorekar et 
al., 2009). Exfoliation prior to IBC maturation promotes pathogen clearance. However, 
exfoliation is a double-edged sword that can benefit both the host and pathogens. While it can 
eliminate pathogens within infected urothelial cells, widespread exfoliation can expose deeper 
layers of the urothelium and disrupt urothelial integrity.  
1.1.6 Summary 
In summary, uropathogens employ various tactics to evade host immunity while hosts have also 
developed complicated defense mechanisms. The ultimate outcome of urinary tract infections 
depends on host-pathogen interactions, among which host risk factors play an important role. 
Genetic variations greatly affect host innate immunity, which in turn contributes greatly to host 
susceptibility or resistance to UTI, especially during the acute cystitis stage (Hagberg et al., 
1984). For example, polymorphisms in TLR4 have been identified in ASB patients and mice 
with TLR4 defects have displayed high susceptibility to persistent infection (Hagberg et al., 




expression. Among other non-behavior host risk factors, two of the most important ones are a 
history of UTIs (2 or more episodes) (Hooton et al., 1996) and UTI at a young age (15 years old 
or younger) (Sholes et al., 2005). However, the specific mechanisms of the diversity of host 
susceptibility to UTI remain unclear. 
1.2 RNA-seq and its application to UTI 
A transcriptome is the complete set of transcripts in a cell in a defined organism or tissue at a 
defined stage, including mRNA, non-coding RNA, and small RNA. The content and relative 
quantity of gene transcripts within the transcriptome depict the gene expression profile of the 
target (organism/tissue/cell), thus it is important to understand the functional state and molecular 
mechanism for development and disease. Hybridization-based and sequence-based approaches 
are high-throughput methods developed to capture the transcriptome. Hybridization-based 
methods, such as DNA microarray, employ probes to detect and quantify transcripts and 
isoforms. Such methods are high-throughput and relatively inexpensive. However, their 
limitations are: 1) bias caused by existing knowledge of the genome sequence in probe design; 2) 
high background levels due to cross-hybridization; 3) limited dynamic range due to signal 
saturation; 4) difficulty in normalizing across experiments (Wang et al., 2009).  
As technologies developed, next-generation sequencing (NGS) gained the advantages of being 
high throughput, high sensitivity, and high speed. Thus, the usage of sequence-based methods 
has become standard practice for investigating transcriptome. RNA sequencing can be 
categorized into two categories: tag-based methods and shotgun methods. With tag-based 
methods, only a short fragment at a defined position in each RNA molecule is sequenced, and the 
result is unbiased and strand-specific. With shotgun methods, all RNA molecules are first 




results are isoform-specific and could be subject to technical bias. RNA-seq is used to describe 
shotgun-based RNA sequencing methods. RNA-seq directly obtains all cDNA sequences created 
from a whole RNA set. This allows a comprehensive snapshot of a complete gene expression 
profile (the transcriptome) that quantifies the abundance level and relative changes of all 
transcripts under defined circumstances. Such sequencing opens up possibilities to detect un-
targeted transcripts expression levels and unidentified expression patterns in an unbiased way, 
which also has high dynamic detection range, high resolution, and low background signals (de 
Klerk et al., 2014).  
The RNA-seq method has been used for UTI pathogenesis investigations. The transcriptomes of 
urine-associated E. coli strains of different phylogeny and virulence was compared using RNA-
seq data. The data revealed that the expression of genes with key conserved functions, such as 
motility, could predict the strain's ability to colonize bladder (Schreiber et al., 2017). Therefore, 
RNA-seq can uncover insights into the link between gene expression and UTI pathogenesis at a 
systematic level. It is applicable to apply RNA-seq method on murine models and investigate 
host gene expression and susceptibility.  
1.3 Research aim and significance 
The molecular basis of various host susceptibility to UTI remains unclear. Therefore, this project 
is focused on investigating the transcriptomic profiles of host with different susceptibilities to 
UTI and their corresponding inflammatory responses, aiming to identify transcriptomic 
signatures that could explain differences in host susceptibilities. Two major host risk factors, 




This thesis employed various murine models that represented the two risk factors and 
investigated host transcriptomic and corresponding inflammatory profiles, before and after 
infections.  
To understand how a history of UTI alters host susceptibility to recurrent and chronic UTI, long-
lasting effects of the initial infection on the mouse bladder were investigated in Chapter 2. The 
experiments were performed using the recurrent cystitis model of female C3H/HeN mice. 
Bladder bacterial colonization, localization, inflammatory status, cell differentiation status, gene 
expression profile, response to vaccination and anti-inflammatory drugs, etc., were measured to 
gain a comprehensive understanding of host bladder condition during convalescence and upon 
challenge infections. In particular, to capture the host gene expression profiles, RNA-seq was 
performed, followed by the differential analysis of gene expression and the enrichment analysis 
of biological pathways. The transcriptomic profiles between mice with various infection histories 
were compared to correlate prior infections imprints with susceptibility to subsequent infections.  
To uncover the molecular mechanisms of the two host risk factors (genetics and disease history) 
regulating host genetics on susceptibility to severe and chronic UTI, the gene expression and 
inflammatory profiles of hosts upon UPEC infection were investigated in Chapter 3. The acute 
cystitis models of female C57BL/6J and C3H/HeOuJ and the recurrent cystitis model of female 
C3H/HeN were used. Upon UPEC infection, early host inflammatory responses, such as bladder 
histopathology, cytokines, and gene expression changes before and after infection, were 
assessed. Bladder transcriptomic profiles were obtained and analyzed as mentioned above. The 
similarities and differences between host responses of the acute cystitis and recurrent cystitis 
models were compared to narrow down distinct and common mechanisms upon UPEC infections 




The molecular mechanisms that connect host risk factors and susceptibility to UTI is of great 
importance to understanding host defenses to urinary tract infections. The findings from this 
thesis could not only facilitate identification of high-risk subjects but also shine light on potential 
therapeutic or preventive approaches. As wide range of host susceptibility is a common 
phenomenon in many infectious diseases observed in the clinics, the findings from this thesis 
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Chapter 2: Prior E. coli bladder infection result in 
long-lasting alterations in bladder 
transcriptome and more 
2.1 A mucosal imprint left by prior Escherichia coli bladder 
infection sensitizes to recurrent disease 
2.1.1 Preface 
This section is a manuscript published in Nature Microbiology, 2016, Valerie P. O’Brien, 
Thomas J. Hannan, Lu Yu, Jonathan Livny, Elisha D.O. Roberson, Drew J. Schwartz, Spenser 
Souza, Cathy L. Mendelsohn, Marco Colonna, Amanda L. Lewis and Scott J. Hultgren. Nature 
Microbiology 2016 2:16196. DOI: 10.1038/nmicrobiol.2016.196. Copyright © 2016 Macmillan 
Publishers Limited. 
For urinary tract infection (UTI), a history of two or more episodes is one of the most significant 
risk factors for acute infection, for unknown reasons. We showed that chronic cystitis caused by 
UPEC infection left a long-lasting molecular imprint on the bladder that persists after antibiotic 
treatment. Such imprint included alterations in proteomic and transcriptomic profiles, and 
reflected on defects in cell maturation, increased resistance to intracellular bacterial colonization, 
and remodeling of the urothelium. But vaccination or anti-inflammatory drugs could offer 
protection to the mice.  
My contribution to this study was in RNA-seq related contents: data analysis, figure generation, 





Recurrent bacterial infections are a significant burden worldwide, and prior history of infection is 
often a significant risk factor for developing new infections. For urinary tract infection (UTI), a 
history of two or more episodes is an independent risk factor for acute infection. However, 
mechanistic knowledge of UTI pathogenesis comes almost exclusively from studies in naive 
mice. Here we show that in mice, an initial E. coli UTI, whether chronic or self-limiting, leaves a 
long-lasting molecular imprint on the bladder tissue that alters the pathophysiology of 
subsequent infections, affecting host susceptibility and disease outcome. In bladders of 
previously-infected versus non-infected, antibiotic-treated mice, we found: i) an altered 
transcriptome and defects in cell maturation; ii) a remodeled epithelium that confers resistance to 
intracellular bacterial colonization; and iii) changes to cyclooxygenase-2-dependent 
inflammation. Further, in mice with a history of chronic UTI, cyclooxygenase-2-dependent 
inflammation allowed a variety of clinical E. coli isolates to circumvent intracellular colonization 
resistance and cause severe recurrent UTI, which could be prevented by cyclooxygenase-2 
inhibition or vaccination. This work provides mechanistic insight into how a history of infection 
can impact the risk for developing recurrent infection and has implications for development of 
therapeutics for recurrent UTI. 
2.1.3 Introduction 
Bacterial infections, particularly recurrent bacterial infections, are a significant health, financial, 
and quality of life burden worldwide (Medzhitov, 2007). Sixty percent of women will have at 
least one urinary tract infection (UTI) in their lifetime (Foxman et al., 2000b) and in ~25% of 
women who suffer an initial UTI, a recurrent UTI (rUTI) will occur with the same or a different 
bacterial strain in the following six months (Foxman, 2010). Further, some women will have 




important independent risk factors for UTI in sexually active pre-menopausal women are a 
history of rUTI (two or more episodes) (Hooton et al., 1996) and a first UTI at age ≤ 15 years 
(Scholes et al., 2005). However, experimental models of UTI have largely been limited to 
animals without prior infections (Anderson et al., 2003; Carey et al., 2015; Mulvey et al., 1998), 
and thus how infection history impacts the risk for and outcome of rUTI remain poorly 
understood. To elucidate the molecular interplay between infection history and increased 
susceptibility to rUTI, we investigated molecular mechanisms in a mouse model of recurrent 
cystitis (bladder infection) (Figure 1A) (Hannan et al., 2010; Hannan et al., 2014).  
 
2.1.4 Results 
In C3H/HeN mice, acute bladder infection with the prototypical uropathogenic Escherichia coli 
(UPEC) isolate UTI89 (Mulvey et al., 2001) results in two distinct outcomes: spontaneous 
resolution of infection within the first 7-14 days, or progression to persistent bladder infection, 
referred to here as chronic cystitis. This bimodal outcome mimics the natural history of 
uncomplicated UTI in placebo-treated women: 25-75% of women spontaneously resolve 
symptoms and bacteriology, while the rest remain symptomatic and bacteriuric for weeks 
(Foxman, 2010). Antibiotic treatment of chronically infected mice sterilizes the urinary tract, 
allowing rapid repair of the bladder mucosal surface (Hannan et al., 2010). However, if infection 
is allowed to persist for >14 days prior to antibiotics, convalescent mice become predisposed to 
developing severe recurrent cystitis upon subsequent challenge and are thus referred to as 
“Sensitized.” In contrast, mice that spontaneously resolved the initial infection are highly 
resistant to challenge infection and are thus called “Resolved” (Figure 1A). Elevation of 
neutrophil chemokines and myeloid cell development factors (CXCL1, CXCL2 and G-CSF) in 




subsequent sensitization to rUTI (Hannan et al., 2010). Similarly, in women with an acute UTI, 
high serum levels of neutrophil chemokines and myeloid cell development factors (CXCL1, 
CXCL8, and M-CSF) correlated with subsequent rUTI (Hannan et al., 2014), supporting the 
relevance of our model. 
2.1.4.1 Infection history has a long-lasting effect on recurrent UTI susceptibility in 
different host genetic backgrounds  
To study the longevity of differential responses to subsequent infections due to prior history of 
infection, we challenged Sensitized, Resolved and age-matched mice with no history of UPEC 
UTI (naive) with UTI89, after six months of antibiotic-induced convalescence. We determined 
bacteriuria over time and assessed the incidence of chronic cystitis, which is defined as persistent 
high titer (>104 CFU/ml) bacteriuria over four weeks and high titer (>104 CFU) bladder infection 
at sacrifice. Sensitized C3H/HeN mice remained significantly more susceptible to developing 
severe rUTI than age-matched naive mice (Figure 1B) and Resolved mice (Figure 1B and Figure 
S1). Furthermore, we found that C57BL/6J mice with a history of chronic cystitis (induced via 
superinfection with two doses of UPEC 24 hours apart (Schwartz et al., 2015) (Figure S2) also 
were prone to significantly increased susceptibility to rUTI (Figure 1C). Thus, “sensitization” to 
rUTI as a result of chronic cystitis is long-lasting and occurs in different host backgrounds. 
2.1.4.2 Prior infection can affect susceptibility to recurrent UTI caused by diverse 
uropathogens  
E. coli cause up to 80% of community-acquired UTI (Foxman, 2010). Clinical isolates recovered 
from women with UTI are phylogenetically, genomically and phenotypically diverse, sharing as 
little as 60% of their genes in pairwise strain comparisons (Marrs et al., 2005), and vary 
significantly in their ability to colonize naive mouse bladders. We thus assessed infection 
outcomes in Sensitized, Resolved and age-matched Adult Naive mice challenged with clinical 




panel of strains differed in the clinical UTI syndrome they were associated with, including: i) 
UTI89, a cystitis isolate (Mulvey et al., 2001); ii) EC958, a multi-drug resistant cystitis isolate 
(Totsika et al., 2011); iii) CFT073, a urosepsis isolate (Mobley et al., 1990); iv) 83972, an 
asymptomatic bacteriuria isolate (Andersson et al., 1991); and v) TOP52, a cystitis isolate of 
Klebsiella pneumoniae, a common cause of UTI with pathogenic mechanisms similar to UPEC 
in Juvenile Naive mice (Rosen et al., 2008). UTI89, CFT073, EC958 and TOP52 caused chronic 
cystitis in 62, 81, 35 and 25% of Sensitized mice, respectively (Figure 1D), compared to 0, 11, 11 
and 10% of Adult Naive female C3H/HeN mice, which become more resistant to chronic cystitis 
as they mature into adulthood(Kline et al., 2014). UTI89, CFT073 and TOP52 caused no chronic 
cystitis in Resolved mice, whereas EC958 caused chronic cystitis in one Resolved mouse (Figure 
1D); this was the only incidence of chronic cystitis in a total of 124 Resolved mice tested in this 
study, suggesting that a previous self-resolving infection results in substantial protection from 
subsequent infections. Strain 83972 did not cause chronic cystitis in any mice (Figure 1D). The 
impact of host history was even more striking when acute cystitis was evaluated: all four UPEC 
strains produced higher urine titers in Sensitized mice than in Adult Naive or Resolved mice at 
24 hpi (Figure 1E). TOP52 also had higher bacteriuria in Sensitized mice than in naive mice, 
which approached statistical significance. Notably, the lab strain E. coli MG1655 (K-12)(Gerdes 
et al., 2003) and the gut commensal E. coli strain Nissle 1917(Nissle, 1916) did not cause 
significant acute or chronic cystitis (Figure S4). Thus, while Sensitized mice have increased 
susceptibility to Gram-negative uropathogens, they are not susceptible to rUTI with all E. coli. In 
total, our data support different degrees of host susceptibility to rUTI that are influenced by 




susceptible hosts, which may help to explain in part the genetic diversity observed in clinical 
UPEC isolates (Marrs et al., 2005). 
2.1.4.3 Convalescent bladders have an altered epithelium 
Scanning electron microscopy (SEM) of Sensitized and Resolved convalescence mice (four 
weeks after the initiation of antibiotics) and Adult Naive controls showed that superficial facet 
cells of the bladder lumen had a mean surface area 21 times smaller in Sensitized and 6 times 
smaller in Resolved than in Adult Naive mice (Figure 2A and Figure S1). Immunofluorescence 
microscopy of bladder sections stained with markers specific for different epithelial cell types 
revealed striking differences in cellular morphology and differentiation in Sensitized mice 
(Figure 2B and Figure 2C In Adult Naive and Resolved mice, the mature urothelium contains 
layers of basal cells, which are keratin (Krt) 5+ (Figure 2B white) and Trp63+ (Figure 2B and 
Figure 2C red); intermediate cells, which are Trp63+ (Figure 2B and Figure 2C red) and Krt5-; and 
a superficial layer of large, flattened, terminally differentiated superficial cells that are uroplakin 
IIIa+ (Figure 2B green), Krt20+ (Figure 2C white), bordered with a basolateral layer of E-cadherin 
(Figure 2C green), and sometimes binucleate (Figure 2B and Figure 2C blue and Figure S6). In 
contrast, the superficial cells in Sensitized mice were small and rounded. They expressed 
uroplakin IIIa (Figure 2B green) but had reduced expression of Krt20 (Figure 2C white), a marker 
of terminal differentiation. Additionally, Sensitized mice had fewer binucleate superficial cells 
(Figure S6) and exhibited a marked expansion of the intermediate and basal cell layers suggestive 
of urothelial hyperplasia (Figure 2B and Figure 2C), which is consistent with proteomics data that 
found increased levels of keratin 14, an indicator of increased basal cell proliferation, in the 
Sensitized urothelium (Hannan et al., 2014). Taken together, these observations suggest that 
urothelial superficial cells may fail to properly regenerate in Sensitized mice, even weeks after 




Defects in terminal differentiation and urothelial hyperplasia have also been reported in girls and 
women with chronic and recurrent UTI (Hansson et al., 1990a; Schlager et al., 2011). In 
addition, these clinical studies reported the presence of lymphoid follicles, which are also present 
in Sensitized mice but are not required for sensitization to rUTI (Hannan et al., 2010). These 
findings suggest the possibility that UTI may induce lasting changes to the bladder in some 
individuals. This hypothesis is consistent with our proteomic evidence that chronic cystitis 
results in urothelial “remodeling,” which renders Sensitized mice more susceptible to severe 
inflammation and mucosal wounding upon bacterial challenge, relative to Resolved mice 
(Hannan et al., 2014). Notably, the observed UTI-induced bladder remodeling is distinct from 
the Th2-driven remodeling seen in urogenital schistosomiasis infection of the urinary bladder 
(Ray et al., 2012) or in allergic remodeling of the lung (Leigh et al., 2002) as we find no 
evidence of increased fibrosis in bladder sections from Sensitized mice (Figure S7).  
2.1.4.4 Gene expression in convalescent bladders differs depending upon the course 
of the initial infection 
We performed RNA-seq analysis of Sensitized and Resolved bladders during convalescence in 
order to expand our understanding of bladder remodeling and sensitization mechanisms. We 
found that Sensitized and Resolved bladders had distinct transcriptomic signatures (Table S1), 
with 837 genes significantly differentially expressed (Figure 2D). The whole bladder RNA-seq 
findings were in concordance with the previously published urothelial membrane proteome 
(Figure S8 and Table S2). Pathway analysis of differentially expressed genes (Figure 2E, Table 
S3, and Table S4) showed that immune-related pathways were significantly enriched in 
convalescent Sensitized bladders, likely due in part to the presence of lymphoid follicles. In 




and proliferation were among the most highly significantly enriched pathways in Sensitized 
compared to Resolved bladders, further supporting the observation of urothelial remodeling.  
2.1.4.5 UTI history impacts acute pathogenesis of recurrent infection 
Naive mice respond to UPEC infection by exfoliating the superficial facet cells and recruiting 
immune cells to the bladder (Hannan et al., 2010; Mulvey et al., 1998). To assess whether 
infection history significantly altered these responses, we performed SEM on bladders harvested 
at 6 and 24 hpi after challenge infections of convalescent mice (Figure 3A and Figure S9). 
Bladders of control Adult Naive mice had patches of exfoliation and extracellular filamentous 
bacteria at 6 and 24 hpi, with relatively few neutrophils visible by SEM. At 6 hpi, bladders from 
both Sensitized and Resolved mice had large patches of urothelial exfoliation bounded by 
transmigrating neutrophils, with few or no bacteria visible by SEM. Two out of four resolved 
bladders at 24 hpi had evidence of epithelial exfoliation, neutrophils and filamentous bacteria, 
but to a lesser degree than Adult Naive bladders (Figure 3A) while the other two had no evidence 
of exfoliation, neutrophils, or bacteria. In contrast, three out of four imaged Sensitized bladders 
had severe urothelial exfoliation, neutrophils and abundant extracellular rod-shaped bacteria at 
24 hpi (Figure 3A). Urine sediments showed pyuria (neutrophil accumulation) in all animals at 6 
hpi. By 24 hpi pyuria had waned in Adult Naive and Resolved mice but remained high in 
Sensitized mice (Figure 3B). Sensitized and Resolved mice also had significantly reduced bladder 
CFUs at 6 hpi compared to Adult Naive mice (Figure 3C). By 24 hpi, bladder titers in Resolved 
mice had uniformly decreased to 103 CFU, whereas Sensitized mice segregated into two distinct 
populations having either: i) undetectable or very low titers (average 102 CFU); or ii) very high 
titers (average 106 CFU). In Juvenile Naive mice, a bimodal response to infection has been 
shown to be due to the presence of an acute host-pathogen checkpoint that determines infection 




extremely polarized at 24 hpi (Figure 3C), suggesting protection from infection in some animals 
and severe rUTI in others.  
Extensive studies of UPEC pathogenesis in Juvenile Naive mice have demonstrated that UPEC 
adhere to, invade into, and replicate within the superficial facet cells of the urothelium, forming 
biofilm-like intracellular bacterial communities (IBCs) that allow UPEC to escape elimination by 
urine flow and killing by professional phagocytic cells (Anderson et al., 2003; Mulvey et al., 
1998). IBCs have been documented in the urines of women and children suffering acute UTI 
(Robino et al., 2014; Rosen et al., 2007). In Juvenile Naive mice, mutant UPEC strains defective 
in IBC formation are highly attenuated(Wright et al., 2007). The altered kinetics of acute bladder 
infection in mice with a history of infection suggested that urothelial remodeling may 
fundamentally change the canonical intracellular pathway defining the pathophysiology of acute 
host-pathogen interactions in naive mice. Indeed, we found that at 6 hpi with UTI89, Resolved 
mice had very few IBCs relative to Adult Naive mice, and IBCs were not detected at all in 
Sensitized mice at 6 or 24 hpi (Figure 3D, Figure S6 and Figure S7). These phenotypes were likely 
due to reduced epithelial invasion and/or intracellular replication inside the altered superficial 
urothelial cells, as at 3 hpi the intracellular bacterial burden was reduced in Resolved mice and 
even further reduced in Sensitized mice, while the extracellular (luminal) bacterial burden was 
statistically indistinguishable among the three groups (Figure 3E). Taken together, these 
experiments demonstrate that in previously-infected mice, bladder remodeling confers resistance 
to initial colonization and IBC formation by UPEC, but that a subset of Sensitized mice 
nevertheless succumb to severe bladder infection by 24 hpi. 
2.1.4.6 Inhibition of cyclooxygenase-2 reduces severe recurrent UTI 
We hypothesized that the trigger for Sensitized mice to develop rUTI was cyclooxygenase-2 




mediates the conversion of arachidonic acid to prostanoids, which act locally to modulate 
inflammation. Previously we found that COX-2 inhibition in Juvenile Naive mice reduced the 
severity of acute cystitis by lowering bacterial burdens and preventing severe neutrophilic 
inflammation and bladder mucosal wounding (Hannan et al., 2014). During convalescence, UTI 
history did not influence expression of the COX-2 gene, Ptgs2, which was minimal in Sensitized, 
Resolved and Adult Naive mice (Figure S8). Upon challenge infection, at 24 hpi, Ptgs2 was not 
expressed in Resolved mice, but was induced by an average of 7.5-fold (median 7-fold) in Adult 
Naive mice (Figure 4A and B), and in Sensitized mice expression ranged from uninduced to up to 
~50-fold induction (average 27-fold, median 32-fold) (Figure 4B) with large clusters of COX-2-
positive epithelial cells evident in some bladders (Figure 4A). This bimodality of COX-2 
expression in infected Sensitized mice likely reflects the triggering of the previously described 
host-pathogen checkpoint that determines the fate of disease (Hannan et al., 2012). COX-2 
expression at 24 hpi was strongly correlated with both urine bacterial burden (Figure 4C) and 
pyuria (Figure 4D). Treatment of Sensitized mice with the COX-2 inhibitor SC-236 prior to 
challenge with UTI89 prevented mucosal wounding (Figure S13) and resulted in a significant 
reduction in pyuria (Figure 4C) and bladder bacterial burden (Figure 4D) at 24 hpi. This was not 
the case for Adult Naive or Resolved mice, which are resistant to severe acute and chronic 
cystitis. Taken together, these data indicate that even though Sensitized and Resolved mice 
demonstrate significant early urothelial resistance to colonization, COX-2-dependent bladder 
inflammation in Sensitized mice can allow UPEC to cause severe rUTI.  
2.1.4.7 Vaccination prevents recurrent UTI 
The observation that sensitization to severe rUTI was long-lasting (Figure 1B) suggests that the 
bladder response to UPEC is irreversibly altered in these animals. We thus tested whether 




proof of concept, we tested systemic vaccination with the type 1 pilus adhesin FimH (Figure S14), 
which in previous studies effectively protected naive mice and cynomolgus monkeys from 
experimental bladder infection (Langermann et al., 2000; Langermann et al., 1997). FimH 
vaccination prevented both acute (Figure 4E) and chronic (Figure 4F) cystitis in Sensitized mice 
upon challenge with UTI89, compared to mock-vaccinated animals. Thus, vaccination may be a 
viable strategy for overcoming the enhanced susceptibility to rUTI caused by bladder remodeling 
as a result of chronic bladder infection. Although relatively little is known about the adaptive 
immune response to UTI in women, and to what extent rUTI is a result of failure by the host to 
mount a protective adaptive response, vaccines have been shown to elicit protection from 
experimental UTI in naive animals (O'Brien et al., 2016a). Our findings demonstrate that 
targeting specific immune response pathways, e.g. COX-2-mediated inflammation, can also 
protect against rUTI in the Sensitized host.  
2.1.5 Discussion 
In a majority of women with acute uncomplicated cystitis, antibiotic treatment is effective and 
the disease does not recur (Foxman, 2010). However, many women experience frequent 
recurrences for reasons that are not well understood. Here we provide mechanistic insight into 
the pathophysiology of rUTI by demonstrating that bladder mucosal remodeling that occurs as a 
consequence of prior infection by the relatively virulent cystitis isolate UTI89 fundamentally 
alters the pathogenesis of acute cystitis upon subsequent UPEC challenge. Notably, the IBC 
cycle is considered essential for UPEC pathogenesis in naive animals. Few IBCs were detected 
in Resolved mice, possibly explaining in part their protection from rUTI. In naive mice, the 
dense actin network in underlying immature urothelial cells is believed to preclude IBC 




cells in Sensitized and Resolved mice, perhaps in tandem with the differential expression of 
cytoskeletal genes observed in Sensitized bladders, may hinder IBC development. However, a 
significant subset of Sensitized mice were susceptible to acute and chronic rUTI despite being 
resistant to IBC formation. The likely determinative factor of acute outcomes in this mouse 
model is severe acute inflammation driven by COX-2 expression during the first 24 hours post-
challenge in Sensitized mice. 
The significant changes in bacterial niche occupation and host immune and exfoliation responses 
in Sensitized mice relative to naive mice influence the outcome of disease and allow various 
clinical isolates to cause severe acute and chronic infections. However, the change in niche 
occupation, and in particular the loss of the IBC pathway in Sensitized mice, leave the bacteria 
particularly vulnerable to therapeutic interventions for rUTI that target the host response, such as 
COX-2 inhibition. The efficacy of COX-2 inhibitors in Sensitized mice supports the recent 
finding that ibuprofen, a non-specific COX-2 inhibitor, was comparable to antibiotics for the 
treatment of uncomplicated cystitis in the clinic (Bleidorn et al., 2010; Gagyor et al., 2015), and 
suggests that COX-2 inhibitors may also be efficacious in preventing rUTI in women. 
Our findings highlight the importance of using clinically relevant models of recurrent infection 
to investigate the pathophysiology and treatment of recurrent infections in which disease history 
is a significant independent risk factor for recurrence, such as otitis media (Froom et al., 2001), 
cellulitis (Bjornsdottir et al., 2005) and C. difficile colitis (Fekety et al., 1997). To our 
knowledge, existing animal models of these and other recurrent infections generally do not 
incorporate the effects of a prior infection, and thus may fail to capture the full spectrum of 
disease pathogenesis. Our studies indicate that mucosal remodeling as a consequence of prior 




needed to characterize the mechanism(s) by which chronic bladder inflammation may cause 
mucosal remodeling. Understanding the pathophysiology of recurrent infections in relevant 
model systems could also reveal vulnerabilities in disease pathogenesis that can be successfully 
targeted with prophylactic and therapeutic interventions, which is urgently needed in the era of 




Mice from different genetic backgrounds with a history of chronic infection have long-
lasting, enhanced susceptibility to recurrent UTI caused by clinical uropathogens. (A) Time 




indicate urine collection to monitor infection status. (B) For this experiment only, the 
convalescent period in C3H/HeN mice was extended for six months after the initiation of 
sterilizing antibiotic therapy. Shown is the incidence of chronic cystitis 28 dpi after challenge 
with 108 CFU UTI89. “Sen,” Sensitized (initial chronic infection) and “Res,” resolved the initial 
infection. (C) C57BL/6J mice were challenged with one 107 CFU dose of UTI89, 4 weeks after 
sterilizing antibiotic therapy, and the incidence of chronic cystitis was determined. Mice were 
initially infected with a single dose of PBS (“Adult Naive”) or 107 CFU of UTI89 (“Single, 
Res”), or were superinfected with two doses of 107 CFU of UTI89 24 hours apart (Schwartz et 
al., 2015), which resulted in either chronic cystitis (“Super, Chronic”) or resolution (“Super, 
Res”) (Figure S1). (D and E) Juvenile (8 week old) and Adult (16 week old) C3H/HeN mice 
were challenged with 107 CFU of the uropathogenic E. coli isolates UTI89, EC958, CFT073, or 
83972, or the Klebsiella pneumoniae isolate TOP52. Headings indicate the type of infection from 
which these strains were isolated (MDR, multi drug resistant). All Sensitized and Resolved mice 
in this experiment were initially infected with UTI89 prior to antibiotic therapy. (D) Urine 
bacterial burden at 24 hpi, indicative of acute cystitis. (E) Incidence of chronic cystitis at 28 dpi. 
Data are combined from 2 independent experiments except for panel B which was 1 experiment. 
For urine titers, data points represent actual values for each individual mouse, zeroes are plotted 
at the limit of detection, bars indicate median values, and Mann-Whitney U test was used. For 
incidence of chronic cystitis, Fisher’s exact test was used and the # of mice per group is shown at 






Prior UPEC infection causes bladder epithelial remodeling that varies according to disease 




bladder. Representative images from N=2 replicates with a total of n=4 mice per group are 
shown; scale bars are 25 µm. (B through D) Cell morphology and differentiation was assessed 
via immunofluorescence of paraffin-embedded bladder sections from N=3 staining experiments 
with bladder sections from n=3 Adult Naive and Resolved and n=6 Sensitized mice; 
representative images are shown. (B) Uroplakin IIIa (green), Trp63 (red), keratin 5 (white), 
nuclei (blue). (C) Keratin 20 (white), E-cadherin (green), Trp63 (red), nuclei (blue). Scale bars 
are 50 µm. (D and E) RNA-seq was performed on whole bladders from n=7 Sensitized and n=6 
Resolved convalescent mice. (D) 837 genes were significantly differentially expressed in 
Sensitized mice relative to Resolved mice (Padjusted < 0.05). Colors indicate each gene’s absolute 
log2 fold change: grey ≤ 0.58; orange between 0.58 and 1; and red > 1. Labeled genes had 
absolute log2 fold change > 1 and –log10 Padjusted > 10. Significance was determined by a Wald 
test and adjusted for multiple comparisons using the Benjamini-Hochberg false-discovery rate 
correction. (E) Pathway analysis was used to assess the biological processes enriched in the most 
significantly differentially expressed genes in convalescent Sensitized bladders relative to 
Resolved bladders; significance was determined by a right-tailed Fisher’s exact test, with Padjusted 
< .05 considered significantly enriched pathways. Shown are the top 25 broad meta-pathways 








Bladder remodeling fundamentally alters acute cystitis pathogenesis upon UPEC challenge, 
conferring resistance to early bladder colonization. (A) Representative scanning electron 
microscopy images of the luminal surface of bladders at 6 or 24 hpi with 108 CFU UTI89. 
Curved arrows show bacteria; arrowheads show neutrophils; “E” denotes regions of exfoliation. 




Scale bars are 25 µm for low-magnification and 5 µm for high-magnification images. N=2 
experiments with n=3-4 bladders per group. (B through E) Mice were challenged with 107 CFU 
UTI89 and acute outcomes were evaluated. (B) Semi-quantitative scale of pyuria in urine 
sediments at 6 and 24 hpi with 107 CFU UTI89. PMN, polymorphonuclear neutrophil. (C) Total 
bladder bacterial burden was determined at 6, 12, and 24 hpi. (D) Mice were challenged with 
GFP-overexpressing UTI89 and intracellular bacterial communities (IBCs) were enumerated by 
fluorescence microscopy at 6 and 24 hpi. (E) At 3 hpi, bladder invasion and intracellular 
replication was determined using an ex vivo gentamicin protection assay (Mulvey et al., 1998). 
Data are combined from 2-3 independent experiments; data points represent actual values for 
each individual mouse, zeroes are plotted at the limit of detection and bars indicate median 






COX-2-dependent inflammation during acute cystitis in Sensitized mice allows UPEC to 
circumvent the early urothelial resistance to colonization. (A and B) Expression of Ptgs2 
(COX-2) in bladders at 24 hpi with 108 CFU UTI89. (A) Immunofluorescence microscopy using 
a mouse monoclonal antibody against COX-2. L, lumen; LP, lamina propria; U, urothelium; 
arrowheads indicate nests of COX-2 positive urothelial cells; dotted line indicates urothelial 
basement membrane. Scale bars 100 µm, n=3-5 bladders per mouse from N=2 experiments. 
COX-2 staining was not seen in any Resolved bladders and was seen in about half of Sensitized 
and Adult Naive bladders, of which representative images are shown. (B) qRT-PCR of bladder 
RNA (normalized to mock-infected Adult Naive bladders). Whiskers are min to max values. (C 
and D) Ptgs2 expression at 24 hpi is positively correlated with urine bacterial burden (C) and 
pyuria (D). (E and F) Mice were pre-treated with the COX-2-specific inhibitor SC-236, or mock 




sediments collected at 24 hpi. PMN, polymorphonuclear neutrophil. (F) Bladder bacterial burden 
was determined at 24 hpi. (G and H) After an initial 2 week chronic infection and 4-5 week 
convalescent period after antibiotics, Sensitized mice were vaccinated with FimH (Langermann 
et al., 1997) or mock-vaccinated, boosted or mock-boosted, and then challenged with 107 CFU 
UTI89 (Figure S14). Urine bacterial burden at 24 hpi (G) and incidence of chronic cystitis at 28 
dpi (H) were determined. Data are combined from 2-3 independent experiments. Data points 
represent actual values for each individual mouse and bars indicate median values. For urine and 
bladder titers, zeroes are plotted at the limit of detection. The Mann-Whitney U test was used for 
qRT-PCR and urine and bladder titers. For XY correlations a Spearman correlation was used. 
For incidence of chronic cystitis, Fisher’s exact test was used and the # of mice per group is 








Sensitized mice have long-lasting susceptibility to recurrent UTI. In this experiment the 
convalescent period in C3H/HeN mice was extended for seven months after the initiation of 
sterilizing antibiotic therapy. Shown is the incidence of chronic cystitis 28 dpi after challenge 
with 107 CFU UTI89. The # of mice per group is shown at the top of each bar; few mice were 
used because of the length of the experiments. ND, not determined. A 108 CFU dose was used in 









Timeline of sensitization experiment in C57BL/6 mice shown in Figure 1.c. This inbred 
mouse strain is resistant to developing chronic cystitis upon infection with one dose of UPEC, 
but superinfection with two doses of 107 CFU UTI89 24 hours apart induces chronic cystitis 
(evidenced by persistent bacteriuria >104 CFU/ml for four weeks) in 30-35% of mice (Schwartz 
et al., 2015), denoted here as “Superinfected, Chronic.” The 65-70% of mice that spontaneously 
resolve the superinfection are denoted here as “Superinfected, Resolved.” As controls, mice 
initially were given one dose of UPEC (“Single, Resolved”), which all mice spontaneously 
resolved, or PBS (“Adult Naive”). Four weeks after the initial infection, all mice received 
antibiotics. Four weeks after the initiation of antibiotics, all mice were challenged with one dose 
of 107 CFU UTI89 and sacrificed after two weeks. Open circles indicate urine collection to 







Type 1 pilus expression in a panel of clinical E. coli isolates. Shown are the mean guinea pig 
red blood cell hemagglutination (HA) titers of indicated bacterial strains. Samples were tested in 







Non-uropathogenic strains of E. coli were not pathogenic in Sensitized mice. Shown are (a) 
the urine bacterial burden at 24 hpi and (b) the incidence of chronic cystitis at 28 dpi after 
challenge infection with 107 CFU of the E. coli strains MG1655 and Nissle 1917. In panel b, the 
numbers at the top of each column represent the number of mice tested. ND, not determined. 







Infection history impacts bladder cell size during convalescence. Shown is the average 
urothelial cell size (pixels2) in convalescent mice sacrificed at one month after the initiation of 
ten days of oral trimethoprim-sulfamethoxazole antibiotics. Cell sizes were measured in ImageJ. 
Five 500x magnification scanning electron micrographs were taken per bladder half (total of ten 
images per mouse) and every cell that was completely contained within the image was measured. 
Data points represent the average of all measurements for a given mouse. * P < 0.05, Mann-










Few superficial cells in Sensitized mice were binucleate. (a) Representative images of DAPI-
stained whole mounted bladders visualized by epifluorescence microscopy show more binucleate 
cells (arrows indicate examples) in Adult Naive and Resolved bladders than Sensitized bladders 
(N=1 replicate with n=3 bladders per group). Scale bars are 100 µm. Images in the first row are 
slightly overexposed to facilitate the visualization of individual cells. (b) Paraffin-embedded 
bladder sections were stained for keratin 20 (white), E-cadherin (green), Trp63 (red), and nuclei 
(blue) and visualized by fluorescence microscopy. Boxes denote examples of binucleate 
superficial cells (keratin 20+, Trp 63-, with a basolateral layer of E-cadherin). Scale bars are 50 
µm. Representative images are shown from N=3 experiments with sections from n=3 Adult 
Naive and Resolved and n=6 Sensitized mice. (c) Nuclei were enumerated in all superficial cells 
(TRP63-, keratin 5-, uroplakin IIIa+, keratin 20+ [weak/patchy staining observed in Sensitized 
mice], with a basolateral band of E-cadherin) in stained bladder sections from the experiment in 
panel b, and the percentage of binucleate cells was calculated. Only 5.3% of luminal cells in 
Sensitized mice were binucleate, compared to 23.4% and 23.3% of superficial cells in Adult 
Naive and Resolved mice, respectively. Shown is the average percentage of binucleate 
superficial cells among all bladders from a given group of mice; error bars represent standard 
error of the means; *** P < 0.001, Fisher’s exact test. Note the smaller superficial cell size in 








Masson’s trichrome staining for collagen deposition did not reveal fibrosis in convalescent 




magnification from n=3-7 mice per group (N=2). Keratin and muscle stain purple and collagen 
stains blue by this method (Metcalfe et al., 2010); in a blinded analysis, there was no difference 







 Whole bladder RNA-seq findings are in concordance with the previously published 
urothelial membrane proteome. Of the 156 most significantly enriched or depleted proteins in 




significantly differentially expressed by RNA-seq (Padjusted < 0.05) (a) and the majority were 
changed in the same direction (b), demonstrating that urothelial remodeling is at least partially 
controlled at the transcriptional level. The 22 genes were among the most enriched/depleted 
proteins from the proteomic analysis, and include cytoskeleton-associated proteins like keratin 
14 (Krt14), septin-1 (Sept1) and formin-like protein-1 (Fmnl1); extracellular matrix-associated 
proteins like collagen (Col6a1); cell death-associated proteins such as caspase 1 and gasdermins 
Gsdmc2 and Gsdmc3; and the polymeric immunoglobulin receptor Pigr. See Table S2. 
for P values and fold changes. Proteomics data are from N=1 experiment with n=3 mice per 
group (Hannan et al., 2014) and RNA-seq data are from N=1 experiment with n=7 Sensitized and 










UTI history impacted host responses at 6 hpi. Additional representative scanning electron 
micrographs of the luminal surface of bladders at 6 hpi with 108 CFU UTI89 are shown. N=2 
experiments with n=3-4 bladders per group. Curved arrows show bacteria; arrowheads show 
neutrophils; “E” denotes regions of exfoliation. All scale bars are 10 µm; Adult Naive images are 
shown at a higher magnification (1000x) than Sensitized and Resolved mice (500x) to facilitate 
the visualization of bacterial filaments. One rod-shaped bacterium (denoted by a box) was 
detected in a Resolved bladder and is shown at 5000x magnification directly underneath the 







Intracellular bacterial communities (IBCs) were not detected in Sensitized mice by a β-
galactosidase activity assay. Mice were challenged with 107 CFU UTI89 and sacrificed at 6 hpi. 
After X-gal staining for β-galactosidase activity, IBCs were visualized using a dissection 
microscope. ** P < 0.01, *** P < 0.001, Mann-Whitney U test. Data are from N=2 experiments 








Intracellular bacterial communities (IBCs) were not detected in Sensitized mice by 
immunofluorescence. Mice were challenged with 108 CFU UTI89 and bladders were fixed in 
methacarn at 6 or 24 hpi, embedded in paraffin and sectioned. Deparaffinized bladder sections 
were stained for E. coli (green) and uroplakin IIIa (red) and visualized by epifluorescence. 
Shown are representative images at the same magnification from n=3-5 bladders per mouse per 







During convalescence, UTI history did not influence expression of the COX-2 gene, Ptgs2. 
qRT-PCR was used to assess bladder Ptgs2 expression relative to 18S expression in mock-
infected Adult Naive, Sensitized and Resolved bladders. Data points represent actual values for 









Inhibition of cyclooxygenase-2 (COX-2) prior to challenge prevented mucosal wounding in 
Sensitized mice. Mice were pre-treated with buffer (top image) or the COX-2 inhibitor SC-236 
(bottom image) and then infected for 24 hpi with 107 CFU UTI89. Most mice were used to assess 
bladder colonization as shown in Figure 4f; bladders from n=3 inhibitor-treated and n=3 SC-236-




Deparaffinized bladder sections were stained for E. coli (green), uroplakin III (red) and DNA 
(blue) and visualized by epifluorescence. Bacterial colonization and mucosal wounding was 
detected in 1 of 3 buffer-treated bladders (representative image shown) and 0 of 3 inhibitor-







Time course of FimH vaccination experiments in Sensitized mice. The initial infection with 
108 CFU UTI89 was shortened to two weeks, which is sufficient to cause sensitization (Hannan 
et al., 2010). After antibiotic-induced convalescence, mice were vaccinated subcutaneously with 
15 µg FimCH (FimH adhesin in complex with its chaperone protein FimC) emulsified 1:1 with 
Complete Freund’s Adjuvant (CFA) for the primary vaccine or Incomplete Freund’s Adjuvant 
(IFA) for the boost. For negative controls, mice received buffer and CFA/IFA, or 15 µg of the 
FimC chaperone protein alone and CFA/IFA. FimC was previously shown not to be protective 
against UTI (Langermann et al., 1997). The buffer and FimC groups are combined and presented 
as “mock” in Figure 4e and Figure 4f as they were statistically indistinguishable. Five weeks 
after boosting, mice were challenged with 107 CFU UTI89. Open circles indicate urine collection 







2.2 Convalescent mice with various susceptibilities to UTI 
displayed distinct transcriptomic signatures 
2.2.1 Preface 
Only the comparison of Sensitized and Resolved mice transcriptomes were used in the 
manuscript in Section 2.1. This section focuses on a more comprehensive analysis of the 
transcriptomes of Adult Naïve, Sensitized, and Resolved mice during convalescent period after 
an initial infection that lasted either 2 or 4 weeks. My contribution to this section include: 
experiment design and performance, data analysis, figure generation, and text editing.  
2.2.2 Introduction 
The recurrent nature of UTI not only burden patients with high financial cost but also greatly 
reduces their life quality, as some patients experience up to half a dozen recurrences within one 
year following the initial episode (FOXMAN, 1990; Foxman, 2010; Ikaheimo et al., 1996). A 
history of UTI, including two or more episodes and the first episode at 15 years old or younger, 
has been identified as host risk factors to rUTI in sexually active premenopausal women (Scholes 
et al., 2000). This raises the question of why and how certain hosts are subject to repeated 
bladder infection while others are more resistant.  
Clinicians have few, if any, effective strategies to offer to their patients to counter the challenge 
of recurrence beyond daily antibiotic prophylaxis. Such a strategy does reduce the risk of UTI 
recurrence to some extent (Ahmed et al., 2017; Al-Badr A, 2013; Williams and Craig, 2011), but 
this method has become less effective as the antibiotic resistance of uropathogens has rapidly 




2008). Therefore, it is urgent to understand the interplay between UTI history and host 
susceptibility to rUTI in order to develop new therapeutic strategies.  
In order to study host response to rUTI, the Hultgren laboratory previously developed a murine 
model (Hannan et al., 2010). In their study, juvenile (7-8 weeks old) naïve female C3H/HeN 
mice were inoculated with 108 CFU UTI89, or PBS-mock infected as control. During four weeks 
following the infection, urine bacterial burdens were regularly monitored to determine the status 
of infection. About half of the infected mice displayed constant high-level bacteriuria (>104 
CFU/ml urine) during the four weeks, which was an indication of developing chronic cystitis, 
hereby referred to as “Sensitized” mice. The other half of the infected mice spontaneously 
resolved the infection with urine bacterial burden dropped below the cut off (104 CFU/ml urine) 
at some point during the four weeks, hereby referred to as “Resolved” mice. PBS-mock infected 
control mice urine remained sterile, hereby referred to as “Adult Naive” mice. At the end of the 
four-week infection period, all mice were provided with a 10-day period of antibiotic treatment 
to clear any persisting infection. The mice were then allowed to convalesce for a four-week 
period starting from the first day of antibiotic treatment. By the end of two months from the 
initial infection (or PBS-mock for control mice), Adult Naïve, Sensitized, and Resolved mice 
have experienced initial bladder inoculation, antibiotic treatment, and convalescence 
sequentially. These three mouse groups now have three disease histories. In this model, upon 
subsequent infection of 107 – 108 CFU UTI89, the incidence of developing chronic cystitis in 
each mouse group were: 8 - 10% (dose-dependent), 40 - 50% (dose-dependent), and 0% for 
Adult Naïve, Sensitized, and Resolved mice, respectively. Therefore, Adult Naïve and Sensitized 
mice are categorized as susceptible while Resolved mice are categorized as resistant. It is clear 




infections, which recapitulates the diverging phenotypes observed in women. Therefore, this 
chapter is focused on elucidating the interplay of prior infection and host susceptibility to rUTI 
using this recurrent cystitis mouse model.  
In addition, an initial infection that lasted for two weeks was sufficient to introduce Sensitized 
mice (Hannan et al., 2010). More importantly, 4-week-Sensitized mice accumulated lymphoid-
like CD45+ cells in large follicle-like aggregates (lymphoid follicles) that are not only found in 
mice with chronic cystitis, but also in human with persistent bacteriuria (Hansson et al., 1990b) 
while 2-week-infected Sensitized mice did not. This did not significantly alter the incidence of 
chronic cystitis in 2-week-infected Sensitized mice compared to that of 4-week-infected ones 
(Hannan et al., 2010).  
There is physiological evidence that the initial infection resulted in remodeling of the bladder 
mucosa in the mice. Specifically, scanning electron microscopy revealed reduction in urothelial 
cell size in Sensitized and Resolved mice compared to Adult Naïve mice, and the urothelial cells 
of Sensitized mice were even smaller than those of Resolved mice (O'Brien et al., 2016b). 
Immunofluorescence microscopy revealed altered urothelial morphology and development. 
Specifically, Sensitized mouse bladders had a decreased frequency of binucleated superficial 
cells, decreased surface expression of terminal differentiation markers, increased roundness in 
superficial cells, and an expansion of intermediate and basal cell layers, relative to both Adult 
Naïve and Resolved mice. Furthermore, acute pathogenesis of rUTI differed depending on 
disease histories. For example, the establishment of intracellular bacterial communities (IBCs) 
varied greatly among these three mouse groups. As an important step to colonizing the bladder, 
Adult Naïve mice were able to harbor tens or hundreds of IBCs, while there were only a few 




were uniformly low (mostly <104 CFU) by 24 hpi in Resolved mice while a strong bimodal 
distribution occurred in Sensitized mice, with some > 106 and some less than 104 CFU, in 
accordance with the presence of host-pathogen checkpoint that determines disease outcome 
(Hannan et al., 2010). In summary, a prior UTI history leads to remodeling of the bladder and 
greatly affects susceptibilities to rUTI. This chapter investigates whether such remodeling also 
manifests at a transcriptional level.  
2.2.3 Results 
To investigate the bladder transcriptome during convalescence is altered by a prior infection, 
RNA-seq was performed on the whole bladders of Adult Naïve, Sensitized, and Resolved mice 
by the end of the four-week convalescence period (eight weeks after the initial infection). This is 
to understand the gene expression profiles of convalescent mice at the baseline (no infection) 
level. The three mouse groups were compared in pairs as follows: Resolved vs Adult Naïve 
(RN), Sensitized vs Adult Naïve (SN), Sensitized vs Resolved (SR). First, the differential 
analysis was performed to yield the differentially expressed genes (DEGs). Based on the DEGs, 
the principal component analysis (PCA) was employed to depict how different the groups were 
in terms of gene expression. Finally, to understand the biological implication of this differential 
gene expression, the pathway enrichment analysis was performed by the Ingenuity Pathway 
Analysis software. 
2.2.3.1 Sensitized mice displayed the most distinct transcriptome  
The numbers of DEGs were quite different among the three comparison groups: RN, SN, and 
SR. In RN comparison, 19 genes were differentially expressed in Resolved mice compared to 
Adult Naïve mice (Figure 5A). Gene fold changes ranged from 1.2 folds up-regulation to 20% 




DEGs reached as low as 0.006. In the SN comparison, 1678 genes were differentially expressed 
in Sensitized mice compared to Adult Naïve mice (Figure 5E), with fold changes between 80% 
down-regulation up to 17 folds up-regulation (Figure 5E, Table S5). The significance reached as 
low as 1.7 x 10-12. In the SR comparison, 837 genes were differentially expressed in Sensitized 
mice compared to Adult Naïve mice, with up to 2.7 folds of up-regulation and down to 60% 
down-regulation, and significance as low as 4.3 x 10-17 (Figure 5G, Table S5). PCA revealed that 
Adult Naïve, Sensitized, and Resolved mice formed three separated clusters (Figure 5I). The 
distances between samples reflected similarities of their transcriptomes. Resolved mice located 
in between Adult Naïve mice and Sensitized mice, and was much closer to Adult Naïve mice 
than Sensitized mice, in particular along principal component 1 (PC1), which accounted for the 
largest variance (83%) in the transcriptomes. Such distribution reflected that Sensitized mice 
displayed the most distinct transcriptomes among the three mouse groups. 
The similarities of transcriptomes of Adult Naïve, Sensitized, and Resolved mice were reflected 
by the number, fold change, and significance of DEGs between the three comparing pairs (RN, 
SN, and SR), as described above. We then investigated the overlap of DEGs of RN, SN, and SN 
comparisons. Almost all DEGs from the RN comparison (18 out of 19 genes) overlapped with 
DEGs from the SN comparison (18 out of 1678 genes), with the same direction of up or down 
regulations (Figure 6A, Table S5). This suggests that the mice with prior infection (Sensitized 
and Resolved) shared transcriptional imprints compared to the mice without (Adult Naïve). The 
majority of DEGs (629 out 837, 75%) from the SR comparison overlapped were also found in 
the SN comparison (629 out of 1678, 37%) (Figure 6B, Table S5). It is clear from our analysis 
that at the level of the whole organ transcriptome the Sensitized bladders have much greater 




2.2.3.2 Immune response and cell morphology related pathways were enriched in 
Sensitized and Resolved mice 
The number and content of enriched pathways were compared in the same pairs as above: RN, 
SN, and SR. In the RN comparison, the DEGs were mostly down-regulated in Resolved mice 
and were mostly cytoplasmic proteins (e.g., Synm) and transmembrane transporters (e.g., 
Atp2b4) (Table S5). Thirteen pathways were enriched (Table S6). Besides cellular immune 
signaling pathways (e.g., antigen presentation, Cytotoxic T lymphocyte-mediated apoptosis), 
cellular maintenance and metabolic pathways (e.g., calcium transport I) and cellular growth and 
processes pathways (e.g., Cdc42 signaling) were also enriched in the Resolved vs Adult Naïve 
mice comparison (Table S6). Such enriched pathways were predicted to result in changes in cell-
mediated immune responses, macromolecule metabolism, organismal injury (Figure 7A), etc., 
suggesting alterations, although slight, exist between Adult Naïve and Resolved mice after four 
weeks of convalescence (Table S6). 
Besides changes to the epithelium, Sensitized bladders are also distinguished from Resolved and 
Adult Naïve bladders by the presence of lymphoid follicles (follicular hyperplasia) that persists 
through convalescence. Therefore, it is not surprising that in the SN comparison, the top up-
regulated genes were mostly transmembrane receptors (e.g., Cd3e) and transcriptional regulators 
(e.g., Tfap2a) that are related to immune signaling and cell growth and death; while most down-
regulated genes were receptors and enzymes that related to extracellular matrix (e.g., Edil3) and 
cell differentiation (e.g., Elf5) (Table S5). The pathway analysis revealed 219 enriched pathways. 
For example, the immune response pathways (CD28 signaling in T helper cells, B cell receptor 
signaling, TNFR1 signaling, TNFR2 signaling, etc.) were highly enriched and activated 
(predicted by the IPA software, quantified by z-score), as expected, as well as cell/tissue 




tissue development (e.g., integrin signaling), and cell-to-cell signaling and interaction (e.g., gap 
junction signaling) (Table S6). The large number of enriched pathways and high extent of 
activation depicted the different landscapes of transcriptome between Sensitized and Adult Naïve 
mice. Sensitized mice were more active in not only immune signaling and inflammatory 
responses but also tissue morphology, cellular development, and differentiation (Figure 7B). 
Similarly, in the SR comparison, the top up-regulated genes were transmembrane receptors (e.g., 
Irf4) and ion channels (e.g., Clca2) that relate to immune signaling while most down-regulated 
genes were extracellular space proteins/peptides (e.g., Rbp4) and transcriptional regulators (e.g., 
Elf5, Sp6) that relate to differentiation and morphology (Table S5). Pathway analysis showed 
157 enriched pathways, including immune responses (e.g., B cell receptor signaling) cell/tissue 
morphology (e.g, cdc42 signaling), and tissue development (e.g., integrin signaling). In 
particular, cellular growth and proliferation (e.g., paxillin signaling) were significantly enriched 
(Table S6), indicating a more immune responsive system and a remodeled mucosal environment 
(Figure 7C). In addition, of the 156 most significantly enriched or depleted proteins in the 
Sensitized urothelial proteome (Padjusted < 0.01), 22 were also significantly differentially 
expressed transcriptionally (Padjusted < 0.05) (Figure S8A). The 22 genes were among the most 
enriched/depleted proteins from the proteomic analysis, including cytoskeleton-associated 
proteins like septin-1 (Sept1) and formin-like protein-1 (Fmnl1), extracellular matrix-associated 
proteins like collagen (Col6a1), and cell death-associated proteins such as caspase 1 and 
gasdermins Gsdmc2 and Gsdmc3. This confirmed that cell morphology alternations penetrated 
from transcriptional to translational level. The rest proteins were not significantly differentially 




S8B), demonstrating that urothelial remodeling is at least partially controlled at the 
transcriptional level. 
Overlapping DEGs of SN and SR comparisons are dominatingly immune response pathways, 
such as immune cell development (e.g., B cell development, T helper cell differentiation) and 
cytokine signaling (e.g., IL-4 signaling), changes which are most likely due in part to the 
presence of lymphoid follicles. In order to remove the follicular hyperplasia remodeling aspect, 
we repeated the RNA-seq on mice that are infected for only 2 weeks prior to antibiotic therapy 
and same comparisons (RN, SN, and SR) were made. Two weeks of chronic cystitis is sufficient 
to sensitize mice to recurrent infection, similar to 4 week chronic infections, but the infection is 
too short to result in the formation of lymphoid aggregates. 
2.2.3.3 Comparison between mice infected for 2 weeks indicated influence of 
lymphoid follicles on Sensitized mice transcriptome 
The numbers of DEGs of mice that were infected for 2 weeks, were also quite different among 
the three comparison groups, and were in the same relative order: RN < SR < SN. In 2-week RN 
comparison, 294 genes were differentially expressed in 2-week-infected Resolved mice 
compared to Adult Naïve mice (Figure 5B). Gene fold changes ranged from 4.7 folds up-
regulation to 75% down-regulation (Figure 5D). In the SN comparison, 1327 genes were 
differentially expressed in 2-week-infected Sensitized mice compared to Adult Naïve mice 
(Figure 5B), with fold changes between 9 folds up-regulation down to 63% down-regulations 
(Figure 5F). In SR comparison, 584 genes were differentially expression in 2-week Sensitized 
mice compared to Resolved mice, with gene fold changes ranged from 79% down-regulation up 
to 3.7 folds up-regulation (Figure 5H). PCA plot revealed that the three mice groups were quite 




the biggest variance (52%) between groups, 2-week Adult Naïve and Resolved mice were close 
located to each other while both of these two groups were more separated from 2-week 
Sensitized mice.  
Different numbers and categories of biological pathways were enriched in Adult Naïve, 
Sensitized, and Resolved mice infected for 2 weeks, compared to each other (Table S6). In RN 
comparison, 62 pathways were significantly enriched in 2-week Resolved vs Adult Naïve mice, 
such as metabolic disease related (e.g., mitochondrial dysfunction) and inflammatory response 
related (e.g., Th1 and Th2 activation pathway) pathways (Figure 7D), suggesting metabolic and 
inflammatory changes in 2-week Resolved mice.  
When compared with 2-week Adult Naïve and Resolved mice, 2-week Sensitized mice had 188 
and 114 pathways enriched, respectively. The top enriched pathways were related to cellular 
development, tissue morphology, metabolic disease, etc (Figure 7E-F). Surprisingly, in SN and 
SR comparisons, including mice were infected for 2 or 4 weeks, all comparisons showed 
pathways categorized and predicted to affect lymphoid tissue structures and development were 
all enriched (Figure 7), and most genes downstream of those pathways were up-regulated. 
However, the significance of the lymphoid tissue structure and development “meta-pathway” 
were more significantly enriched in 4-week Sensitized mice than in 2-week Sensitized mice, 
when compared to Adult Naïve and Resolved mice being infected for the same period of time. 
The number of genes involved in the lymphoid tissue structure and development “meta-pathway” 
were also more in 4-week SN (390 genes) and 4-week SR (182 genes) than in 2-week SN (165 
genes) and 2-week SR (119 genes). In RN 2-week and 4-week comparisons, lymphoid tissue 
structure and development were also slightly enriched, even though no lymphoid follicles were 




and SR comparisons (data not shown, much lower than top 25). Therefore, mice with the more 
severe and chronic the infection was, the more enriched of the lymphoid follicles related 
pathways.   
2.2.4 Discussion 
Disease history has been shown to be an important host risk factors to rUTI. Correspondingly, a 
murine model has been developed to recapitulate such phenotype: mice with different infection 
history, either self-resolving or chronic cystitis, display distinct susceptibilities to subsequent 
infections. Mice with three different disease histories were investigated: 1) Adult Naïve mouse, 
no prior infections, 2) Sensitized mouse, one prior infection, developed chronic cystitis lasting at 
least 2 weeks, 3) Resolved mouse, one prior infection, spontaneously resolved. Such indications 
strongly suggest long-lasting alterations left by prior infections. Previous studies discovered that 
Sensitized and Resolved mice displayed altered urothelial morphology and acute pathogenesis 
compared to Adult Naïve mice (O'Brien et al., 2016b). Furthermore, mice with chronic infections 
lasting 4 weeks, but not those lasting only 2 weeks, develop lymphoid hyperplasia (Hannan et 
al., 2010).  In this study, the transcriptomes of Adult Naïve, Sensitized, and Resolved mice were 
analyzed during convalescence after either 2 or 4 week infections to reveal molecular 
mechanisms that correlate with host susceptibilities to rUTI. As in pathway enrichment analysis, 
several genes and pathways related cell/tissue development and morphology showed high extent 
of differential regulation in all three different comparisons.  
It has been discovered that upon challenge infection, Adult Naïve, Sensitized, and Resolved mice 
displayed 10%, 40%, and 0% incidence of developing chronic cystitis (Hannan et al., 2010). 
Both Adult Naïve and Sensitized mice are categorized as susceptible, while Resolved mice are 




Resolved mice possess quite similar transcriptomes, whether previously infected for 2 or 4 weeks 
prior to antibiotic therapy. On one hand, this result is consistent with their close rate of 
susceptibilities to rUTI, 10% and 0%; on the other hand, although not as dramatic, such 
susceptibility differences separate Resolved mice (resistant) from Adult Naïve mice (susceptible) 
in nature. This could be due at least three possibilities: 1) underlying mechanisms that separate 
Adult Naïve and Resolve mice are non-transcriptional; 2) the transcriptional differences are not 
constitutively present and the differences could emerge after infection; or 3) a change in a cell 
population (e.g. expanded resident or recruited immune cell populations) that is a minor 
component of the bladder such that the differences in whole bladder gene transcription is not 
significantly changed.   
Sensitized mice displayed the most distinct transcriptome compared to both Adult Naïve (1678 
DEGs) and Resolved mice (837 DEGs). In particular, cell/tissue development and morphology 
related genes and pathways showed high extent differential regulation, which is consistent with 
physiological signs such as much smaller urothelial cells observed by SEM (O'Brien et al., 
2016b). It is surprising that such differences were dramatic and were present even after antibiotic 
treatment and four weeks of convalescence. Even though lymphoid follicles were not observed in 
2-week Sensitized mice, two weeks of infection already induced related transcriptomic changes 
to some extent. Resolved mice showed no signs of lymphoid follicles as well yet lymphoid 
follicle related pathways were still enriched when compared to Adult Naïve mice, likely due to 
up-regulations of shared genes between lymphoid follicle related and other immune pathways. 
This implied that as the initial infection period extend and infection get more severe and chronic, 




between Sensitized and Adult Naïve and Resolved mice, could be explained by the further or full 
development of lymphoid follicles.  
Gene expression profile changes were consistent with such long-lasting effect. Furthermore, 
alterations related to extracellular matrix, cytoskeleton, etc., were observed at the protein level in 
urothelial cells isolated from convalescent bladders (Hannan et al., 2014), suggesting certain 
transcriptional changes, in particular cell morphology related, were able to be translated to 
protein level. It is also possible that imprints left by prior infection have gone deep down to the 
epigenetic level such that the transcriptome could remain altered in Sensitized and Resolved 
mice.  
The transcriptomic differences (837 DEGs in 4-week-infected mice, 584 DEGs in 2-week-
infected mice) between Sensitized and Resolved mice seemed to be moderate compared to that 
of Sensitized vs Adult Naïve (1678 DEGs in 4-week-infected mice, 1327 DEGs in 2-week-
infected mice) and Resolved vs Adult Naïve mice (19 DEGs in 4-week-infectede mice, 294 
DEGs in 2-week-infected mice). These similarities between Sensitized and Resolved mice might 
result from prior infection that Adult Naïve mice did not share. Meanwhile, the differences 
between these two mouse groups, mostly showed enrichment in immune-related pathways, could 
be due to several reasons: 1) lymphoid follicles have been reported in Sensitized mice but not in 
Resolved mice, although undetected, 2-week Sensitized mice might have lymphoid follicles in 
pre-forming state, with genes related to CD45+ cells account for such differences, 2) although 
both experienced an initial infection, different disease outcomes might render unique effects on 
Sensitized and Resolved mice, represented by genes unique to 4-week SN (1049 genes) and 4-
week SR comparisons (208 genes). Such differences could correlate with the mechanisms of 




specific molecular mechanisms that affects host susceptibility to rUTI, further investigations 
need to be conduct on Sensitized and Resolved mice after they are infected with UPEC (see 
Chapter 2). 
In conclusion, long-lasting and distinct imprints (bladder remodeling) can be observed in mice 
that have been previously infected with UTI89, regardless of the disease outcome. Such 
remodeling is manifested at both the transcriptional level and the translational level. More 
specifically, different disease outcomes of the initial infection leave complicated, but distinct 
bladder signatures, mostly immune response related, partially due to visible, well-developed, and 
lasting lymphoid follicle formations, separating Sensitized from Resolved mice after 
convalescence. Such distinct transcriptional signatures could lay the basis of various 









Figure 5.  
Sensitized showed the most distinct differences from Adult Naïve and Resolved mice in the 
transcriptome after 2 or 4 weeks of convalescence. A-B) The number of differentially 
expressed genes (Padjusted < 0.05) in Resolved vs Adult Naïve, Sensitized vs Adult Naïve, and 
Sensitized vs Resolved mice comparison. RNA-seq was performed on whole bladders from n = 7 
or 7 Adult Naïve, n = 7 or 9 Sensitized, and n = 6 or 7 Resolved convalescent mice infected by 4 
or 2 weeks, respectively. C-D) DEGs of Resolved vs Adult Naive mice. E-F) DEGs of Sensitized 
vs Adult Naive mice. G-H) DEGs of Sensitized vs Resolved mice.  I-J) PCA of Adult Naïve, 
Sensitized, and Resolved mice. In volcano plot of DEGs, colours indicate each gene’s absolute 
log2(fold change): grey ≤0.58; orange between 0.58 and 1; and red >1. In PCA plot, each dot 
represents one mouse gene expression profile based on DEGs. Black = Adult Naïve mice, red = 
Sensitized mice, blue = Resolved mice. Significance = -log10Padjusted. A, C, E, G, I were mice 




DEGs of three comparisons: Resolved vs Adult Naïve, Sensitized vs Adult Naïve, and Sensitized 
vs Resolved mice comparison, showed certain degree of overlap. The number of genes that were 
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Figure 7.  
Similar meta-pathway enriched in RN, SN, and SR (mice infected for 4 weeks and 2 weeks) 
transcriptomic comparisons. Top 20 broad meta-pathways assembled from the specific enriched 
pathways by Ingenuity IPA, ordered by most significant P value in A) Resolved vs Adult Naive 
mice (4 weeks), B) Sensitized vs Adult Naïve mice (4 weeks), C) Sensitized vs Resolved mice (4 
weeks), D) Resolved vs Adult Naive mice (2 weeks), E) Sensitized vs Adult Naïve mice (2 
weeks), F) Sensitized vs Resolved mice (2 weeks). 
 
2.3 Material and Methods 
Ethics statement. All animal experimentation was conducted according to the National 
Institutes of Health guidelines for the housing and care of laboratory animals. All experiments 
were performed in accordance with institutional regulations after review and approval by the 
Animal Studies Committee at Washington University School of Medicine in St. Louis, MO. 
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Bacterial strains. The uropathogenic E. coli isolates used in this study were the human cystitis 
isolate UTI89(Mulvey et al., 2001) and the following derivatives thereof: UTI89 
attHK022::COMGFP (kanamycin-resistant) and UTI89 attl::PSSH10-1 (spectinomycin-
resistant)(Wright et al., 2005); the human urosepsis isolate CFT073 Hk::Cm (chloramphenicol-
resistant)(Mobley et al., 1990); the multi-drug resistant human cystitis isolate EC958 (sequence 
type 131)(Totsika et al., 2011); and the human asymptomatic bacteriuria isolate 83972 
(Andersson et al., 1991). The non-uropathogenic E. coli isolates used were the lab strain 
MG1655 (Gerdes et al., 2003) and the gut commensal strain Nissle 1917 (Nissle, 1916). Strains 
were cultured statically in lysogeny broth (LB) at 37°C. The Klebsiella pneumoniae human 
cystitis isolate TOP52 1721 (Rosen et al., 2008) was cultured statically in LB at 37°C. Bacterial 
strains were cultured for two to three overnight passages to induce type 1 pilus expression. In 
experiments where mice had an initial infection and subsequent challenge infection (i.e. 
challenge experiments in Sensitized and Resolved mice), UTI89 attHK022::COMGFP 
(kanamycin-resistant) was always used for the initial infection, whereas the challenge strain 
varied and was differently antibiotically-marked.  
Type 1 pilus expression. Type 1 pilus expression of bacterial strains was assessed by 
hemagglutination (HA) of guinea pig red blood cells as previously described(Hultgren et al., 
1985). Briefly, bacterial strains used in the “heterologous challenge” experiments in Figure 1 
were normalized to an optical density OD600 of 1, and guinea pig red blood cells were 
normalized to OD640 of 2. Red blood cells were incubated overnight at 4°C with a 1:2 dilution 
series of bacteria. The last dilution at which hemagglutination was observed is reported as the 




Mouse infections. C3H/HeN mice were obtained from Harlan Sprague Dawley, Inc (now 
Envigo). C57BL/6 mice were obtained from The Jackson Laboratory. All mice were female and 
were 7-8 weeks old (“Juvenile”) at the time of the first infection. E. coli inocula were prepared as 
previously described(Hannan et al., 2010) and 107 or 108 CFU of bacteria were inoculated into 
the bladders of C3H/HeN mice by transurethral catheterization as previously described(Hung et 
al., 2009). For the initial infection, 108 CFU UTI89 was always used, as C3H/HeN mice develop 
chronic cystitis in an infectious dose-dependent manner and this inoculum results in chronic 
cystitis in ~50% of mice. For challenge infections, 107 or 108 CFU was used. We have found that 
Adult Naive and Sensitized mice are susceptible to recurrent cystitis in an infectious dose-
dependent manner, whereas Resolved mice will resolve the challenge infection regardless of 
infectious dose (Hannan et al., 2010; Hannan et al., 2014). A 108 dose was used for microscopy 
experiments (SEM shown in Figure 3 and immunofluorescence shown in Figure S11) to increase 
the likelihood of observing bacteria in Sensitized and Resolved bladders; for RNA-seq 
experiments to induce a more uniform response in Sensitized bladders; and for the six month 
convalescent experiment (Figure 1.B) because of the increased resistance to UPEC infection in 
aged nulliparous mice (Kline et al., 2014). All other experiments used a 107 dose. To monitor 
infection outcomes, urine was collected and urine, bladder and kidney bacterial burden was 
determined as previously described(Hannan et al., 2010). We previously found that 104 CFU/ml 
persistent bacteriuria was a highly specific and sensitive cutoff for detecting chronic cystitis 
(Hannan et al., 2010). Chronic cystitis during the initial infection was defined as persistent high-
titer bacteriuria (>104 CFU/ml urine) at every time point collected (1, 3, 7, 10, 14, 21, and 28 
days post-infection). Resolution of cystitis during the initial infection was defined as urine 




post-infection, all mice were treated with trimethoprim and sulfamethoxazole in the drinking 
water (54 and 270 µg/ml water, respectively) for ten days. Urine samples were collected weekly 
after the initiation of antibiotics to confirm sterile urines and any mice with treatment failure 
were excluded from subsequent analysis according to pre-established criteria. Four to five weeks 
after the initiation of antibiotics, mice were challenged with 107 or 108 CFU of bacteria 
inoculated into the bladders by transurethral catheterization. To assess acute outcomes, mice 
were sacrificed 3 to 24 hours post-challenge and bacterial burdens were determined. To assess 
chronic outcomes, mice were monitored for 28 to 30 days and then sacrificed. Chronic cystitis 
during the challenge infection was defined as persistent high-titer bacteriuria (>104 CFU/ml 
urine) at 1, 3, 7, 10, 14, 21, and 28 or 30 days post-infection coupled with high bladder bacterial 
burden (>104 CFU/bladder) and visibly enlarged, inflamed bladder at time of sacrifice. 
Resolution of cystitis during the challenge infection was defined as urine bacterial titer dropping 
below 104 CFU/ml urine during at least one time point, and/or bladder bacterial burden <104 
CFU at time of sacrifice. For vaccine studies, the initial infection was shortened to two weeks 
(chronic infection lasting two weeks was previously shown to be sufficient to result in 
sensitization to rUTI (Hannan et al., 2010)), with urine collected at days 1, 3, 7, 10 and 14 post-
infection. For experiments in C57BL/6 mice, the challenge infection was shortened to 14 days, 
with urine collected at days 1, 3, 7, 10 and 14 post-challenge. For studying how long the 
sensitization phenotype lasts, the “convalescent” period after the initiation of antibiotics was 
extended from four weeks to six months.  
Mouse infections: experimental design. Our experience with this model shows that five mice 
per replicate (two replicates minimum) is the minimum number necessary to overcome any 




experiment; a statistical analysis was not used to determine the number of mice per experiment. 
For vaccine and COX-2 inhibitor experiments, mice were randomly assigned to receive 
intervention or sham intervention. Investigators were not blinded to the infection history of the 
animals, except for Masson’s trichrome staining to assess collagen deposition.  
RNA isolation and qRT-PCR. Mice were infected with 108 CFU UTI89 attl::PSSH10-1 
(spectinomycin-resistant) and sacrificed at indicated time points, or mock-infected with PBS and 
sacrificed at 3.5 hpi. Bladders were aseptically harvested and flash-frozen in liquid nitrogen. 
RNA was extracted using the RNeasy Plus Mini kit (QIAGEN) and reverse-transcribed with the 
iScript Reverse Transcription Supermix (Biorad). qRT-PCR for Ptgs2 (cyclooxygenase-2) 
expression was performed as previously described(Hannan et al., 2014). Briefly, 1 µl of 12.5 
ng/µl cDNA was used with mPtgs2-specific intron-spanning primers: F: 5’-gatgctcttccgagctgtg-
3’,R:5’-ggattggaacagcaaggattt-3’. Expression values were normalized to 18S expression levels 
(F: 5’-cggctaccacatccaaggaa-3’,R: 5’-gctggaattaccgcggct-3’) and the fold change in expression 
relative to mock-infected Adult Naive bladders was determined by the 2-ΔΔCt method(Pfaffl, 
2001). Each sample was tested in triplicate in N=1 experiment.  
RNA-seq. Illumina cDNA libraries were generated using the RNAtag-seq protocol as 
described(Shishkin et al., 2015). Briefly, 1ug of total RNA was fragmented, depleted of genomic 
DNA, and dephosphorylated prior to its ligation to DNA adapter carrying 5’-AN8-3’ barcodes 
with a 5’ phosphate and a 3’ blocking group. Barcoded RNAs were pooled and depleted of 
rRNA using the Ribo-Zero Gold rRNA depletion kit (Illumina). These pools of barcoded RNAs 
were converted to Illumina cDNA libraries in 3 main steps: (i) reverse transcription of the RNA 
using a primer designed to the constant region of the barcoded adaptor; (ii) degradation of the 




using primers that target the constant regions of the 3’ and 5’ ligated adaptors and contain the 
full sequence of the Illumina sequencing adaptors. cDNA libraries were sequenced on the 
Illumina HiSeq 2500 platform. Fastq files were trimmed by cutadapt twice (cutadapt-v1.6), once 
by base quality and once by polyA or polyT repeats. Trimmed reads were then aligned to the 
Mus musculus mm10 genome using tophat2 (Trapnell et al., 2009) (tophat2-v2.0.11, bowtie2-
2.2.2). Gene counts were conducted by HTSeq (Anders et al., 2015) (HTSeq-v0.6.0, options: --
format=bam --order=name --stranded=no --idattr=gene_id --mode=union) and the output was 
used for principal component analysis using R stats (R-v3.2.2) and subsequent statistical 
analyses. We sequenced n=8 Sensitized and n=8 Resolved mice; after eliminating outliers due to 
low read depth (<15,000,000 reads), n=7 Sensitized and n=6 Resolved mice were available for 
subsequent analyses. An average of 4.65% of reads mapped to rRNA confirming good depletion. 
RNA-seq data has been deposited at NCBI under the BioProject ID number PRJNA327807. 
Statistical analysis: RNA-seq. DESeq2 (DESeq2-v1.8.1)(Love et al., 2014) was used to assess 
differential gene expression (Table S1) due to its consistency and precise performance across a 
subset of varying numbers of replicates, its tolerance for a small number of replicates, its low 
proportion of false detections, and its superior integration with R. It assumes a negative binomial 
distribution for gene counts, normalizes for read depth, and fits a generalized linear model. 
Statistically significant differences in gene expression were assessed by the Wald test and 
adjusted for multiple comparisons using the Benjamini-Hochberg false-discovery rate correction. 
Padjusted < .05 was deemed significantly differentially expressed. Pathway analysis of 
differentially expressed genes was performed with QIAGEN’s Ingenuity® Pathway Analysis 
(IPA® , QIAGEN Redwood City, www.qiagen.com/ingenuity). Significantly enriched pathways 




enriched. Enriched pathways were categorized into canonical pathways (e.g. Table S3) and also 
used for a broader analysis of “meta-pathways” (Figure 2E and Table S4). For comparison to the 
previously published proteomics dataset (Hannan et al., 2014) (Table S2 and Figure S8), a 
stringent significance cutoff of Padjusted < .01 was used to determine the most significantly 
enriched or depleted proteins in the urothelial proteome of convalescent Sensitized mice relative 
to convalescent Resolved mice (n=156 proteins). The corresponding genes were assessed by 
RNA-seq and deemed significantly differentially expressed (n=22) if Padjusted < .05 in 
convalescent Sensitized mice relative to convalescent Resolved mice. 
Histopathology and immunofluorescence. Bladders were aseptically harvested and fixed 
overnight in methacarn (60% methanol, 30% chloroform, 10% glacial acetic acid), bisected to 
give two halves per bladder, paraffin-embedded and sectioned. Slides were stained with 
Masson’s trichrome and imaged with a Zeiss Axio Scan Z.1 brightfield slide scanner for a 
blinded investigator to assess collagen deposition and fibrosis (Metcalfe et al., 2010; Ray et al., 
2012). For immunofluorescence experiments, slides were deparaffinized, hydrated, blocked with 
10% HIHS and 0.3% triton X-100 in PBS, incubated with primary antibody in 1% HIHS and 
PBS overnight at 4°C and secondary antibody in PBS for 30-60 minutes at room temperature. 
Primary antibodies used were uroplakin IIIa (mouse monoclonal, 10R-U103a, Fitzgerald), Trp63 
(rabbit polyclonal, GTX102425, GeneTex), E-cadherin (goat polyclonal IgG, AF748, R&D 
Systems), cytokeratin 5 (chicken polyclonal, 905901, BioLegend) and cytokeratin 20 (mouse 
monoclonal, M7019, DAKO). Samples were mounted in DAKO glycergel mounting medium 
with DAPI (Life Technologies) and fluorescence was visualized on a ZEISS Axioskop 
Observer.Z1 microscope. Cyclooxygenase-2 expression was detected as previously 




(mouse monoclonal, 610204, BD Transduction Laboratories) and Escherichia coli O, K serotype 
(rabbit polyclonal, E3500-06, US Biological). Fluorescence was visualized on a ZEISS Axio 
Imager M2 microscope. Antibodies are verified at 1DegreeBio (http://1degreebio.org/), except 
cytokeratin 5 and cytokeratin 20 (verified at manufacturers’ websites).    
Binucleate superficial cells. Binucleate superficial cells in convalescent bladders were 
examined by two methods. First, paraffin-embedded sections were stained and visualized on a 
ZEISS Axioskop Observer.Z1 microscope as described above. To determine the percentage of 
binucleate superficial cells, nuclei were enumerated in all superficial cells (TRP63-, keratin 5-, 
uroplakin IIIa+, keratin 20+ [weak/patchy staining observed in Sensitized mice], with a 
basolateral band of E-cadherin). Adult Naive bladders (n=3) had 69-77 superficial cells; 
Sensitized bladders (n=6) had 135-202 superficial cells; Resolved bladders (n=3) had 81-94 
superficial cells, reflecting the smaller superficial cell size in Sensitized and Resolved mice. 
Next, binucleate cells were imaged in bladder whole mounts as described by Blango et 
al.(Blango et al., 2014) with the following modifications: bladders were aseptically harvested 
from Adult Naive, Sensitized and Resolved mice (n=3 bladders per group), bisected, splayed, 
fixed for 20 minutes in 4% paraformaldehyde, and washed 3x5 minutes in 1x PBS. Bladders 
were incubated for 10 min in 1:5,000 DAPI in 1x PBS with 0.002% saponin, rinsed 3x5 min in 
PBS and mounted in ProLong Gold antifade reagent (Thermo Fisher) and imaged on a ZEISS 
Axio Imager M2 microscope.  
Scanning electron microscopy. Bladders were aseptically harvested prior to challenge or at 6 or 
24 hours post-challenge with 108 CFU UTI89 and bisected, splayed, and fixed in EM fixative 
(2% paraformaldehyde, 2% glutaraldehyde in 0.1M sodium phosphate buffer, pH 7.4). Samples 




tetroxide, dehydrated in increasing concentrations of ethanol, then dehydrated at 31.1°C and 
1072 PSI for 16 minutes in a critical point dryer. Samples were mounted on carbon tape-coated 
stubs and sputter-coated with gold/palladium under argon. Bladders shown in Figure 2, Figure 3, 
and Figure S9 were imaged on a Zeiss Crossbeam 540 FIB-SEM. For preliminary analysis, 
samples were imaged on a Hitachi S-2600H SEM. ImageJ 1.47v (National Institutes of Health, 
USA) was used to calculate epithelial cell surface area in five 500x magnification fields per 
bladder half (ten per mouse). Adobe Photoshop CS5.1 was used to slightly decrease the 
brightness and increase the contrast of the SEMs in Figure 3 to enhance visibility.  
Acute pathogenesis. Mice were challenged with 107 CFU UTI89 attl::PSSH10-1 
(spectinomycin-resistant)(Wright et al., 2005) and sacrificed at acute time points. Urine 
sedimentation to determine neutrophil influx was performed as previously described(Hannan et 
al., 2010). Briefly, 80 µl of a 1:10 dilution of urine was centrifuged onto poly-L-lysine-coated 
glass slides and stained with a Hema 3 kit (Fisher Scientific). Slides were examined by light 
microscopy and the average number of polymorphonuclear leukocytes (PMN) per high-powered 
field (hpf; 400x magnification) was calculated from counting 5 fields. A semi-quantitative 
scoring system was created to facilitate analysis: 0, less than 1 PMN/hpf; 1, 1–5 PMN/hpf; 2, 6–
10 PMN/hpf; 3, 11–20 PMN/ hpf, and 4, >20 PMN/hpf. Bladder burden was determined at 6, 12 
and 24 hours post-challenge as previously described(Hannan et al., 2010). Briefly, bladders were 
aseptically harvested, homogenized in PBS, serially diluted and spotted onto LB agar plates 
containing appropriate antibiotics. Intracellular bacterial communities were enumerated at 6 and 
24 hours post-challenge by LacZ staining and fluorescent microscopy as previously 
described(Anderson et al., 2003; Justice et al., 2006b). Bladder invasion assays were performed 




modifications: after washing three times in PBS, bladders were incubated for 75 minutes in 
gentamicin in RPMI cell culture medium without added serum, rather than in PBS. 
Inhibitor treatments. To test the effect of cyclooxygenase-2 inhibition on acute cystitis, mice 
were pre-treated with SC-236 (Sigma) as previously described(Hannan et al., 2014). The drug 
was solvated in 1% Tween 80 and mice received 100 µl of drug, or buffer alone, per 20 g body 
weight by oral gavage. Mice were sacrificed at 24 hpi with 107 CFU UTI89 and bladder bacterial 
burden was determined. 
FimH vaccination. C3H/HeN mice were initially infected with 108 CFU UTI89 
attHK022::COMGFP (kanamycin-resistant) and antibiotic therapy was initiated two weeks post-
infection, which is sufficient to cause sensitization (Hannan et al., 2010). Four to five weeks after 
the initiation of antibiotics, mice were vaccinated with the type 1 pilus adhesin FimH coupled 
with its periplasmic chaperone FimC, or with FimC alone (previously shown not to be protective 
against UTI (Langermann et al., 1997)), or buffer alone; five weeks post-vaccination, mice were 
boosted. Vaccination was performed as previously described(Langermann et al., 1997) with the 
following modifications: 15 µg of FimCH, FimC, or buffer were emulsified 1:1 with Complete 
Freund’s Adjuvant for the primary vaccination or Incomplete Freund’s Adjuvant for the boost. 
Mice were injected subcutaneously with 50 µl per hind flank for a total of 100 µl. Five weeks 
post-boost, mice were challenged with 107 CFU UTI89 attl::PSSH10-1 (spectinomycin-resistant) 
and infection outcomes were monitored over four weeks.  
Statistical analysis: mouse experiments. Statistics were performed in GraphPad Prism v6.07. A 
two-tailed Fisher’s exact test was used to test for significant differences in incidence of chronic 




pyuria, IBC formation), surface area differences in superficial cells, and qRT-PCR, the 
D’Agostino and Pearson Omnibus normality test was used to test for normality of distribution, 
Kruskal-Wallis tests were used to assess statistical significance, and subsequent pairwise 
comparisons were performed with a two-tailed Mann-Whitney U test. For XY correlations, the 
D’Agostino and Pearson Omnibus normality test was used to test for normality of distribution 
and Spearman correlations were performed to test for statistical significance. P < 0.05 was 
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Chapter 3: Genotype and disease history affect 
susceptibility to recurrent UTI by shaping 
TNFɑ signaling kinetics 
3.1 Preface 
Urinary tract infections (UTI) are common and recurrent. Both host genetics and UTI history 
impact susceptibility to recurrent UTI (rUTI) in women and in animal models. To identify shared 
patterns of host response that correlate with susceptibility, we investigated bladder inflammatory 
and transcriptional kinetics in acute and rUTI models. We found that TNFɑ signaling kinetics 
differed with mouse strain and infection history. Mice resistant to severe UTI/rUTI displayed a 
robust TNFɑ-dependent inflammation during the first 6 hours of acute cystitis, which waned by 
24 hours; mice that are susceptible varied in their early responses but were prone to severe 
inflammation at 24 hours post-infection. Depletion of TNFɑ in an rUTI model revealed that early 
TNFɑ signaling promoted colonization resistance via exfoliation of infected bladder cells, but 
prolonged TNFɑ signaling exacerbated inflammation, thereby worsening infection. In summary, 
changes in TNFɑ signaling kinetics alter host susceptibility to severe rUTI. This part is a 
manuscript in preparation. In collaboration with the following people: Valerie O’Brien1, Denise 
Dorsey, Jonathan Livny, Elisha Roberson, Marco Colonna, Scott J. Hultgren2, Thomas J. 
Hannan2 (1, co-first author, 2, co-corresponding author). My contributions to this manuscript 






Urinary tract infections (UTI) are common and recurrent. Both host genetics and UTI history 
impact susceptibility to recurrent UTI (rUTI) in women and in animal models. To identify shared 
patterns of host response that correlate with susceptibility, we investigated bladder inflammatory 
and transcriptional kinetics in acute and rUTI models. We found that TNFɑ signaling kinetics 
differed with mouse strain and infection history. Mice resistant to severe UTI/rUTI displayed a 
robust TNFɑ-dependent inflammation during the first 6 hours of acute cystitis, which waned by 
24 hours; mice that are susceptible varied in their early responses but were prone to severe 
inflammation at 24 hours post-infection. Depletion of TNFɑ in an rUTI model revealed that early 
TNFɑ signaling promoted colonization resistance via exfoliation of infected bladder cells, but 
prolonged TNFɑ signaling exacerbated inflammation, thereby worsening infection. In summary, 
changes in TNFɑ signaling kinetics impact alter host susceptibility to severe rUTI. 
3.3 Introduction 
Urinary tract infections (UTI) are very common and can be highly recurrent, leading to over $2 
billion in direct and indirect costs in the United States in 2010 (Foxman, 2010) and are ever 
increasing. The vast majority of these infections involve the lower urinary tract and specifically 
the urinary bladder, causing cystitis (bladder infection). Women are disproportionately affected: 
over 60% of women will experience at least one UTI during their lifetime (Foxman et al., 
2000a), and of these 20-30% will experience a recurrence within 6 months (Foxman et al., 
2000c). Some individuals experience highly recurrent UTI (6+ episodes per year) (Ikaheimo et 
al., 1996). Clinical studies of UTI show that the natural course of infection and symptoms can 
vary greatly among patients: for some, the infections are self-resolving within a few days, while 




1972). The basis for this variability may be due at least in part to the known risk factors for 
recurrent UTI (rUTI) in sexually active young women, which include a prior history of UTI (≥ 2 
previous UTI); first UTI before age 15; a maternal history of rUTI; and certain genotypic traits 
(e.g. TLR polymorphisms) (Hooton et al., 1996; Scholes et al., 2000) 
Over 80% of community-acquired UTI are caused by uropathogenic Escherichia coli (UPEC) 
(Gupta and Bhadelia, 2014; Ronald, 2003). Much has been discovered about the acute 
pathogenesis of UPEC in the urinary tract through the use of small animal models, which have 
both recapitulated and predicted findings in humans (Carey et al., 2016). During infection, UPEC 
adhere to and invade into bladder epithelial (urothelial) cells, replicate and aggregate into 
intracellular bacterial communities (IBCs), which allow the bacteria to increase in number and 
avoid innate immune defenses and the flow of urine (Gregory G. Anderson, 2003; Justice et al., 
2004; Mulvey et al., 1998). To circumvent ongoing infection, the host initiates defense 
mechanisms such as urothelial cell exfoliation (Mulvey et al., 1998), resident macrophage 
activation (Schiwon et al., 2014), and myeloid cell recruitment (Haraoka et al., 1999; Loughman 
and Hunstad, 2011; Schiwon et al., 2014). Previous studies in C3H/HeN mice revealed an early 
immune checkpoint that determines whether the host spontaneously resolves the infection or 
develops chronic cystitis with persistent bacteriuria, ongoing bladder inflammation, continuous 
infiltration of leukocytes, etc. (Hannan et al., 2010). Specifically, at 24 hours post-inoculation 
(hpi), elevated serum cytokines (IL-5, IL-6, G-CSF, CXCL1), significant bladder edema, and 
pyuria (neutrophils in urine) are the hallmarks of checkpoint activation. In mice that trigger the 
checkpoint, robust cyclooxygenase-2 (COX-2) expression by urothelial cells at 24 hpi promotes 
neutrophil transmigration through the urothelium, causing mucosal damage and ultimately the 




infection, whether self-resolving or chronic, was found to determine future susceptibility to 
rUTI, with those mice that developed chronic cystitis lasting 2 or more weeks prior to antibiotic 
therapy being highly susceptible to rUTI upon challenge, whereas those that spontaneously 
resolved infection prior to 2 weeks were highly resistant to challenge (Hannan et al., 2010; 
O'Brien et al., 2016b). Translating these findings, we found that serum cytokine biomarkers 
associated with more robust granulocytic responses, similar to those associated with chronic 
cystitis in mice, were also predictive of susceptibility to rUTI in women (Hannan et al., 2014).  
Here, we leveraged the power of mouse genetics, transcriptional analysis and multiple mouse 
models of UTI to interrogate non-behavioral clinical risk factors of rUTI in sexually active 
premenopausal women, i.e. genetics and UTI history. We discovered underlying molecular and 
cellular mechanisms that confer host resistance to manifestations of acute UTI and correlate with 
specific outcomes. In our different UTI models, we identified distinct patterns of bladder 
inflammation during acute cystitis that correlated with disease outcome. Transcriptomic analysis 
identified TNFɑ signaling as a major driver of this inflammation, whether associated with 
protective or harmful host responses, and in vivo TNFɑ depletion experiments confirmed the 
central role of this cytokine in directing acute bladder inflammation. Strikingly, we found that a 
prior infection significantly altered the kinetics of TNFɑ-mediated inflammation upon challenge, 
with significant consequences for host susceptibility to recurrent infection. These findings 






3.4.1 Host genetics impact acute bladder inflammation kinetics during UTI 
To investigate how host genetic background may affect susceptibility to severe acute and chronic 
UTI, we compared the host response to UPEC infection of the urinary bladder between two 
inbred mouse strains that together recapitulate two distinct UTI infection phenotypes seen in 
clinical studies of the natural course of UTI in women (Ferry et al., 2009; Foxman et al., 2000a): 
self-resolving infection vs. the development of chronic cystitis (Hannan et al., 2010). 
Experimental UTI was induced by transurethral inoculation of 108 colony-forming units (CFU) 
of the well-studied clinical UPEC cystitis isolate UTI89 into the bladders of 7-9 week old 
C57BL/6J and C3H/HeOuJ mice with no prior history of infection (“Juvenile Naive”). In this 
model, acute cystitis is mild to moderate in severity and spontaneously resolves within a few 
days in ~90% of C57BL/6J mice (Hannan et al., 2010) and this strain is thus referred to herein as 
“resistant” to chronic cystitis. In contrast, UTI89 infection of C3H/HeOuJ mice results in ~90% 
incidence of severe acute and chronic cystitis, and thus this strain is referred to herein as 
“susceptible” to chronic cystitis (Hannan et al., 2010). Scanning electron microscopy (SEM) of 
the infected bladder epithelium (urothelium) of Juvenile Naive C57BL/6J mice (resistant) and 
Juvenile Naive C3H/HeOuJ mice (susceptible) showed substantial differences during the course 
of acute cystitis (Figure 8A). At 6 hpi, the C57BL/6J bladder surface was visibly perturbed, with 
broad expanses of exfoliating superficial umbrella cells, surface-adherent bacteria, and 
accumulating neutrophils. At the same time point the urothelium of C3H/HeOuJ mice was 
relatively unperturbed, appearing more similar to uninfected tissue, with only sporadic small 
patches of surface-adherent bacteria and few exfoliating umbrella cells or accumulated 




bacteria and immune cells on the urothelial surface, whereas in C3H/HeOuJ mice the bladder 
surface showed evidence of urothelial cell inflammation with widespread urothelial exfoliation, 
surface bacterial colonization, and marked immune cell accumulation. These findings correlated 
with a blinded histopathological assessment of hematoxylin and eosin-stained bladder sections, 
using a well-established scoring system that assesses the degrees of inflammatory cell infiltrate, 
edema, and urothelial integrity (Hopkins et al., 1998) (Figure 8B). Infected bladders of 
C57BL/6J mice at 6 hpi displayed moderate signs of inflammation, including edema and limited 
infiltration of immune cells, but by 24 hpi had dramatically reduced bladder edema and mild to 
moderate levels of other parameters of histopathology, such as immune cell infiltration. In 
contrast, C3H/HeOuJ bladders displayed mild signs of inflammation at 6 hpi, but at 24 hpi, 
bladder inflammation was severe in most mice, with marked edema and immune cell infiltration, 
and frequent urothelial erosion down to the basement membrane. These findings demonstrate a 
kinetic difference in the gross histological and immunopathological manifestations of bladder 
mucosal responses during experimental UPEC infection in a mouse strain that is likely to self-
resolve infection vs. a mouse strain that is likely to develop chronic cystitis. As well, these 
findings are consistent with earlier studies showing that severe mucosal immune responses at 24 
hpi correlate with the development of chronic cystitis (Hannan et al., 2010). 
The different kinetics of bladder inflammation were not a consequence of early differences in 
bladder bacterial burdens, which were essentially the same (~106 CFU/bladder) in C57BL/6J and 
C3H/HeOuJ mice at 6 hours (Figure 9A). However, as seen previously, bladder bacterial burdens 
in C57BL/6J mice dropped precipitously by 24 hpi (mean log10-transformed titer reduced from 
6.6 to 4.0) and 72 hpi (mean log10-transformed titer reduced from 6.6 to 4.9), with only 3 of 9 




at 24 and 72 hpi, respectively. In contrast, bladder bacterial burdens remained at high levels in 
nearly all mice throughout acute infection, with 9 of 10 and 8 of 10 C3H/HeOuJ mice having 
bladder bacterial burdens >106 CFU at 24 and 72 hpi, respectively. Further, bladder weights 
differed significantly between C57BL/6J and C3H/HeOuJ mice, indicating differences in edema 
and immune cell infiltration. In C57BL/6J mice, bladder weights peaked at 6 hpi, then gradually 
decreased over 72 hpi. In C3H/HeOuJ mice, bladder weights increased only slightly during the 
first 12 hpi, even though bladder titers were similar to those in C57BL/6J mice during this time. 
However, after 12 hpi, instead of decreasing, C3H/HeOuJ bladder weights peaked at 24 hpi and 
remained elevated at 72 hpi (Figure 9B). 
Recruitment of myeloid cells, particularly neutrophils, to the urinary bladder in the late acute 
phase of bladder inflammation (around 24 hpi) has been previously demonstrated to contribute to 
bladder mucosal damage, allowing chronic infection in mice (Hannan et al., 2014). Furthermore, 
high levels of CCL2, CXCL1, and CXCL8 in the serum of women with UTI have been shown to 
constitute a biomarker signature predicting rUTI (Hannan et al., 2014). To investigate the nature 
of the inflammation seen in our inbred mouse strains, bladder homogenate supernatants collected 
at 6 and 24 hpi were evaluated for the presence of 23 soluble cytokines by a cytometric bead 
array. Three cytokines displayed the same kinetic patterns as the bladder weights did: the 
proinflammatory cytokine IL-6, the neutrophil chemokine CXCL1, and the monocyte chemokine 
CCL2 peaked in C57BL/6J mice at 6 hpi and peaked in C3H/HeOuJ mice at 24 hpi (Figure S15). 
To better understand these kinetics, bladder homogenate supernatants were assayed at 6, 12, 24 
and 72 hpi for these three cytokines by ELISA (Figure 9C), confirming that cytokine levels 
peaked at 6 hpi in C57BL/6J mice and at 24 hpi in C3H/HeOuJ mice. Taken together, these data 




two strains, but that both the timing of onset and persistence of the response differ significantly 
between strains. 
3.4.2 Bladder transcriptomic profiles reveal differential TNFɑ-dependent 
inflammatory signatures that are strain-specific 
We reasoned that the different inflammatory and infection patterns observed in mice with 
different susceptibility to severe chronic UTI would be reflected by differences in bladder gene 
expression patterns during acute infection that would illuminate the critical signaling pathways 
upstream of these responses. Therefore, we performed RNA-seq on whole bladders obtained at 
3.5, 6, and 24 hpi. At each time point, UTI89-infected mice were compared with mock (PBS)-
infected mice of the same strain (Figure 10A, Figure S17). We first observed that the change in 
the number of significantly differentially expressed genes (DEGs) between 6 and 24 hpi (Figure 
10A) mirrored the changes in magnitude of bladder inflammation demonstrated above (Figure 8, 
Figure 9). C57BL/6J mice (resistant) showed the greatest number of DEGs at 6 hpi (7174 genes, 
increased from 3529 at 3.5 hpi), as well as the greatest fold changes and significances (Figure 
S17A), followed by a decrease in the number of DEGs at 24 hpi (3101, with reduced fold 
changes and significances). In contrast, DEGs in C3H/HeOuJ mice (susceptible) started low at 
3.5 hpi (1173 genes), increased at 6 hpi (5003 genes) and peaked at 24 hpi (7975 genes). 
Pathway analysis of the biological processes represented by the most significantly differentially 
expressed genes showed that in both mouse backgrounds, the majority of pathways were related 
to inflammation and immunity, including immune cell development and recruitment, cytokine 
expression and pattern recognition receptor signaling (Table S6). Among the most highly 
upregulated pathways were those downstream of tumor necrosis factor-alpha (TNFɑ), including 
both TNFR1 and TNFR2 signaling pathways. TNFɑ is a cytokine involved in systemic 




upregulated in C57BL/6 mice shortly after bladder infection (2 hpi) (Chan et al., 2013), 
suggesting its importance in mounting a strong innate immune response to acute UTI. We found 
that the timing and levels of expression of genes known to be activated by TNFɑ (indicated by 
the blue-red spectrum) correlated with inflammation kinetics: comparing within a mouse strain 
over time, C57BL/6J mice (resistant) showed higher expression at 3.5 and 6 hpi that was reduced 
at 24 hpi, whereas C3H/HeOuJ mice (susceptible) showed low expression levels at 3.5 hpi and 
higher levels at 6 hpi and 24 hpi (Figure 10B). In terms of intensity across strains, at 3.5 hpi and 
6 hpi, C57BL/6J mice showed stronger activation of TNFɑ pathways than C3H/HeOuJ mice, 
while at 24 hpi, this was reversed. Specifically, 32 of 49 (65%) and 23 or 29 (79%) genes in the 
TNFR1 and TNFR2 signaling pathways, respectively, were up-regulated up to 80-fold, including 
kinases (e.g., MAP2K4), enzymes (e.g., Birc3), cytokines (e.g., Tnf), membrane receptors (e.g., 
Tnfrsf1a), and transcription factors (e.g., NF-κB). Only a few genes, mostly kinases (e.g., Pak3) 
that are primarily involved in other, non-inflammatory processes (e.g., actin cytoskeleton 
signaling), were down-regulated (Table S7). We also specifically analyzed the expression pattern 
of cyclooxygenase-2 (COX-2), encoded by the Ptgs2 gene, a downstream target of TNFɑ that is 
critical in mediating urothelial inflammation during severe acute cystitis (Hannan et al., 2014; 
O'Brien et al., 2016). Ptgs2 and Tnf expression levels followed similar patterns, peaking at 6 hpi 
and 24 hpi in C57BL/6J and C3H/HeOuJ mice, respectively (Figure 10C). 
3.4.3 TNFɑ depletion impacts inflammation at different time points 
according to mouse strain 
To elucidate whether early TNFɑ pathway activation plays an essential role during acute UTI, 
we depleted TNFɑ prior to infection and measured parameters of bladder colonization and 
inflammation during acute infection. Juvenile Naive mice received anti-TNFɑ antibody, or 




expression of the pro-inflammatory cytokines IL-6 and CXCL1 (Figure 10E) were reduced in 
TNFɑ-depleted C57BL/6J (resistant) mice at 6 hpi, suggesting that without TNFɑ pathway 
activation, the early phase host inflammatory response is weakened. However, bladder bacterial 
titers at 6 or 24 hpi did not differ between TNFɑ-depleted mice and controls (Figure 10D), 
suggesting the presence of alternative (TNFɑ-independent) systems that promote bacterial 
clearance. In TNFɑ-depleted C3H/HeOuJ (susceptible) mice no statistically significant change in 
bladder edema was observed relative to isotype-treated controls at either 6 or 24 hpi (data not 
shown). We also investigated C3H/HeN mice, another C3H sub-strain susceptible to developing 
severe acute and chronic cystitis. In Juvenile Naive C3H/HeN mice the phenotype is less 
extreme than in C3H/OuJ mice, meaning that fewer mice develop chronic cystitis that does not 
self-resolve (~50% chronic infection in C3H/HeN vs. ~90% in C3H/HeOuJ). The development 
of chronic cystitis in C3H/HeN mice was previously shown to be dependent upon COX-2 
activity (Hannan et al., 2010, Hannan et al, 2014). We found that C3H/HeN mice displayed a 
bladder transcriptional pattern similar to C3H/HeOuJ mice at 3.5 and 6 hpi (Figure S16), with 
mild to moderate responses. At 24 hpi there was a bimodal response that suggested diverging 
bladder inflammation patterns: some mice had a response similar to C3H/HeOuJ (i.e. the 
development of severe bladder inflammation) and other mice had a response similar to C57BL/6 
mice (i.e. muted bladder inflammation at 24 hpi) (Figure S16A). TNFɑ pathway expression was 
also enriched during acute cystitis in Juvenile Naive C3H/HeN mice, particularly after 6 hpi, 
similar to C3H/HeOuJ mice (Table S6). TNFɑ depletion in C3H/HeN mice resulted in a 
significant reduction in bladder edema at 24 hpi, but not in overall bacterial burdens, relative to 
isotype-treated controls (Figure 10F). Taken together, these data show that the different patterns 




susceptibilities to UTI, and TNFɑ depletion had a measurable impact on the intensity of 
inflammation at these different stages, though it was not sufficient to significantly impact acute 
bacterial burdens. As well, TNFɑ depletion prior to infection did not significantly affect the 
incidence of chronic cystitis in superinfected C57BL/6J mice or C3H/HeOuJ, although a trend of 
increased chronic cystitis was observed in TNFɑ-depleted C3H/HeOuJ mice (Figure S16B). This 
suggests that TNFɑ pathway activation alone is not sufficient to dictate strain resistance or 
susceptibility to acute or chronic cystitis in Juvenile Naive mice and that additional factors 
related to genetic background are responsible for determining inherent UTI susceptibility in these 
strains.  
3.4.4 History of UTI alters acute bladder inflammation kinetics during 
recurrent UTI 
A history of UTI is the second leading risk factor, after sexual activity, for rUTI in women 
(Hooton et al., 1996). Thus, to assess the contribution of host infection history to rUTI 
susceptibility while also controlling for the confounding factor host genetic background, we 
expanded our findings in Juvenile Naive mice to our previously described recurrent cystitis 
model in Adult (16 week old) C3H/HeN mice. In this model, isogenic mice have divergent 
susceptibilities to rUTI as a consequence of the outcome of a prior infection (either self-resolving 
or chronic in nature), due to bladder remodeling that alters the pathophysiology of acute cystitis 
upon bacterial challenge (secondary infection) (O'Brien et al., 2016). Relative to age-matched 
Adult Naive mice, C3H/HeN mice that spontaneously resolved a prior acute bladder infection are 
resistant to future challenge infections and are referred to herein as “Resolved”, whereas mice 
with a history of chronic cystitis lasting two weeks or more prior to antibiotic therapy to sterilize 
the bladder are predisposed to developing severe rUTI upon challenge infection and are referred 




develop chronic cystitis in response to challenge infection (susceptible), whereas Resolved mice 
are almost completely resistant to chronic cystitis during the challenge infection (Hannan et al., 
2010, O'Brien et al., 2016). We performed acute UPEC infections in Resolved and Sensitized 
mice during “convalescence” (four weeks after the initiation of antibiotics to clear the initial 
infection) and compared them to age-matched Adult Naive mice as a control. Histopathological 
analysis of the urinary bladder after UPEC infection revealed robust inflammation at 6 hpi in all 
“convalescent” (Resolved and Sensitized) mice relative to Adult Naive mice, but inflammation 
waned in most Resolved mice by 24 hpi, while the bladder pathology scores of Sensitized mice 
had a clear bimodal distribution, with some resolving and others having persistent severe 
inflammation at 24 hpi (Figure 11A). The degree of bladder inflammation at 6 hpi did not 
correlate with bladder bacterial burdens, as Adult Naive mice had bladder bacterial titers that 
were generally ten-fold or more higher than in Resolved or Sensitized mice (Figure 11B), in line 
with previous observations (O'Brien et al., 2016b). However, similar to what has been reported 
previously, at 24 hpi bladder bacterial burdens in a subset of Sensitized mice bloomed to surpass 
those of Adult Naive mice, many were >106 CFU (severely infected), while a greater proportion 
of Resolved mice were beginning to clear the challenge infection (Figure 11B). Strikingly, 
average bladder weights peaked at 6 hpi in both Resolved and Sensitized mice, whereas Adult 
Naïve bladder weights peaked at 24 hpi, similar to the severity of the histopathology Figure 
11C). Bladder weights tended to decline in Resolved mice by 24 hpi, whereas they tended to stay 
high in Sensitized mice. Bladder levels of the pro-inflammatory cytokines IL-6, CXCL1, and 
CCL2 followed a similar pattern, with a more obvious reduction in expression level at 24 hpi in 




C3H/HeN mice confers the ability to mount a robust early phase (6 hpi) inflammatory response 
to UPEC infection not seen in Adult Naive mice. 
3.4.5 Transcriptomic analysis indicates that convalescent C3H/HeN mice 
have acquired the capacity to mount a strong early phase TNFα 
response to UPEC challenge 
To explore the transcriptomic signatures driving the different responses in C3H/HeN mice with 
different UTI histories, we performed RNA-seq on whole bladders from Adult Naive, Sensitized 
and Resolved mice obtained at 3.5, 6 and 24 hpi (Figure 12, Figure S17) and compared the 
differential gene expression relative to mock infected mice at 24 hpi. The transcriptomic profiles 
of C3H/HeN bladders over the first 24 hours after UPEC challenge displayed patterns similar to 
those seen in the inflammatory profiles (Figure 12A). In Adult Naïve mice, the number of DEGs 
increased with time, starting low (291 genes at 3.5 hpi) and peaking at 24 hpi (9249 genes). 
However, in both Resolved and Sensitized mice, the number of DEGs were relatively low at 3.5 
hpi (127 and 944 genes, respectively), but peaked at 6 hpi (10872 and 10133 genes, 
respectively), and decreased somewhat by 24 hpi (7793 and 8935 genes, respectively). 
Interestingly, TNFɑ pathway genes displayed a more complex pattern. At 3.5 hpi, 3 of 8 
Resolved and 7 of 8 Sensitized mice demonstrated robust activation of up to 16 TNFɑ pathway 
genes, which differentiated them from the other mice in the experiment, including all infected 
Adult Naïve mice (Figure 12B). All Resolved and Sensitized mice, but only one of four Adult 
Naïve mice, demonstrated robust TNFɑ pathway activation at 6 hpi, with significant up-
regulation of up to 23 TNFɑ pathway genes. TNFɑ activation was sustained at 24 hpi only in a 
subset of Adult Naïve (2 out of 4) and Sensitized (4 out of 7) mice, but not in any Resolved mice. 
The fold change in Ptgs2 (COX-2) expression was again co-regulated with Tnf expression: it 




and was reduced by 24 hpi in Resolved mice (Figure 12C), confirming that Ptgs2, a TNFɑ 
downstream target, is strongly associated with host susceptibility to UTI. Thus, the gene 
expression profiles of convalescent mice demonstrate that a prior bladder infection, whether 
chronic (Sensitized) or self-limiting (Resolved), confers to C3H/HeN mice the ability to have a 
robust early (6 hpi) inflammatory and TNFɑ signaling response to a subsequent challenge 
infection. However, among previously infected mice (Sensitized and Resolved), TNFɑ signaling 
is only sustained through 24 hpi in Sensitized mice and is highly correlated with sustained 
bladder Ptgs2 expression, which is known to mediate mucosal immune damage to the urothelium 
and precipitate severe chronic and recurrent cystitis (Hannan et al., 2014; O'Brien et al., 2016).   
3.4.6 TNFɑ signaling restricts bladder colonization in Resolved mice by 
promoting the exfoliation of infected bladder epithelial cells  
To investigate the specific mechanism of TNFɑ affecting host susceptibility to rUTI, we depleted 
TNFɑ prior to bacterial challenge of Adult Naïve, Resolved and Sensitized mice as described 
above. We hypothesized that early robust TNFɑ signaling exerts a protective effect in Resolved 
mice, but that late robust TNFɑ signaling induces detrimental inflammation in Sensitized mice, 
regardless of early TNFɑ signaling status. Upon TNFɑ depletion, at 6 hpi, bladder titers in 
Resolved mice were increased, while titers in Adult Naïve and Sensitized mice were unchanged 
(Figure 13A). In addition, bladder titers of TNFɑ-depleted Resolved mice were still higher than 
control-treated mice at 24 hpi (Figure S18A). Combined with a reduction in urine titers of TNFɑ-
depleted Resolved mice (Figure S18A), we hypothesized that the intracellular bacterial 
population in the bladder was increased, likely in the form of intracellular bacterial communities 
(IBCs), which allow the bacteria to evade host immune responses and establish robust bladder 
colonization (Anderson et al., 2003; Justice et al., 2004; Mulvey et al., 1998). Notably, we 




whereas 9-65 IBCs were detected in Adult Naive mice (O'Brien et al., 2016). Here we found that 
TNFɑ depletion resulted in significantly more IBCs in Resolved bladders at 6 hpi, compared to 
isotype treated controls (Figure 13B). In contrast, TNFɑ depletion did not affect IBC counts at 6 
hpi in Adult Naive or Sensitized mice (Figure 13B). 
We then sought to delineate how TNFɑ signaling restricts IBC formation in Resolved mice. We 
found that TNFɑ depletion did not affect the intracellular bladder bacterial burdens in Resolved 
mice at 3 hpi (Figure S18B), nor did it affect the number of IBCs present at 4.5 hpi (Figure 
S18C, D), indicating that TNFɑ signaling was neither limiting bacterial entry into urothelial cells 
nor affecting early IBC formation. We reasoned therefore that TNFɑ signaling was inducing 
exfoliation of the IBC-containing urothelial cells into the urine. SEM analysis of the urothelial 
surface of TNFɑ-depleted vs. control-treated Resolved mice at 6 hpi revealed subtle but 
consistent differences: without TNFɑ depletion, clusters of neutrophils regularly gathered on the 
bladder surface, often underneath or around bulging umbrella cells that were likely ready to 
exfoliate, or in the gaps left by already exfoliated cells (Figure 13C), consistent with previous 
observations (O'Brien et al., 2016). With TNFɑ depletion, however, the bladder surface appeared 
calmer, with occasional bacteria on the surface and fewer neutrophils that were more scattered, 
rather than clustered, and little evidence of exfoliation (Figure 13C). Concordantly, pyuria and 
edema were reduced in TNFɑ-depleted Resolved mice at 6 hpi (Figure 13D). Neutrophil 
recruitment to the bladder and subsequent transmigration into the lumen is associated with 
urothelial exfoliation and is required to prevent overwhelming infection (Haraoka et al., 1999), 
but excessive neutrophil-induced inflammation can increase the incidence of severe acute and 
chronic cystitis by causing mucosal wounding (Hannan et al., 2014). To test whether TNFɑ 




across the urothelium, we performed flow cytometry of single cell suspensions generated from 
Resolved bladders at 6 hpi. TNFɑ-depleted Resolved mice had significantly fewer bladder-
associated neutrophils than isotype-treated control mice (Figure 13E). Thus, in C3H/HeN mice, a 
history of self-resolving UTI imparts colonization resistance that protects against rUTI and is 
mediated by bladder TNFɑ signaling, which promotes neutrophilic inflammation and umbrella 
cell exfoliation, thereby causing the shedding of IBC-containing cells. 
3.4.7 TNFɑ signaling promotes bladder severe inflammation during late 
acute cystitis in Sensitized mice 
In Sensitized mice, TNFɑ depletion did not restore IBC formation at 6 hpi (Figure 14B), 
suggesting that colonization resistance during the first hours of challenge infection is unrelated to 
TNFɑ signaling in these mice. Previous work revealed that COX-2 mediated inflammation in the 
bladders of Sensitized mice during the first 24 hours of challenge infection overcame this 
colonization resistance to allow severe acute and chronic rUTI (Hannan et al., 2014, O’Brien et 
al., 2016). Therefore, we reasoned that prolonged TNFa signaling was exacerbating COX-2 
inflammation, leading to severe rUTI in Sensitized mice. At 24 hpi TNFɑ depletion resulted in a 
shift in overall bladder bacterial burdens, as 13 out of 22 control-treated Sensitized mice (59%) 
vs. 6 out of 21 TNFɑ-depleted mice (29%) were still severely infected (>106 CFU/bladder) 
(Figure 14A). Bladder titers of the control-treated mice showed a clear clustering of high titer 
bacterial burdens (>106 CFU) that was absent upon TNFɑ depletion (Figure 14B). Bladder 
inflammation (edema) was also significantly reduced (Figure 14C). Thus, by 24 hpi, robust 
TNFɑ signaling in Sensitized mice induces more severe inflammation and promotes the 






Although UTI are among the most common infectious diseases, individuals vary dramatically in 
their susceptibility to infection. While two strong non-behavioral host-intrinsic risk factors, 
genetic background and infection history (Hooton et al., 1996; Scholes et al., 2000), are well 
recognized, the specific mechanisms by which these risk factors affect susceptibility are poorly 
understood. UTI can develop rapidly in premenopausal women within hours after bladder 
exposure to uropathogenic bacteria, most often in conjunction with sexual activity (Lindsay E. 
Nicolle, 1982). Previous studies in mice revealed that the outcome of infection, whether mild and 
self-resolving or severe and persistent, is determined during the first 24 hours of infection 
(Hannan et al., 2010; Hannan et al., 2014; Schwartz et al., 2015). We hypothesized that early 
host-pathogen interactions trigger time-sensitive checkpoints that determine the outcome of 
infection, but that the kinetics and character of these disease checkpoints differ with host 
genetics and history of bladder infection. In this study, we investigated the nature of acute 
inflammation during the first three days of UPEC infection in two different cohorts of mice: 1) 
naïve mice of two different, distantly related inbred strains that represent different infection 
susceptibility phenotypes; and 2) mice from the same inbred strain that differ in their 
susceptibility due to differences in disease history. 
We found that mice that are resistant vs. susceptible to severe acute and chronic cystitis share 
similar pattern of inflammatory and transcriptomic response, despite differing in their genetic 
backgrounds or disease histories. In resistant mice (Juvenile Naïve C57BL/6J, C3H/HeN 
Resolved), inflammatory profiles and gene expression, particularly TNFa signaling, peak at 6 hpi 
and wane by 24 hpi, while in susceptible mice (Juvenile Naïve C3H/HeOuJ, C3H/HeN 




variable. Concordantly, TNFɑ signaling shared similar kinetics with those of inflammatory and 
transcriptomic profiles, not only as a consistent hallmark of inflammation but also a 
distinguishing manifestation with regards to the timing of onset and duration between resistant 
and susceptible mice.   
TNFɑ pathway signaling is a key determinant of the early bladder response to experimental 
UPEC infection that varies in character, timing, duration, and effect depending upon host genetic 
background and UTI history. This cytokine can activate a wide range of downstream pathways 
(NF-κB, caspase-8, MAPK, etc.) to induce systemic and local inflammation, and to mediate the 
balance between cell death and cell proliferation in response to stimuli such as pathogen-
associated molecular patterns (e.g., LPS) (Thomas D. Geppert, 1994 ). Its involvement in both 
tissue damage and tissue regeneration represents an interesting functional duality, and 
consequently, the host must tightly regulate TNFɑ activation to prevent harmful, excessive 
inflammation. Here we found that mice that are resistant to severe acute and chronic cystitis -- 
Juvenile Naïve C57BL/6J and C3H/HeN Resolved mice -- shared a pattern of TNFɑ signaling 
that was robust in the early phase of infection (up to 6 hpi) and waned in the later phase (6 to 24+ 
hpi). In Juvenile Naive C57BL/6J mice, abrogation of TNFɑ signaling resulted in reduced 
bladder edema (Figure 10D) and reduced levels of IL-6 and CXCL1 at 6 hpi, but did not impact 
bacterial burdens. In Resolved C3H/HeN mice, abrogation of TNFɑ signaling resulted in 
increased bacterial burdens at 6 and 24 hpi, which we found was due to impaired exfoliation of 
intracellular bacterial community (IBC)-containing bladder epithelial cells resulting from 
reduced neutrophil recruitment to the bladder. Exfoliation has been shown to be a double-edged 
sword that can benefit both host and pathogen during UTI: while it clears adherent and 




dissemination of bacteria to deeper layers of the urothelium that further leads to chronic cystitis 
(Mulvey et al, 2001, Mysorekar et al, 2006). However, in Resolved C3H/HeN mice, TNFɑ-
induced exfoliation occurred early enough to eliminate the few IBC-containing superficial 
urothelial cells without promoting bacterial dissemination. TNFɑ also induces downstream 
targets (e.g. inflammatory cytokines such as CXCL1) that stimulate neutrophil recruitment to the 
site of infection, supporting our observations of decreased exfoliation and neutrophil infiltration 
in TNFɑ-depleted C3H/HeN mice. However, we found that TNFɑ depletion did not significantly 
alter the number of IBCs at 6 hpi in C57BL/6J mice, and a prior study found no effect on 
neutrophil recruitment to the bladder in TNFR-/- vs WT C57BL/6J at 6 hpi (Schiwon et al., 
2014). Taken together, these observations suggest an alternative mechanism, likely genotype-
dependent, that nonetheless converges on TNFɑ signaling to promote resistance to UTI.  
In contrast to resistant mouse strains, susceptible mice -- Juvenile Naïve C3H/HeOuJ, C3H/HeN 
Adult Naïve and C3H/HeN Sensitized mice -- shared a pattern of robust-late-phase TNFɑ 
signaling, although early phase inflammation was more variable among these groups. We found 
that in both mouse models, the kinetics of TNFɑ expression and pathway activation correlated 
strongly with the kinetics of Ptgs2 (COX-2) expression, suggesting that TNFɑ signaling may be 
associated with Ptgs2 expression. COX-2 signaling is known to affect susceptibility to chronic 
and recurrent UTI in C3H/HeN mice, and experimental suppression of COX-2-mediated acute 
inflammation prevented chronic and recurrent UTI (Hannan et al., 2014, O'Brien et al., 2016). 
Sensitized mice were unable to harbor IBCs in the presence or absence TNFɑ signaling, probably 
because of their previously described significantly smaller urothelial cell size (O'Brien et al., 
2016). However, in Sensitized mice TNFɑ depletion reduced the severity of bladder 




combined with the data from Juvenile Naïve C3H/HeOuJ mice, we conclude that robust TNFɑ 
signaling and severe bladder inflammation that persists during late acute cystitis, namely 
between 6 and 72 hpi, is a signature of host susceptibility to severe acute and chronic UTI. 
Extended TNFɑ signaling in the bladder is associated with persistent severe inflammation and 
neutrophil infiltration. Previously, severe inflammation and neutrophil transmigration through 
the bladder was shown to cause urothelial barrier damage and increased incidence of chronic 
cystitis (Hannan et al., 2014). Here, we observed that both Resolved and Sensitized C3H/HeN 
mice mounted strong early TNFɑ signaling and COX-2 expression, similar to Juvenile Naïve 
C57BL/6J mice, yet showed different susceptibilities to severe rUTI, suggesting that early TNFɑ 
signaling alone is not sufficient for resolution of recurrent infection. Interestingly, Resolved mice 
treated with anti-TNFɑ have increased bacterial burdens, but are still resistant to chronic rUTI, 
indicating that these mice do not mount prolonged COX-2 dependent inflammation regardless of 
bacterial burden. What the resistant mice have in common is the ability to mount robust early 
inflammatory responses that are rapidly quenched during the later acute phase, allowing bladder 
healing. The nature of TNFɑ signaling is greatly affected by its timing, which further determined 
disease outcome. 
In the present study we did not identify the cell type(s) responsible for making TNFɑ. TNFɑ 
binds to TNFR1 (expressed in most tissues, including urothelial cells) and/or TNFR2 (typically 
expressed by immune cells) and can activate distinct signaling cascades based on the receptors it 
binds to (H Wajant, 2003). As well, TNFɑ can function in either soluble or membrane-bound 
form, the latter being the precursor of the former; both forms possess functional pleiotropy. Even 
in the membrane-bound form, TNFɑ is able to activate both TNFR1 and TNFR2 to be involved 




cytokines, mediation of cytotoxic activity, etc., to promote host defense (Horiuchi et al., 2010). 
As we were not able to detect significant differences in levels of soluble TNFɑ by ELISA during 
early phase in Juvenile Naïve C57BL/6J mice (data not shown), membrane-bound TNFɑ may be 
the critical mediator in inflammation in our models. Finally, our study was limited to different 
mouse models, and thus does not directly address the role of TNFɑ in women with UTI. 
However, we note with interest that anti-TNFɑ therapy used in treating rheumatoid arthritis is 
associated with various infection risks, including a slight increase in UTI rate (Goh et al., 2013)(, 
suggesting potential relevance of TNFɑ signaling in affecting susceptibility to UTI in the clinic.  
In summary, we show here that patterns of acute host inflammatory and transcriptomic responses 
correlate with host resistance to UTI, and specifically that TNFɑ signaling is a critical central 
mediator of bladder mucosal immune response to UPEC. Overall, these findings suggest that 
non-behavioral risk factors, i.e. host genetic background and infection history, which we have 
modeled here, contribute to host responses to UTI through shaping both the nature and the 
kinetics of the mucosal immune response. TNFɑ-mediated early phase inflammation protects the 
host by promoting rapid clearance of the pathogen via mediating bladder inflammation and 
disrupting the IBC cycle, while TNFɑ-induced, likely COX-2-mediated, late phase inflammation 
exacerbates mucosal damage and increases the severity of rUTI. Understanding how and why 
patients with recurrent infections have altered mucosal responses to bacteria is critical for 
developing effective new therapies that target the inflammatory response as an alternative 






3.6 Figures  
 
Figure 8. 
The timing and severity of bladder immunopathology correlates with host susceptibility to 
severe UTI. Juvenile Naive C57BL/6J (resistant) and C3H/HeOuJ (susceptible) mice were 
infected with 108 CFU UTI89 or PBS and sacrificed at denoted time points. A) Scanning electron 
microscopy was used to assess the luminal surface. Scale bar = 50 um. A total of n = 6 mice 
were used in N=2 independent experiments. B and C) Hematoxylin and eosin (H&E)-stained 
bladder sections were assessed in a blinded fashion. N=2 independent experiments were 
conducted with n=5 mice per group. B) Representative images are shown; scale bar = 50 um. C) 
Histopathology scores were determined as described in Hopkins et al., 1998. *P<0.05, **P<0.01, 







Bladder pathophysiology suggests a host-specific biphasic pattern of inflammation during 
acute cystitis. Juvenile Naive C57BL/6J (resistant) and C3H/HeOuJ (susceptible) mice were 
infected with 108 CFU UTI89 or PBS and sacrificed at denoted time points.  A) Bladder bacterial 
burdens and B) bladder edema were assessed in N=2-3 independent experiments with n=5-
11mice per group. C)Levels of the cytokines CXCL1, IL-6, and CCL2 were assessed by ELISA 
of bladder homogenate supernatants from panel A, in N = 3 independent experiments. Bars 
indicate median values; for box and whisker plots, boxes extend from 25th to 75th percentiles and 
whiskers indicate minimum and maximum values.  *P<0.05, **P<0.01, ***P<0.001, Mann-







Time-course transcriptomic profiles and TNF⍺ pathway activation extent of inbred mice 
reflect the host-specific biphasic response pattern during acute inflammation. (A-C) 
Juvenile Naive C57BL/6J (resistant) and C3H/HeOuJ (susceptible) mice were infected with 108 
CFU UTI89 or PBS. RNA-seq was performed on whole bladders obtained at the indicated time 
points. N=3 independent experiments were performed with n=x-y mice per group. A) The 
number of significantly differentially expressed genes at each time point are shown for each 
mouse strain. B) Heatmaps of expression of up-regulated genes in TNFa signaling pathways 
from the mice in A. Black are UTI89-infected and grey are mock-infected C57BL/6J mice; red 
are UTI89-infected and pink are mock-infected C3H/HeOuJ mice. The dendrogram at the top of 
each heat map was produced by hierarchical clustering of gene expression. Specific fold changes 
and down-regulated genes are listed in Table S7. C) Shown are Ptgs2 (COX-2) and Tnf log2 fold 
changes at the indicated time points. D-G) Mice were treated with anti-TNF⍺ or isotype control 
antibody 18 hours prior to 108 CFU UTI89 infection, and sacrificed at denoted time points. N=2-
3 independent experiments were conducted with n=x-y mice per group. D) Bladder bacterial 
burdens, E) bladder edema, and F) bladder expression of the pro-inflammatory cytokine IL-6 and 
CXCL1 were assessed in C57BL/6J (resistant) mice. G) Bladder edema was assessed in Juvenile 
Naive C3H/HeN mice (susceptible). *P<0.05, **P<0.01, Mann-Whitney U test (two-tailed for 








C3H/HeN mice with a history of infection are able to mount strong early acute response 
compared to Adult Naive mice. C3H/HeN Resolved and Sensitized mice, and Adult Naive 
mice as a control, were infected with 108 CFU UTI89 or PBS and sacrificed at denoted time 
points. A and B) Hematoxylin and eosin (H&E)-stained bladder sections were assessed in a 
blinded fashion. N=2 independent experiments were conducted with n=5-9 mice per group. A) 
Representative images are shown; scale bars = X microns. B) Histopathology scores were 
determined as described in Hopkins et al., 1998. C and D) Bladder bacterial burdens (C) and 
bladder edema (D) were assessed in N=2-3 independent experiments with n=x-y mice per group. 
E) Levels of the cytokines CXCL1, IL-6, and CCL2 were assessed by ELISA of bladder 
homogenate supernatants from panel C, in N = 3 independent experiments. Bars indicate median 
values; for box and whisker plots, boxes extend from 25th to 75th percentiles and whiskers 
indicate minimum and maximum values.  *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, 









C3H/HeN mice with a history of infection are able to mount strong early acute response 
compared to Adult Naive mice. C3H/HeN Resolved and Sensitized mice, and Adult Naive 
mice as a control, were infected with 108 CFU UTI89 or PBS and sacrificed at denoted time 
points. A and B) Hematoxylin and eosin (H&E)-stained bladder sections were assessed in a 
blinded fashion. N=2 independent experiments were conducted with n=5-9 mice per group. A) 
Representative images are shown; scale bars = X microns. B) Histopathology scores were 
determined as described in Hopkins et al., 1998. C and D) Bladder bacterial burdens (C) and 
bladder edema (D) were assessed in N=2-3 independent experiments with n=x-y mice per group. 
E) Levels of the cytokines CXCL1, IL-6, and CCL2 were assessed by ELISA of bladder 
homogenate supernatants from panel C, in N = 3 independent experiments. Bars indicate median 
values; for box and whisker plots, boxes extend from 25th to 75th percentiles and whiskers 
indicate minimum and maximum values.  *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, 







TNF⍺ reduces bacterial colonization and increases bladder inflammation in Resolved mice 
at 6 hpi by promoting neutrophil recruitment to the bladder and subsequent exfoliation of 
infected cells. Adult Naïve and Resolved mice were treated with anti-TNF⍺ or isotype control 
antibody 18 hours prior to infection with 107 CFU UTI89, and sacrificed at 6 hpi. A) Bladder 
titers and B) intracellular bacterial communities (IBCs) were enumerated in N=7 independent 
experiments with n= 3-9mice per group. C) Scanning electron microscopy was used to assess the 
bladder luminal surface in N=2 independent experiments with n=6 mice per group. Scale bars = 
50 µm; white boxes outline areas visualized at a higher magnification below. D) Bladder edema 
and E) pyuria were assessed in Resolved mice shown in A. E) Flow cytometry was performed on 
bladder single cell suspensions from Resolved mice in N=2 experiments with n=4-5 mice per 
group. Neutrophils were defined as CD45+, CD11b+, Ly6G+, F4/80- cells. Data points represent 
actual values for each mouse and bars represent median values. *P<0.05, **P<0.01, Mann-









TNF⍺ depletion in Sensitized mice reduces inflammation and severe infection at 24 hpi 
through regulation of COX-2 expression. Sensitized mice were treated with anti-TNF⍺ or 
isotype control antibody 18 hours prior to 108 CFU UTI89 infection and sacrificed at denoted 
time points. N=2-3 independent experiments with n=17-22 mice per group were performed. A) 
Shown is the incidence of severe infection, defined as >106 CFU per bladder. *P<0.05, Barnard’s 
test (two-sided).B) Bladder titers and C) bladder edema were assessed. *P<0.05, Mann-Whitney 








Bladder cytokines of C57BL/6J and C3H/HeOuJ at 6 and 24 hpi UTI89 infected or PBS-mock 






Volcano plot of DEGs in Juvenile Naïve C57BL/6J, C3H/HeOuJ, and C3H/HeN, 108 CFU 
UTI89 vs PBS-mock infected, sacrificed at denoted time points. Number of DEGs denoted on 
each graph. B) Percentage of chronic cystitis in Juvenile Naive C57BL/6J mice (superinfected by 
107 UTI89) and C3H/HeOuJ (infected by 108 CFU UTI89) after 4 weeks of infection, mice were 
either pre-treated with 50 ug of  anti-TNF⍺ or isotype control antibody or untreated 18 hours 








Volcano plot of DEGs in C3H/HeN Adult Naïve, Resolved, and Sensitized mice, 108 CFU 









Adult Naïve, Resolve, and Sensitized mice were pre-treated with anti-TNF⍺ or isotype control 
antibody 18 hours prior to 107 CFU UTI89 infection, and sacrificed at denoted time points. A) 
Adult Naïve and Resolved mice 6 hpi urine titers. Resolved mice bladder titers at 24 hpi. B) 
Resolved mice bladder IBCs at 3 hpi. C) Resolved mice IBC at 4.5 hpi, pyuria at 24 hpi. D) 
Fluorescent microscopy of Resolve mice bladder IBCs at 4.5 hpi. Scale bar = 50 µm. E) Pyuria 
of Resolved mice at 24 hpi. F) Bladder titer of Sensitized mice at 24 hpi. Data points represent 
actual values for each mouse and bars represent median values. 
 
3.7 Materials and Methods  
Ethics Statement All animal experimentation was conducted according to the National Institute 
of Health guidelines for the housing and care of laboratory animals and performed in accordance 
with institutional regulations after reviewed and approved by the Animal Studies Committee at 
Washington University in St. Louis, Missouri. 
Bacterial strains. The UPEC strain primarily used in this study was a kanamycin-resistant 
derivative of the human cystitis isolate, UTI89 (Mulvey et al., 2001): UTI89 attHK022::COM-GFP 
(UTI89-KanR) (Wright et al., 2005). For UPEC challenge of previously infected mice, we used a 




For enumeration of IBCs by epifluorescence microscopy, we used UTI89 pANT4, which contains 
a plasmid that constitutively expresses eGFP. Bacteria were routinely cultured in lysogeny broth 
(LB). 
Mouse infections and superinfections. Female C57BL/6J and C3H/HeOuJ mice were 
purchased from Jackson Laboratories (Bar Harbor, ME), which has a rigorous genetic stability 
program in place, thus controlling for environmental (husbandry) effects. Female C3H/HeN mice 
were purchased from Envigo (Indianapolis, IN). Bacterial strains were inoculated into 20 ml of 
LB directly from freezer stock, grown statically at 37°C overnight, and sub-cultured 1:1000 into 
20 ml of fresh LB and again grown statically at 37°C for 18 h. These cultures were spun at room 
temperature for 10 min at 3,000g, re-suspended in 10 ml phosphate-buffered saline, pH = 7.4 
(PBS), and diluted to approximately 2–4 × 109 colony forming units (CFU)/ml (OD600 = 3.5). 50 
µl of this suspension (~1–2 × 108 CFU) was inoculated into the bladders of 7–8-week old female 
Juvenile Naive mice by transurethral catheterization. C57BL/6J mice used for chronic cystitis 
incidence experiments were superinfected as described in Schwartz et al., 2015. Briefly, Juvenile 
Naive C57BL/6J were infected with 107 CFU UTI89 twice, 24 hours apart, in order to promote 
the development of chronic cystitis in a subset (approximately one third) of mice.  
IBC Enumeration. Bladders were aseptically removed and hemisected. Each hemisphere was 
pinned out on silica plates using forceps and pins. Bladders were fixed with 4% 
paraformaldehyde (room temperature, 1 hour, shaking), washed with PBS, and incubated with 
0.01% Triton-X in PBS (10 min). Bladders were stained with wheat germ agglutinin Alexa Fluor 
594 conjugate (Molecular Probes) and 4’,6-diamidino-2-phenylindole DAPI (Life Technologies), 
washed with PBS, and mounted on slides with Prolong Gold Anti-Fade (ThermoFisher). Images 




fluorescence microscope or a Zeiss Observer D1 inverted wide-field fluorescence microscope) 
and the number of IBCs was enumerated by ImageJ (NIH, ImageJ bundled with Jave 1.8.0_101). 
Tissue Bacterial Titer Determinations. At the indicated time points, mice were humanely 
euthanized and bladders were aseptically harvested and homogenized in PBS using a FastPrep-
24 bead beater (MP Biomedicals, Santa Ana, CA). Homogenates were then serially diluted in 
PBS and spotted onto LB agar plates with and without antibiotic selection. 
Urine Collection, Bacterial Titering, and Urine Sediment Analysis. Urines were collected by 
applying suprapubic pressure with proper restraint and collecting the urine stream in sterile 1.5 
ml Eppendorf tubes. Urines were then serially diluted in PBS and 10 µl total of each dilution was 
spotted onto LB and LB with 25 µg/ml kanamycin (LB/Kan25) agar plates. Urine sediments 
were obtained by cyto-centrifuging 80 µl of a 1:10 dilution of the collected urine onto poly-L-
lysine-coated glass slides and stained as described (Rosen et al., 2007). Stained urine sediments 
were examined by light microscopy on an Olympus BX51 light microscope (Olympus America), 
and the average number of polymorphonuclear leukocytes (PMN) per 400x magnification field 
(hpf) calculated from counting 5 fields. A semi-quantitative scoring system of 0–5 was modified 
from an earlier study to facilitate analysis: 0, less than 1 PMN/hpf; 1, 1–5 PMN/hpf; 2, 6–10 
PMN/hpf; 3, 11–20 PMN/hpf, 4, 21–40 PMN/hpf, and 5, >40]  PMN/hpf (Hannan et al., 2010; 
Hannan et al., 2014). 
Recurrent UTI Model. Mice were initially inoculated with either 108 CFU of UTI89-KanR 
(convalescent) or PBS (Adult Naïve) and longitudinal urinalysis was performed to determine 
disease outcome. Urines were collected at 1, 3, 7, 10, 14, 21, and 28 days post-infection (dpi) and 




UTI89-KanR at every time point, were deemed to have chronic cystitis (Sensitized), and all other 
UPEC-infected mice were deemed to have resolved the infection (Resolved). At 28 dpi, all mice 
were treated with trimethoprim and sulfamethoxazole in the drinking water daily for 10 days at 
concentrations of 54 and 270 µg/ml, respectively (Schilling et al., 2002). During this time, 
longitudinal urinalysis was continued weekly to confirm clearance of bacteriuria. Four weeks 
after the initiation of antibiotic therapy mice were challenged with 107 or 108 CFU of UTI89-
SpcR. Mice were humanely euthanized at various time points and tissue titers determined as 
above. 
TNFɑ depletion in mice. Mice were administered anti-TNF antibody (clone XT3.11) or isotype 
control (clone HRPN) (BioXCell, West Lebanon, NH) via intraperitoneal injection 18 hours 
before infection. Given the recommended dosage of 10 mg/kg, Juvenile Naive mice were 
administered 200 µg, and Adult mice (rUTI model) were administered 300 µg, unless otherwised 
denoted. 
Inflammation profiling. Mice were infected with 108 CFU of UPEC or PBS and were humanely 
euthanized at indicated time points. Bladder edema was determined obtained by weighing 
bladders in pre-weighed Eppendorf tubes and calculating bladder weight. Bladder homogenates 
were obtained via bead beating as described above, and after CFU plating, the remaining 
homogenates were spun down at 15,000 rpm for 5 minutes at 4C and kept at -80C. The presence 
and amount of 23 mouse cytokines were analyzed by a Luminex-based multiplex cytometric 
bead array platform (Bioplex, Bio-Rad, Hercules, CA) in the same way described previously 
(Hannan et al., 2010). The 23 cytokines are: IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-
10, IL-12 (p40 subunit), IL-12 (p70 subunit), IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFNγ, 




cytokines expression were measured with enzyme-linked immunosorbent assays (ELISAs). 
ELISA with DuoSet kit (R&D Systems, DY406, DY453, DY479) were performed on the 
supernatants following the manufacturer’s instructions, with the following modifications: 
incubation with the capture antibody was lengthened to overnight at 4C, and washes between 
incubations were performed 5 times instead of 3.    
Histopathology and immunofluorescence. Mice were infected with 108 CFU of UPEC or PBS 
and were humanely euthanized at indicated time points. For histopathology assessment, bladders 
were excised, fixed with methacarn, embedded in paraffin blocks, and cut into 5 um sections. 
Hematoxylin & eosin (H&E) staining was performed and bladder sections were scored in a 
blinded fashion using a semi-quantitative scoring system: 0 = normal up to 5 = “necrosis with 
full-thickness inflammatory cell infiltration” (Hopkins et al., 1998). 
Flow cytometry. Mice were infected with 107 CFU UPEC and were humanely euthanized at 
indicated time points. Bladders were harvested and made into single-cell suspension via 
collagenase IV/DNase I digestion for 90 min at 37°C and passing through a 40-µm filter as 
previously described (Ingersoll et al., 2008). Cell surface markers were stained with 
fluorochrome-conjugated monoclonal antibodies (MAbs) (CD45, F4/80, CD11b, Ly6G) in FcR 
block. Cells were counterstained with propidium iodide (PI) prior to flow cytometry and analysis 
only included live cells. To identify neutrophils, the following surface markers were used: CD45, 
Ly6G, CD11b, and F4/80. Data were analyzed by FlowJo software version 7.6.4. 
Scanning electron microscopy. Mice were infected with 108 CFU UPEC or PBS. Bladders were 
fixed in their native state (prior to harvest) using the “balloon method” (Walker et al., 2017). 




inoculated with 50 ul freshly prepared SEM fixative (2% paraformaldehyde, 2% glutaraldehyde 
in 0.1 M cacodylate, pH 7.4, warmed to 37C). The bladder was clamped with a hemostat before 
the catheter was withdrawn, and then excised and placed in 1 ml 37C EM fixative overnight. 
Bladders were then bisected, post-fixed in 1.0% osmium tetroxide, dehydrated in increasing 
concentrations of ethanol, then dehydrated at 31.1 °C and 1,072 p.s.i. for 16 min in a critical 
point dryer, then sputter-coated with iridium and imaged on a Zeiss Crossbeam 540 FIB-SEM or 
a Zeiss Merlin FE-SEM. ImageJ (NIH) was used to add scale bars. 
RNA isolation. Mice infected with 108 CFU of UPEC or PBS were humanely euthanized at 
indicated time points. Bladders were aseptically harvested, flash-frozen in liquid nitrogen, and 
stored at -80C. RNA isolation from whole bladders was performed using the with QIAGEN 
RNeasy Plus kit (74136).  
RNA-seq analysis and pathway enrichment analysis. After RNA extraction, cDNA libraries 
were generated using RNAtag-seq protocol in Shishkin et al., 2015 (Shishkin et al., 2015). 
Briefly, whole bladder total RNA was fragmented, depleted of genomic DNA, and 
dephosphorylated before ligating to DNA adaptors carrying 5’-AN8-3’ barcodes with a 5’ 
phosphate and a 3’ blocking group. Barcoded RNAs were pooled and depleted for rRNA with 
the Ribo-Zero rRNA removal kit (Illumina MRZG12324), then synthesized corresponding 
cDNA libraries. RNA-seq data were analyzed with the following pipeline: de-barcode, quality 
check, alignment (bbmap_37.10), gene counts (Salmon_0.8.2), differential analysis 
(DESeq2_1.14.0), pathway analysis (Ingenuity Pathway Analysis, 
https://www.qiagenbioinformatics.com/). Statistical significance in gene expression differences 
were assessed by the Wald test and multiple comparison errors were corrected by Benjamini-




off by default in all statistical tests. Each mice group IPA analysis used various gene fold change 
cutoff to achieve a reasonable and appropriate number of DEGs: Juvenile Naive C57Bl/6J and 
C3H/HeOuJ cutoff: 2 fold; C3H/HeN Adult Naive, Resolved, Sensitized mice at 6 and 24 hpi 
cutoff: 2 fold; at 3.5 hpi cutoff: 1.5 fold.  
Statistical analysis. 1) RNA-seq: DESeq2 assumes a negative binomial distribution for gene 
counts, normalizes for read depths and fits a generalized linear model. Statistical significance in 
gene expression differences were assessed by the Wald test and multiple comparison errors were 
corrected by Benjamini-Hochberg false-discovery rate correction (Padjusted). Padjusted < 0.05 were 
used as the cut off for significantly differentially expressed genes. IPA employes a right-tailed 
Fisher’s exact test, with Padjusted < 0.05 deemed significantly enriched. Each mouse group IPA 
analysis used various gene fold change cutoff to achieve a reasonable and appropriate number of 
DEGs: Juvenile Naive C57Bl/6J and C3H/HeOuJ cutoff: 2 folds; C3H/HeN Adult Naive, 
Resolved, Sensitized mice at 6 and 24 hpi cutoff: 2 folds; at 3.5 hpi cutoff: 1.5 folds. 2) Pathology: 
statistical significance of bladder and urine bacterial titers, histopathology scores, bladder edema, 
cytokine expression level, pyuria, IBC counts, and flow cytometry were assessed by Mann-
Whitney U test. All the above items used two-tailed test, except for bladder edema: if compared 
to PBS-mock infected mice, bladder edema employed one-tailed test, to test the null hypothesis 
that UTI89 infected mice would show increased edema in the bladder, otherwise employed two-
tailed test. 3) Percentage of severe infection: the ratio of severely infected antibody pre-treated 
Sensitized mice at 24 hpi were assessed by Barnard’s test (two-sided) because it is a more powerful 
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Chapter 4: Conclusion and Future Directions 
4.1 Conclusion and Future Directions 
This thesis investigated the molecular mechanism of host risk factors that affect susceptibility to 
urinary tract infections in murine models. Two major factors were: 1) host genetic background, 
modeled by various inbred strains of mouse, and 2) host UTI history, modeled by isogenic mice 
with acute cystitis that either self-resolved or developed into chronic cystitis. In particular, the 
effect of host UTI history was investigated before and after subsequent infections.  
Post infection responses of C57BL/6J and C3H/HeOuJ mice, including inflammatory and 
transcriptomic responses, indicated the following pattern: during early stage of acute cystitis, a 
robust but short inflammation and activation of TNFα signaling pathway promotes rapid 
pathogen clearance without causing excessive damage and renders host resistance to urinary 
infections; a robust but late-onset and persisting TNFα signaling leads to increase ratio of 
chronic severe infections. The same patterns were observed in C3H/HeN Resolved and 
Sensitized mice, respectively. Two seemingly unrelated host risk factors, genotype and disease 
history, are able to mediate host susceptibility through regulating the pattern of the same immune 
signaling pathway. This confirms my hypothesis that host gene expression, especially during 
acute cystitis, greatly impacts host susceptibility to urinary tract infections. In particular, host 
genotype and disease history can affect susceptibility to recurrent and chronic cystitis via 
regulation of the same molecular mechanisms, e.g., TNFα signaling activation onset, intensity, 
and duration.  
In all the mice that I have investigated (Juvenile Naïve C57BL/6J and C3H/HeOuJ mice, 




differentially expressed in all the comparisons made in Chapter 2 and Chapter 3. A total of about 
30000 genes were detected by RNA-seq in the transcriptome. Therefore, over half of the 
transcribed genes have shown altered expression at some point, indicating a global change of 
transcriptomes in mice.  
The majority of genes (1554 out of 1887) differentially expressed in Adult C3H/HeN mice 
during convalescence (in Chapter 2) were found differentially expressed in Adult C3H/HeN mice 
upon challenge infection (19139 unique genes, Chapter 3). This suggested that most genes that 
have altered expression levels after the initial infection were also up or down regulated upon 
subsequent infection. It is the specific direction and timing of regulation that separated resistant 
mice from susceptible ones. 
In addition, disease histories affect host transcriptome not only upon subsequent infections but 
also during convalescence after the initial infection, which may prime the differences upon 
subsequent infections, although the specific connections require further investigation.  
Although this thesis has investigated overall bladder TNFα signaling pattern and its effect, it is 
unclear which specific cells express Tnf, whether it is secreted or membrane bound in these cells, 
and what cells responds to TNFα by activating downstream signaling pathways to implement 
such function. These unanswered questions are worth further investigation in the future. 
TNFα is primarily expressed by macrophages, which are also strong responders to TNFα 
stimulation (Murray et al., 2005; Parameswaran and Patial, 2010). However, many other cell 
types, such as neutrophils and epithelial cells (Cassatella, 1995; Roulis et al., 2011), can also 
express and respond to TNFα. The source of TNFα could be from residential cells, recruited 




3.5 hpi and other studies have shown strong TNFɑ upregulation in C57BL/6 mice as early as 2 
hours after bladder infection (Chan et al., 2013). Such rapid and robust response could imply a 
residential source of TNFα in the infected bladders. Several methods could be employed in 
narrowing down the TNFα expressing cell types. For example, RNA in situ hybridization 
optimized by ACDbio are now able to detect multiple gene transcripts with high sensitivity and 
specificity at a single cell resolution in histological sections of tissue. Probes that detects Tnf and 
multiple cell markers such as Krt5 (a marker for urothelial cells) and Ly6g (a marker for 
neutrophils) could be applied to the same tissue section and co-localization of the probes could 
reveal TNFα expressing cell types. Revealing the specific cell types that produce TNFα would 
promote a clearer understanding of host TNFα signaling at a cellular level. 
On the receiver side, almost all nucleated cells express receptors to TNFα, although TNFR1 is 
more widely expressed while TNFR2 is primarily restricted to immune and endothelial cells 
(Chen and Oppenheim, 2010; Probert, 2015). TNFα can be produced in two forms and both are 
bioactive: the membrane-bound/transmembrane form (tmTNF) functions through cell-to-cell 
contact through TNFR1 and TNFR2 (Black et al., 1997); the soluble form (solTNF), converted 
from tmTNF by TNFα converting enzyme (TACE), functions mainly through TNFR1 (Grell et 
al., 1995). According to enriched pathways upon UPEC infection (Chapter 3), both TNFR1 and 
TNFR2 signaling pathways were activated in Juvenile Naïve C57BL/6J, C3H/HeOuJ, C3H/HeN 
Adult Naïve, Resolved, and Sensitized mice, as many genes up-regulated are downstream of both 
pathways. Therefore, it is difficult to infer which form of TNFα is the major player here. Current 
anti-TNF agents, such as Infliximab and adalimumab are able to bind to both solTNF and tmTNF 
(Arora et al., 2009; Mitoma et al., 2004), although their affinities to tmTNF are lower 




studies could consider: 1) develop antibodies that only block solTNF; 2) use mouse strains that 
has mutation in TACE to allow production of only tmTNF but not solTNF (possibly Taceflox 
mice from the Jackson lab). Determining the specific form of TNFα would shine light on how 
TNFα signaling regulate host response at a molecular level.  
It remains unclear how such different patterns of TNFα signaling in mice with various 
susceptibilities were induced. Pathogen-associated molecular pattern molecules, such as LPS, are 
known to induce TNFα expression through Toll-like receptors (TLRs) (Covacu et al., 2009). 
Mutations in TLRs have been shown to alter susceptibility to UTI (Andersen-Nissen et al., 2007; 
Schilling et al., 2003). Therefore, mutations in various TLRs, or effector elements downstream of 
TLRs interactive pathway, such as Myd88 (Yan et al., 2004), are potential targets that could 
elucidate the events prior to distinct TNFα signaling patterns.   
From a long-term perspective, TNFα depletion experiments have shown that the effect of TNFα 
signaling pattern is limited to host susceptibility to severe acute cystitis (initial and recurrent) but 
does not penetrate to alter final disease outcome, at least in some circumstances (Juvenile Naïve 
C57BL/6J, C3H/HeN Resolved mice). It is worth investigating what other molecular 
mechanisms affect the ultimate disease outcome. As prior infections left imprint on bladder 
transcriptome long after the clearance of pathogens, it is possible that such imprint penetrates to 
the epigenetic level. Identification of such epigenetic changes could promote understanding of 
disease history and susceptibility and discover diagnostic targets to determine high-risk patients 





Andersen-Nissen, E., Hawn, T.R., Smith, K.D., Nachman, A., Lampano, A.E., Uematsu, S., 
Akira, S., and Aderem, A. (2007). Cutting Edge: Tlr5-/- Mice Are More Susceptible to 
Escherichia coli Urinary Tract Infection. The Journal of Immunology 178, 4717-4720. 
Arora, T., Padaki, R., Liu, L., Hamburger, A.E., Ellison, A.R., Stevens, S.R., Louie, J.S., and 
Kohno, T. (2009). Differences in binding and effector functions between classes of TNF 
antagonists. Cytokine 45, 124-131. 
Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, J.L., Wolfson, M.F., Castner, 
B.J., Stocking, K.L., Reddy, P., Srinivasan, S., et al. (1997). A metalloproteinase disintegrin that 
releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733. 
Cassatella, M.A. (1995). The Production of Cytokines by Polymorphonuclear Neutrophils. 
Immunol Today 16, 21-26. 
Chen, X., and Oppenheim, J.J. (2010). TNF-alpha: an activator of CD4+FoxP3+TNFR2+ 
regulatory T cells. Curr Dir Autoimmun 11, 119-134. 
Covacu, R., Arvidsson, L., Andersson, A., Khademi, M., Erlandsson-Harris, H., Harris, R.A., 
Svensson, M.A., Olsson, T., and Brundin, L. (2009). TLR activation induces TNF-alpha 
production from adult neural stem/progenitor cells. J Immunol 182, 6889-6895. 
Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., 
Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995). The transmembrane form of tumor 
necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 
83, 793-802. 
Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L.M., Hanzatian, D.K., Salfeld, J., 
and Sasso, E.H. (2009). Comparisons of affinities, avidities, and complement activation of 
adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis 
factor. Clin Immunol 131, 308-316. 
Mitoma, H., Horiuchi, T., and Tsukamoto, H. (2004). Binding activities of infliximab and 
etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 126, 934-935; author 
reply 935-936. 
Murray, R.Z., Kay, J.G., Sangermani, D.G., and Stow, J.L. (2005). A role for the phagosome in 
cytokine secretion. Science 310, 1492-1495. 
Parameswaran, N., and Patial, S. (2010). Tumor necrosis factor-alpha signaling in macrophages. 
Crit Rev Eukaryot Gene Expr 20, 87-103. 
Probert, L. (2015). TNF and its receptors in the CNS: The essential, the desirable and the 
deleterious effects. Neuroscience 302, 2-22. 
Roulis, M., Armaka, M., Manoloukos, M., Apostolaki, M., and Kollias, G. (2011). Intestinal 
epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like 




Schilling, J.D., Martin, S.M., Hung, C.S., Lorenz, R.G., and Hultgren, S.J. (2003). Toll-like 
receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic 
Escherichia coli. Proc Natl Acad Sci U S A 100, 4203-4208. 
Yan, S.R., Qing, G., Byers, D.M., Stadnyk, A.W., Al-Hertani, W., and Bortolussi, R. (2004). 
Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear 





Chapter 5: Appendix 
Table S1, S2, S3, and S4 may be found online at DOI: 10.1038/nmicrobiol.2016.196 
Table S1. 
Gene list from whole-bladder RNA-seq experiment, in which gene expression was compared 
between Sensitized and Resolved mice during convalescence (four weeks after the initiation of 
antibiotics). Significantly differentially expressed genes are shown in green. Significance was 
determined using a Wald test and adjusted for multiple comparisons using the Benjamini-
Hochberg false-discovery rate correction, with Padjusted < 0.05 deemed significantly 
differentially expressed. RNA-seq data has been deposited at NCBI under the BioProject ID 
number PRJNA327807. 
Table S2. 
The fold changes in gene expression from whole-bladder RNA-seq, compared to the fold 
enrichment/depletion of the most significantly enriched/depleted proteins (Padjusted < 0.01) 
from a previously published analysis of the urothelial proteome enriched for membrane-
associated glycoproteins (Hannan et al., 2014) (grey columns). Genes/proteins that were 
significant in both analyses are shown in green. N/A, not applicable (due to all samples in a 
group having no counts).   
Table S3.  
Pathway analysis showing the canonical pathways enriched in the differentially expressed genes 
in the RNA-seq experiment. See Legend in the second tab.  
Table S4. 
Broad meta-pathways assembled by Ingenuity IPA from the specific enriched pathways given in 
Table S3. In the histogram in Figure 2.e, the smallest P value from the range of P values in column 
B is reported.   
Table S5. 
Differentially expressed genes in convalescent mice comparions. Data generated by DESeq2. 
Log = log2 fold change, p = adjusted p values.  
Resolved vs Adult Naive C3H/HeN 
Genes log P Genes log P Genes log P 
Acer2 0.270 2.55E-02 Mylk -0.194 2.97E-02 Synm -0.253 2.97E-02 
Atp2b4 -0.308 3.56E-02 Pde5a -0.253 2.97E-02 Synpo2 -0.274 2.55E-02 
Ccnd2 -0.312 2.97E-02 Rc3h1 -0.184 4.40E-02 Tgfbr3 -0.188 4.86E-02 
H2-K1 0.301 3.56E-02 Samd4 -0.283 2.97E-02 Thsd4 -0.275 2.55E-02 
Lmod1 -0.216 4.38E-02 Serinc1 -0.300 2.97E-02 Tmem106b -0.274 4.38E-02 




Mrvi1 -0.257 2.97E-02       
Sensitized vs Adult Naive C3H/HeN 
Genes log P Genes log P Genes log P 
1700049G17Rik -0.462 1.84E-02 Fgfrl1 -0.39 1.02E-02 Pim1 0.596 1.66E-03 
1810019D21Rik 0.692 1.23E-08 Fgl2 -0.426 7.35E-05 Pip5k1b -0.708 9.86E-04 
1810041L15Rik -0.352 3.86E-03 Fgr 0.565 3.26E-02 Pisd-ps1 0.715 7.05E-09 
1810055G02Rik -0.45 6.09E-03 Fhl1 -0.354 1.40E-02 Pisd-ps2 0.591 1.19E-02 
2010016I18Rik 0.628 5.02E-03 Fhl3 0.554 3.67E-02 Pitpnm1 0.52 1.04E-03 
2010315B03Rik 0.339 4.81E-02 Fign -0.437 6.42E-03 Pja2 -0.306 4.16E-04 
2510009E07Rik -0.289 7.86E-03 Filip1 -0.273 2.11E-02 Pkhd1l1 0.443 3.79E-02 
2810403A07Rik 0.262 1.01E-02 Firre 0.627 2.25E-08 Pkia -0.49 4.00E-03 
3110002H16Rik 0.476 1.35E-03 Fkbp14 -0.579 5.71E-05 Pkn3 0.661 2.03E-03 
3632451O06Rik -0.595 8.34E-04 Fkbp15 0.273 6.22E-03 Pkp1 1.363 2.27E-15 
4921506M07Rik 0.471 4.61E-02 Fkbp1a -0.349 7.91E-04 Pkp3 0.369 4.99E-02 
4930426D05Rik 0.625 1.01E-02 Fkbp9 -0.233 3.08E-02 Pla1a 0.52 1.82E-02 
4930443O20Rik -0.535 4.06E-02 Flna -0.252 1.95E-03 Pla2g4f 0.613 1.65E-02 
4930594C11Rik 0.563 4.70E-04 Flnc -0.295 1.47E-02 Pla2g7 -0.663 4.52E-10 
4931406C07Rik -0.243 3.84E-02 Flt3 0.647 1.01E-02 Pla2r1 0.523 1.26E-08 
5830411N06Rik 0.693 9.62E-04 Flt3l 0.686 2.11E-03 Plaa -0.247 4.14E-02 
6030458C11Rik 0.33 7.26E-03 Flt4 0.824 1.71E-05 Plag1 -0.665 1.59E-03 
6330403A02Rik -0.322 2.36E-02 Fmn1 0.374 1.91E-02 Plagl1 -0.52 7.34E-05 
8430419L09Rik 0.555 1.09E-03 Fmnl1 0.879 4.97E-06 Plau -0.28 1.73E-02 
9330182L06Rik -0.522 5.57E-03 Fmnl3 0.446 5.82E-03 Plbd1 0.754 4.14E-04 
9430015G10Rik 0.497 1.52E-02 Fmod -0.696 1.95E-07 Plcb2 1.04 7.35E-07 
9430018G01Rik 0.551 3.50E-02 Fnbp4 0.301 2.42E-03 Plcd3 0.388 3.59E-02 
9530068E07Rik -0.383 1.62E-03 Fndc1 -0.461 7.20E-05 Plcg1 0.286 5.35E-03 
A330023F24Rik 0.328 7.70E-03 Fndc3b -0.273 8.74E-04 Plcg2 0.648 2.96E-05 
A430078G23Rik 0.61 3.42E-03 Fnip1 -0.235 1.67E-02 Plch2 0.349 4.07E-03 
A430088P11Rik 0.57 1.58E-02 Foxf1 -0.445 1.80E-06 Plcl1 -0.446 6.52E-03 
A4galt -0.418 1.40E-03 Foxp2 -0.316 3.87E-03 Pld2 0.362 1.31E-02 
A530013C23Rik 0.627 1.10E-02 Fras1 -0.363 3.23E-03 Plekhb1 -0.693 1.77E-04 
A630001G21Rik 0.587 2.30E-02 Frzb 0.363 4.98E-02 Plekhh1 0.232 3.25E-02 
A630072M18Rik -0.407 1.02E-02 Fsd1l -0.32 4.98E-02 Plekhn1 0.435 8.32E-03 
Abat -0.508 3.88E-03 Fundc2 -0.501 6.63E-06 Plekhs1 0.675 3.96E-03 
Abca7 0.334 2.04E-02 Fxyd4 0.669 6.06E-03 Plin3 -0.315 3.76E-03 
Abca8b -0.418 5.78E-03 Fyb 0.58 1.46E-05 Plk2 -0.703 8.26E-08 
Abcc3 0.378 6.38E-06 Fzd1 -0.224 4.46E-03 Pls1 1.552 3.71E-16 
Abcc5 0.296 5.12E-03 Fzd2 -0.348 2.39E-03 Plscr1 0.638 7.83E-03 
Abcc9 -0.229 1.07E-02 Fzd3 -0.69 5.00E-10 Plxnd1 0.356 4.15E-06 
Abi2 -0.268 6.25E-04 Fzd7 -0.287 2.61E-03 Pm20d2 -0.373 2.25E-02 
Abi3 0.916 2.87E-05 Gab2 -0.232 4.79E-02 Pmp22 -0.259 7.92E-03 
Ablim1 0.22 6.28E-03 Gabarapl1 -0.24 4.50E-02 Pnisr 0.501 2.54E-07 
Acap1 1.189 3.31E-08 Gabbr1 0.384 6.75E-03 Pnkp 0.414 3.90E-02 
Acer2 0.231 7.62E-04 Gabrb2 -0.528 3.22E-02 Pnn 0.34 3.82E-03 
Acsbg1 0.605 1.51E-02 Gabrp 0.868 1.46E-05 Podnl1 1.492 1.14E-12 
Acsl3 0.347 2.11E-02 Galnt5 0.606 1.51E-02 Pofut2 -0.279 1.82E-02 
Acss1 0.361 1.18E-02 Gas5 0.462 5.73E-03 Polr2m -0.236 1.21E-02 
Acta2 -0.383 1.82E-04 Gas7 -0.281 1.22E-02 Polr3f -0.307 1.12E-02 
Actb -0.208 4.62E-02 Gata6 -0.338 1.57E-03 Popdc2 -0.339 4.18E-03 
Actc1 -0.765 1.26E-03 Gatm -0.596 9.68E-06 Pou2af1 0.536 1.02E-02 
Actr10 -0.313 1.02E-02 Gatsl2 -0.583 5.32E-06 Pou2f2 0.76 1.43E-03 




Adam23 -0.384 1.08E-02 Gclc 0.192 4.42E-02 Ppapdc1a -0.595 3.14E-03 
Adam8 0.846 2.67E-04 Gdpd3 0.654 1.08E-03 Ppfibp2 0.194 1.32E-02 
Adamdec1 0.581 1.93E-03 Gfra4 -0.507 2.65E-02 Ppic -0.561 9.66E-04 
Adamts10 0.658 2.46E-06 Ggta1 0.492 1.57E-03 Ppl 0.367 4.61E-03 
Adamts9 -0.475 5.02E-03 Gid4 -0.258 4.55E-02 Ppm1j 0.531 1.61E-02 
Adap2 0.55 8.89E-03 Gimap1 0.608 1.54E-02 Ppox 0.467 4.45E-03 
Adarb2 -0.586 2.22E-02 Gimap3 1.342 1.05E-10 Ppp1cb -0.275 4.02E-05 
Adcy1 -0.653 7.63E-04 Gimap4 0.875 1.72E-05 Ppp1r14c 0.718 3.27E-03 
Adcy5 -0.31 1.32E-02 Gimap6 0.672 2.75E-04 Ppp1r16b 0.718 1.43E-04 
Adcy7 0.349 3.59E-02 Gimap7 0.572 2.41E-02 Ppp1r3c -0.631 1.96E-04 
Adcy9 -0.251 2.69E-02 Gimap8 1.21 4.71E-14 Ppp3ca -0.272 1.36E-03 
Adgrd1 -0.434 1.50E-04 Gja1 -0.454 3.59E-05 Pqlc3 0.416 1.44E-02 
Adgre1 0.453 4.82E-02 Gjb2 0.498 4.11E-02 Prdm2 0.183 2.57E-02 
Adgrg3 0.636 6.49E-03 Gli3 -0.344 3.02E-03 Prdm6 -0.461 1.55E-03 
Adgrg5 1.366 9.12E-11 Glo1 -0.276 1.70E-02 Prex1 0.797 3.14E-07 
Adipor1 -0.294 3.16E-04 Glp2r -0.635 4.90E-04 Prf1 0.476 4.79E-02 
Adrbk1 0.319 1.89E-02 Gm10471 -0.589 1.91E-02 Prickle2 -0.389 1.40E-04 
Agap2 0.492 3.21E-02 Gm15708 0.653 4.86E-03 Prkaa2 -0.306 1.68E-03 
Agl -0.324 2.03E-03 Gm15987 0.499 2.90E-02 Prkacb -0.222 1.77E-02 
AI464131 -0.394 1.01E-02 Gm20300 -0.342 2.50E-03 Prkcb -0.327 3.28E-02 
AI467606 0.571 3.02E-02 Gm2a -0.374 7.27E-07 Prkcd 0.537 2.96E-07 
AI504432 1.475 6.23E-13 Gm4759 0.717 3.39E-03 Prkch 0.434 2.27E-03 
AI593442 -0.605 1.67E-02 Gm4961 -0.672 4.23E-03 Prkcq 0.496 7.43E-03 
AI662270 0.572 2.96E-02 Gm9199 0.497 4.19E-02 Prnp -0.304 3.77E-02 
Aim2 1.165 3.36E-08 Gm9926 0.541 4.28E-02 Prodh 0.606 1.65E-05 
Akap12 -0.295 8.56E-03 Gmfg 0.526 3.15E-02 Prokr1 -0.523 4.92E-02 
Akap6 -0.457 6.71E-03 Gmip 0.593 1.15E-04 Prr11 -0.619 1.54E-02 
Akap8 0.268 1.81E-02 Gmnn 0.573 2.83E-02 Prss23 -0.349 3.22E-02 
Akap8l 0.52 3.22E-05 Gna12 -0.276 2.72E-02 Prss35 -0.967 3.11E-09 
Akna 1.015 1.72E-10 Gnai1 -0.406 2.33E-03 Prtg -0.607 1.30E-02 
Akr1b8 0.546 3.07E-03 Gnao1 -0.374 1.25E-03 Psapl1 0.417 2.93E-02 
Aldh2 -0.303 1.14E-02 Gnaq -0.177 3.31E-02 Psd -0.371 6.72E-03 
Aldh3a1 0.566 6.58E-06 Gnas -0.175 1.88E-02 Psd3 -0.227 2.63E-02 
Alg10b -0.308 1.53E-02 Gnaz -0.623 9.11E-04 Psd4 0.513 6.99E-06 
Alg3 -0.476 3.09E-02 Gng11 -0.369 4.99E-02 Psma3 0.437 9.81E-03 
Alkbh5 -0.223 7.54E-03 Golim4 -0.243 2.38E-02 Psmb8 1.151 5.01E-14 
Alpk1 0.385 5.71E-03 Golph3 -0.245 5.83E-03 Psmb9 0.989 2.55E-06 
Als2cl 0.483 9.05E-05 Gpam -0.223 4.17E-03 Psme1 0.433 7.46E-03 
Amica1 0.96 1.42E-07 Gpc3 -0.507 1.19E-03 Pspc1 0.263 2.83E-02 
Amotl1 -0.394 1.32E-07 Gpnmb 1.07 1.57E-16 Pstpip1 0.976 8.39E-06 
Ankrd35 0.534 3.04E-04 Gpr153 -0.432 5.47E-03 Pstpip2 0.596 9.79E-04 
Ankrd40 -0.195 2.66E-02 Gpr174 0.535 1.26E-02 Ptbp2 -0.29 2.17E-02 
Ankrd44 0.306 1.25E-02 Gpr176 0.58 1.47E-02 Ptch1 -0.348 5.12E-03 
Ano4 0.453 2.74E-02 Gpr35 0.565 3.25E-02 Ptgs1 0.252 2.21E-02 
Ano9 0.932 3.96E-05 Gpr55 0.42 3.44E-02 Ptgs2 -0.643 5.25E-03 
Anxa5 -0.217 4.79E-02 Gpr63 -0.547 1.37E-02 Ptn -0.709 2.90E-04 
Anxa8 0.911 3.20E-09 Gpr65 0.825 4.39E-04 Ptpn22 0.852 2.67E-04 
Aox3 -0.821 1.85E-06 Gpr68 0.598 2.59E-03 Ptpn6 0.702 1.77E-04 
Apbb1 -0.486 1.84E-02 Gprin3 0.699 4.41E-03 Ptpn7 0.861 8.61E-05 
Apbb1ip 0.517 5.78E-03 Gpx2 0.68 3.91E-03 Ptprc 1.071 1.62E-09 
Apbb2 -0.309 9.20E-05 Gpx3 -0.49 3.09E-06 Ptprcap 0.562 3.32E-02 




Apobec3 0.324 3.14E-02 Grap2 1.407 1.06E-15 Ptrf -0.289 1.38E-02 
Apobr 0.922 3.22E-05 Grb7 0.408 9.97E-03 Pxylp1 -0.455 3.06E-02 
Apod -0.432 8.34E-03 Greb1 -0.753 1.91E-04 Pygm -0.488 1.26E-03 
Arap3 0.557 5.16E-03 Grem2 -0.455 1.25E-04 Pyhin1 0.727 2.73E-03 
Arhgap15 0.572 2.83E-02 Gria3 -0.52 4.16E-03 Qpct -0.732 5.11E-05 
Arhgap25 0.474 3.55E-02 Grik1 -0.497 4.06E-02 Qsox1 -0.29 2.53E-03 
Arhgap27 0.398 1.54E-02 Grik3 -1.188 5.30E-13 Rab1 -0.22 1.54E-02 
Arhgap27os3 0.577 8.74E-03 Grk5 0.321 3.79E-02 Rab27a 0.446 3.11E-03 
Arhgap28 -0.542 1.78E-03 Grk6 0.318 4.16E-02 Rab37 0.632 2.84E-03 
Arhgap29 -0.203 4.11E-02 Gsap 0.603 1.40E-02 Rab3c -0.647 4.63E-03 
Arhgap30 0.956 4.80E-10 Gsdma 0.598 1.54E-02 Rab44 0.558 3.29E-02 
Arhgap4 0.907 4.30E-05 Gsdmc2 1.04 9.30E-07 Rab7 -0.266 9.44E-04 
Arhgap6 -0.334 2.50E-02 Gsdmc3 1.147 6.53E-08 Rac2 0.996 3.12E-06 
Arhgap9 1.269 3.94E-12 Gsdmd 0.524 1.68E-03 Rai2 -0.481 3.79E-02 
Arhgef1 0.397 5.86E-04 Gsg2 0.52 4.24E-02 Ralgps2 -0.311 6.16E-03 
Arhgef18 0.242 1.48E-02 Gsk3b -0.193 8.77E-03 Rasa4 0.594 4.45E-03 
Arhgef9 -0.267 1.66E-02 Gsta2 0.513 2.12E-02 Rasal2 -0.231 1.28E-02 
Arid3b 0.65 1.26E-03 Gstm1 -0.284 5.72E-04 Rasal3 1.216 1.41E-08 
Arid4a 0.315 2.59E-03 Gstm4 -0.303 2.94E-02 Rasgrp1 1.483 2.44E-13 
Armcx1 -0.555 1.85E-03 Gxylt2 -0.54 6.15E-03 Rassf2 0.351 2.50E-02 
Armcx2 -0.441 3.16E-02 Gyk 0.619 4.31E-04 Rassf3 -0.306 1.51E-02 
Arrb2 0.456 3.26E-02 H2-Aa 1.07 2.69E-09 Rassf5 0.447 1.68E-03 
Arrdc1 0.456 2.06E-02 H2-Ab1 1.006 5.24E-07 Rassf7 0.571 2.30E-04 
Arsj -0.494 1.43E-03 H2-D1 0.706 3.67E-07 Raver2 -0.47 1.79E-02 
Art2a-ps 0.523 2.71E-02 H2-DMa 0.617 3.07E-03 Rbbp8nl 0.487 3.84E-02 
Art3 -0.318 2.54E-02 H2-DMb1 0.675 6.69E-03 Rbfox2 -0.248 5.89E-04 
Arv1 0.529 1.82E-02 H2-Ea-ps 0.749 1.11E-03 Rbfox3 -0.555 3.81E-03 
Arxes2 -0.743 1.07E-03 H2-Eb1 1.38 5.68E-21 Rbm24 -0.358 3.69E-02 
Asap3 0.516 1.49E-04 H2-Eb2 0.55 1.60E-02 Rbm39 0.213 1.90E-03 
Asic2 -0.649 9.84E-03 H2-K1 0.973 1.33E-14 Rbm46 -0.651 1.28E-04 
Astn2 -0.481 4.10E-02 H2-K2 0.543 2.50E-02 Rbm5 0.263 1.70E-02 
Atat1 0.486 2.12E-02 H2-M2 1.209 2.18E-08 Rbp4 -0.763 7.83E-06 
Atl3 -0.186 6.36E-03 H2-M3 0.701 8.22E-04 Rbpms2 -0.401 1.61E-04 
Atoh8 0.439 2.88E-02 H2-Oa 0.502 3.33E-02 Rc3h1 -0.179 1.80E-02 
Atp10d 0.361 1.88E-02 H2-Ob 1.021 4.73E-06 Rdh12 0.588 1.23E-02 
Atp13a3 -0.202 1.54E-02 H2-Q4 1.101 7.56E-14 Rdx -0.24 2.82E-03 
Atp2a2 -0.233 1.71E-03 H2-T10 0.819 4.26E-04 Reep3 -0.28 3.16E-03 
Atp2b4 -0.443 2.75E-04 H2-T23 0.822 2.93E-09 Reln 0.759 1.69E-05 
Atp6v0e -0.289 1.11E-02 Hadh -0.535 1.18E-05 Rexo2 -0.328 3.98E-02 
Atxn1 -0.187 4.65E-02 Hagh 0.397 9.79E-03 Rftn1 0.531 9.89E-03 
Atxn7l3b -0.233 2.44E-02 Has2 -0.602 1.84E-02 Rfx1 0.4 1.21E-02 
Avpr1a -0.726 1.50E-07 Havcr2 0.612 1.52E-02 Rgl2 0.466 7.48E-04 
Axl -0.297 4.83E-03 Hc 0.969 5.64E-06 Rgma -0.397 4.48E-02 
B230219D22Rik -0.331 5.72E-04 Hcls1 0.83 1.63E-04 Rgs14 0.64 8.32E-03 
B2m 0.61 9.39E-03 Hdgfrp3 -0.384 2.63E-03 Rgs22 -0.577 9.83E-03 
B4galnt1 1.063 1.22E-12 Herc6 0.701 1.74E-05 Rgs3 0.56 6.12E-04 
B4galnt4 0.517 1.97E-02 Hgfac 0.756 1.63E-03 Rgs4 -0.52 3.04E-02 
B4galt2 -0.511 1.37E-02 Hhip -0.908 2.94E-08 Rgs5 -0.386 1.96E-03 
Bag2 -0.383 1.06E-02 Hip1 -0.236 3.54E-02 Rgs6 -0.445 4.95E-02 
Bag4 -0.279 4.35E-02 Hipk3 -0.225 7.73E-03 Rgs7bp -0.378 4.28E-02 
Baiap2l1 1.425 5.54E-26 Hk2 0.742 9.38E-07 Rhoc -0.342 2.46E-02 




Baz1a 0.517 1.89E-05 Hmgcs2 -0.593 4.00E-04 Rhoj -0.436 3.61E-04 
Bbox1 0.621 8.77E-03 Hmha1 1.079 1.20E-12 Rhoq -0.3 9.12E-03 
Bbx -0.229 8.26E-03 Hnrnpa0 -0.266 3.08E-03 Rhou -0.309 1.20E-02 
BC021614 1.246 6.83E-09 Hnrnpa2b1 0.259 2.74E-03 Rian -1.169 4.32E-12 
BC037034 0.416 3.02E-02 Hook3 -0.155 4.53E-02 Rilpl1 -0.408 8.95E-03 
BC051019 -0.556 3.07E-02 Hotair -0.44 3.34E-02 Rilpl2 0.52 2.94E-02 
BC094916 0.381 4.63E-02 Hoxa13 -0.342 1.82E-02 Rimklb -0.682 3.63E-03 
Bcar3 0.331 3.73E-02 Hoxa5 0.647 8.51E-03 Rin3 0.495 1.23E-02 
Bcas1 -0.715 5.42E-05 Hpse2 -0.413 1.16E-02 Rinl 0.824 4.11E-04 
Bcat1 -0.557 3.33E-02 Hs3st3b1 1.441 2.31E-12 Rltpr 0.674 4.48E-03 
Bcl11b 1.362 2.21E-15 Hsd17b14 0.578 1.31E-02 Rmnd5a -0.217 9.77E-03 
Bcl2l2 -0.274 1.56E-02 Hspb6 -0.53 3.97E-04 Rnf11 -0.351 8.52E-04 
Bcl3 0.543 2.12E-02 Hspb8 -0.363 8.40E-07 Rnf128 -0.319 9.84E-03 
Bdh1 -0.363 7.72E-04 Hspg2 -0.262 1.38E-02 Rnf19b 0.355 1.36E-02 
Bean1 -0.651 7.61E-03 Htra1 -0.277 2.38E-02 Rnf31 0.426 1.50E-02 
Bend4 -0.449 3.99E-02 Htra2 0.484 3.25E-02 Rnf38 -0.236 4.76E-03 
Bhlhb9 -0.425 1.04E-02 Hunk -0.893 3.97E-06 Rora -0.281 4.62E-03 
Bhmt2 -1.382 5.06E-12 Hvcn1 0.682 3.89E-03 Rorb -0.62 9.89E-03 
Bin2 0.957 3.67E-06 Hykk -0.59 1.11E-03 Rorc 0.868 9.90E-11 
Birc2 0.398 1.85E-03 Icam1 0.632 9.70E-06 Rpa1 -0.249 4.24E-02 
Birc3 0.623 3.91E-04 Icos 1.144 1.44E-07 Rpl15 -0.298 2.43E-02 
Blk 1.214 1.58E-08 Ide 0.235 4.55E-02 Rpl35a 0.593 1.03E-02 
Blnk 0.917 6.44E-07 Ifi27 0.688 2.55E-06 Rpl37a -0.373 3.97E-02 
Bmp2 -0.489 1.07E-09 Ifi44l 0.636 1.17E-02 Rpp38 0.524 3.87E-02 
Bmp4 -0.295 4.60E-02 Ift172 0.417 1.60E-03 Rps10 0.542 1.92E-02 
Bmp5 -0.607 1.07E-03 Ift46 -0.372 1.60E-02 Rps29 0.66 8.34E-03 
Bmpr1a -0.247 2.60E-02 Igf1r -0.165 1.02E-02 Rps6ka1 0.701 2.05E-06 
Bnip3 -0.541 9.12E-03 Igf2 -0.781 1.07E-08 Rps6kb2 0.656 1.40E-04 
Brca2 -0.425 4.72E-02 Igf2bp1 -1.68 2.38E-16 Rraga -0.474 1.15E-04 
Btbd8 0.716 3.47E-03 Igfbp3 0.42 9.50E-03 Rrn3 -0.251 1.54E-02 
Btg2 -0.365 1.02E-02 Igfbp5 -0.365 1.04E-02 Rsph4a 0.645 8.37E-04 
Btla 0.925 2.70E-05 Igsf10 -0.942 3.72E-10 Rsrp1 0.629 1.39E-12 
Bves -0.431 1.26E-03 Igsf11 -0.852 2.17E-04 Rsu1 -0.286 4.55E-02 
Bzw2 -0.33 5.39E-03 Igsf5 0.542 2.18E-05 Rtp4 0.565 1.81E-02 
C030006K11Rik -0.438 4.39E-02 Igsf9b -0.378 2.13E-02 Runx3 1.653 5.10E-19 
C030034L19Rik 0.953 2.00E-05 Ikbkb 0.332 2.04E-02 Rusc2 -0.303 4.17E-02 
C130026I21Rik 0.727 1.46E-05 Ikbke 0.71 4.02E-05 Rwdd2a 0.622 1.14E-02 
C1qa 0.337 2.09E-02 Ikzf1 0.962 9.32E-07 S100a14 0.548 9.67E-03 
C1qb 0.423 6.91E-03 Ikzf3 0.355 3.07E-02 S1pr2 -0.455 8.07E-03 
C230091D08Rik -0.311 2.34E-02 Il13ra1 0.438 2.25E-02 Samd12 0.624 1.43E-02 
C2cd4c -0.429 3.39E-02 Il16 0.564 1.09E-03 Samd4 -0.368 2.75E-03 
C3 0.398 9.69E-03 Il17ra 0.48 1.81E-02 Samd9l 0.373 3.14E-02 
C3ar1 0.447 2.46E-02 Il18 0.69 5.33E-03 Samsn1 0.553 3.70E-02 
C5ar2 -0.546 3.59E-02 Il18r1 1.563 6.14E-34 Sash3 0.965 1.20E-05 
C7 -0.497 5.44E-04 Il18rap 0.958 2.57E-06 Satb1 -0.328 1.52E-03 
C77080 0.22 2.12E-02 Il1r2 0.588 1.82E-02 Sbno2 0.493 1.65E-06 
C77370 0.968 1.31E-05 Il1rl2 0.629 1.25E-03 Scn7a -0.35 4.83E-04 
Cacna1c -0.248 2.90E-02 Il1rn 0.816 3.51E-04 Scrib 0.357 2.30E-02 
Cacna1e 1.092 6.32E-07 Il21r 0.801 7.52E-04 Sdc2 -0.435 1.26E-08 
Cacna1h -0.424 3.13E-05 Il23r 0.713 2.03E-03 Sdc3 -0.383 9.51E-06 
Cacna2d1 -0.369 8.63E-05 Il27ra 1.296 1.33E-09 Sdpr -0.264 2.29E-02 




Cadps -0.558 6.09E-03 Il2rg 1.402 6.02E-13 Secisbp2 0.289 3.08E-02 
Calcoco1 -0.248 3.65E-02 Il33 1.107 5.34E-08 Seh1l -0.28 4.44E-03 
Calcrl -0.395 1.24E-03 Il7 0.645 9.69E-03 Sel1l3 0.593 1.25E-03 
Cald1 -0.381 4.51E-03 Il7r 1.775 8.13E-19 Sell 0.601 1.47E-02 
Calm2 -0.311 2.70E-06 Impad1 -0.276 1.04E-04 Selplg 0.76 9.97E-04 
Calu -0.387 5.78E-03 Inf2 0.382 2.16E-03 Sema3e -0.497 2.12E-02 
Camk1d -0.306 1.92E-02 Inhba 0.521 4.09E-02 Sema4a 0.23 3.61E-02 
Camk2d -0.187 3.55E-02 Inhbb -0.37 3.37E-02 Sema4d 0.797 2.31E-06 
Camk2g -0.289 3.51E-02 Inpp5a -0.349 1.25E-03 Sema5a -0.396 1.24E-02 
Camk2n1 -0.459 4.01E-03 Inpp5d 0.795 4.59E-07 Sepn1 -0.28 2.34E-02 
Camk4 1.226 1.00E-08 Irak2 0.378 1.61E-02 Sept1 1.022 3.48E-06 
Cap2 -0.45 2.06E-08 Irf1 0.486 8.34E-03 Sept2 -0.355 1.39E-05 
Capn13 1.176 5.06E-12 Irf4 0.898 1.20E-05 Serinc1 -0.278 4.40E-02 
Capn3 0.69 3.95E-03 Irf6 0.281 7.01E-03 Serpina3g 0.84 1.06E-04 
Capn6 -0.659 2.56E-03 Irs1 -0.526 1.55E-06 Serpina3h 0.427 2.68E-02 
Capns1 -0.342 1.69E-03 Isg15 0.65 8.96E-03 Serpinb1a 0.603 3.89E-03 
Car3 -0.569 5.90E-03 Islr -0.339 5.96E-03 Serpinf1 -0.576 3.33E-05 
Card10 0.591 1.02E-02 Itga11 -0.513 3.23E-03 Serping1 -0.326 6.27E-03 
Card11 1.259 3.59E-09 Itga2 0.435 3.54E-02 Serpinh1 -0.403 1.01E-02 
Card14 0.5 5.52E-03 Itga6 0.279 5.83E-03 Setd7 -0.242 1.95E-03 
Casc4 -0.532 2.97E-05 Itgae 0.775 8.50E-04 Sfi1 0.636 8.44E-08 
Casp1 1.048 3.86E-07 Itgal 1.522 1.06E-15 Sfrp1 -0.284 9.99E-03 
Casp4 0.718 2.21E-03 Itgax 1 2.67E-06 Sgcb -0.341 4.49E-02 
Catsperd 0.64 3.23E-03 Itgb1 -0.289 7.48E-04 Sgk1 0.395 2.29E-02 
Cav1 -0.426 4.41E-03 Itgb2 0.801 2.96E-07 Sgms2 -0.538 5.25E-03 
Cblc 0.362 4.03E-02 Itgb2l 0.709 2.70E-05 Sgpl1 -0.245 9.34E-03 
Cbr2 0.46 2.59E-03 Itgb4 0.615 2.79E-08 Sgsm3 0.607 1.59E-06 
Cbx5 -0.217 8.07E-03 Itgb6 0.332 6.29E-03 Sh2d2a 0.847 2.86E-04 
Cbx6 -0.272 2.29E-02 Itgb7 1.227 3.85E-10 Sh2d3c 0.485 1.99E-02 
Ccdc113 -0.48 3.88E-02 Itk 1.345 1.79E-10 Sh3bp1 0.411 2.43E-02 
Ccdc3 -0.313 1.15E-03 Itm2a -0.509 6.32E-07 Sh3bp2 0.522 1.59E-02 
Ccdc34 -0.413 1.58E-02 Itpr2 0.431 4.82E-04 Sh3d21 0.476 1.58E-02 
Ccdc82 0.424 1.19E-03 Itpr3 0.281 1.12E-02 Sh3gl3 -0.554 2.74E-04 
Ccdc88b 1.497 3.45E-15 Itsn1 -0.264 8.49E-03 Sh3glb2 0.368 5.35E-03 
Cchcr1 0.466 2.83E-02 Itsn2 0.243 2.43E-02 Sh3tc1 0.508 1.87E-02 
Cck -0.796 7.65E-04 Jak3 0.603 1.47E-04 Sh3tc2 0.38 3.39E-02 
Ccl11 -0.52 2.52E-02 Jakmip1 0.537 1.93E-02 Shc3 -0.43 7.73E-03 
Ccl8 0.542 2.49E-02 Jchain 1.595 4.59E-15 Shh -0.348 4.40E-03 
Ccm2l 0.569 2.12E-02 Jmy -0.272 2.10E-03 Siglecg 0.502 4.15E-02 
Ccnd1 -0.379 1.01E-03 Jph2 -0.362 7.00E-03 Siglech -0.78 1.11E-03 
Ccnd2 -0.489 3.59E-09 Kank2 -0.318 6.99E-04 Sipa1 0.509 6.56E-03 
Ccne1 0.651 5.93E-03 Kank4 -0.464 2.13E-02 Sirt7 0.46 7.67E-03 
Ccni -0.264 5.37E-03 Kazald1 -0.589 1.94E-02 Skap1 0.578 2.71E-02 
Ccnl2 0.568 3.21E-07 Kcna1 -0.769 1.27E-07 Skint6 0.504 3.18E-02 
Ccr1 0.647 7.92E-03 Kcna2 -0.437 1.39E-02 Sla 1.3 1.69E-13 
Ccr2 0.701 4.40E-03 Kcna3 0.812 3.16E-04 Slamf1 0.562 1.25E-02 
Ccr4 0.611 3.81E-03 Kcna6 -0.515 2.86E-02 Slamf6 1.024 1.91E-06 
Ccser2 -0.236 4.70E-02 Kcnb1 -0.31 7.20E-03 Slamf7 0.836 3.04E-04 
Cd101 0.541 3.29E-02 Kcnb2 -0.837 2.68E-04 Slc15a2 -1.194 1.32E-08 
Cd14 0.414 1.25E-02 Kcnc1 0.794 8.55E-04 Slc15a4 0.504 1.22E-03 
Cd163 -1.075 2.32E-07 Kcnd3 -0.397 1.94E-04 Slc16a1 -0.402 1.80E-04 




Cd19 1.095 1.42E-07 Kcng4 -0.644 9.31E-03 Slc1a3 -0.493 4.06E-02 
Cd209b -1.354 1.79E-10 Kcnh2 -0.387 4.02E-02 Slc24a3 -0.393 2.53E-03 
Cd209d -0.943 1.72E-05 Kcnj10 0.684 2.50E-03 Slc25a23 -0.268 3.54E-02 
Cd209f -1.08 8.44E-08 Kcnk2 -1.177 3.31E-13 Slc25a4 -0.271 1.56E-02 
Cd209g -0.618 1.16E-02 Kcnma1 -0.301 5.64E-04 Slc25a51 -0.229 4.96E-02 
Cd22 0.928 3.81E-05 Kcnmb1 -0.503 3.02E-05 Slc26a2 0.263 1.56E-02 
Cd226 1.145 1.51E-07 Kcnmb4os2 0.458 3.48E-02 Slc26a5 -0.437 2.54E-02 
Cd24a 0.416 8.09E-03 Kcnv2 -0.479 4.58E-02 Slc27a6 0.611 4.80E-03 
Cd27 0.533 3.53E-02 Kctd10 -0.284 4.78E-02 Slc2a13 -0.517 1.58E-03 
Cd300a 0.538 3.87E-02 Kctd12b 0.478 3.74E-03 Slc2a4 -0.4 4.39E-05 
Cd36 -0.477 6.23E-03 Kctd17 -0.329 1.28E-02 Slc2a4rg-ps 0.746 1.28E-04 
Cd37 0.914 6.86E-05 Khdrbs3 -0.298 3.37E-02 Slc35e3 -0.405 2.43E-02 
Cd3d 0.7 1.52E-03 Kif1a -1.099 4.06E-11 Slc35f1 -0.517 3.12E-02 
Cd3e 2.033 1.25E-25 Kif21b 1.121 1.02E-10 Slc35f5 -0.263 1.16E-02 
Cd3g 1.928 3.45E-21 Kifc3 0.459 2.48E-04 Slc37a1 0.669 1.15E-03 
Cd4 1.083 1.28E-07 Kirrel -0.223 3.65E-02 Slc38a1 -0.481 1.37E-06 
Cd48 0.536 4.58E-02 Klhdc10 -0.335 1.82E-04 Slc38a4 -0.69 4.47E-03 
Cd5 0.713 2.75E-03 Klhdc8b 0.607 1.11E-03 Slc39a4 1.105 2.83E-07 
Cd52 1.038 2.95E-06 Klhl13 -0.534 2.12E-02 Slc45a3 0.55 3.12E-02 
Cd53 0.682 1.84E-03 Klhl23 -0.368 1.22E-03 Slc47a1 -0.841 1.04E-04 
Cd6 0.61 9.67E-03 Klhl29 -0.309 4.49E-02 Slc4a7 -0.285 1.80E-04 
Cd72 0.853 2.31E-04 Klhl6 0.607 1.30E-02 Slc5a9 0.565 2.75E-02 
Cd74 1.108 7.98E-11 Klk1b22 0.657 8.74E-03 Slc6a15 -0.728 2.14E-03 
Cd79a 0.742 8.72E-04 Klrb1b 0.422 2.70E-02 Slc6a17 -0.474 9.83E-05 
Cd81 -0.25 2.45E-02 Klrk1 0.777 9.56E-04 Slc7a11 1.294 1.04E-14 
Cd82 0.406 1.02E-04 Kpna6 -0.23 4.91E-03 Slc7a6os 0.435 3.37E-02 
Cd84 0.877 2.81E-05 Kri1 0.447 1.54E-02 Slc7a8 -0.44 1.12E-02 
Cd86 0.839 1.48E-04 Krt14 0.915 2.62E-06 Slc8a1 -0.356 5.97E-04 
Cd8a 0.498 1.65E-02 Krt20 -0.331 1.76E-04 Slc8a2 -0.541 8.67E-03 
Cd96 1.117 1.45E-07 Krt23 0.777 1.12E-03 Slfn2 0.975 1.24E-07 
Cdc14b -0.408 1.31E-02 Krt4 1.12 2.49E-07 Slfn5 0.445 3.03E-06 
Cdcp1 0.33 1.77E-02 Krtcap3 0.499 1.28E-02 Slit3 -0.257 7.79E-03 
Cdh6 -0.472 3.49E-02 Kynu 0.558 1.73E-02 Slmap -0.216 3.78E-02 
Cdkn2a 0.684 3.52E-03 Lacc1 0.536 2.94E-03 Smarca1 -0.623 9.50E-04 
Cdo1 0.997 7.10E-09 Lair1 0.619 1.52E-02 Smim11 -0.487 2.97E-03 
Cds1 -0.185 3.28E-02 Lama5 0.282 2.25E-03 Smo -0.232 3.73E-02 
Ceacam1 0.407 2.71E-02 Lamb1 -0.32 2.30E-04 Smoc1 -1.037 8.95E-09 
Cecr2 -0.813 2.40E-07 Lamc1 -0.312 3.10E-05 Smoc2 -0.354 9.08E-03 
Cela1 -0.433 1.88E-02 Laptm5 0.663 9.70E-06 Smpd3 -0.478 8.77E-03 
Cep152 0.539 1.13E-02 Las1l 0.431 1.85E-02 Snhg11 0.649 6.44E-07 
Cep250 0.404 1.32E-02 Lat 1.345 2.48E-10 Snhg20 0.519 4.23E-02 
Cercam -0.401 1.06E-02 Lat2 0.556 3.28E-02 Snora3 0.684 3.27E-03 
Cerk 0.567 6.63E-06 Lax1 1.543 1.24E-13 Snora61 0.673 5.57E-03 
Ces2f 0.881 1.00E-04 Lck 0.782 9.21E-04 Snord15a 0.528 3.70E-02 
Cfb 0.521 7.10E-04 Lclat1 -0.639 3.61E-05 Snord34 0.541 3.79E-02 
Cfl2 -0.387 5.34E-04 Lcp1 0.361 2.62E-03 Snord47 0.593 1.91E-02 
Cggbp1 -0.232 4.11E-02 Lcp2 1.073 1.29E-08 Snord49a 0.717 7.58E-04 
Chd7 0.49 1.11E-03 Ldb3 -0.367 1.28E-04 Snord53 0.598 2.09E-02 
Chic1 -0.369 1.01E-02 Ldhd 0.551 1.49E-02 Snord72 0.574 2.88E-02 
Chl1 0.799 1.04E-06 Ldlr 0.483 2.30E-04 Snord85 0.422 4.59E-02 
Chrdl1 -0.542 1.28E-04 Ldlrad3 -1.012 6.96E-17 Snord87 0.703 3.81E-03 




Chst8 -0.595 2.17E-02 Leng8 0.554 8.60E-08 Snx10 0.383 1.85E-02 
Ciita 0.901 9.68E-06 Lfng 0.546 3.02E-03 Snx20 0.711 3.52E-03 
Ckb -0.455 5.75E-04 Lgals2 0.492 3.75E-02 Snx29 0.366 3.00E-02 
Ckm -0.506 6.00E-03 Lgals3 0.419 8.92E-03 Snx31 0.171 1.68E-02 
Clasrp 0.63 2.48E-04 Lgr4 -0.25 2.60E-02 Soat1 -0.376 2.36E-04 
Clca1 0.587 8.41E-03 Limch1 -0.549 8.61E-05 Soga1 -0.296 7.06E-03 
Clca2 1.278 2.43E-09 Limd2 0.512 1.58E-02 Sorbs1 -0.266 2.71E-03 
Clca3a1 1.584 8.21E-18 Lime1 0.703 1.38E-05 Sort1 -0.457 3.74E-11 
Clca3a2 1.644 1.57E-16 Limk2 0.295 6.64E-03 Sox11 -0.645 7.20E-03 
Cldn1 -0.696 2.12E-07 Lin28b -0.426 4.08E-02 Sox5 -0.779 7.18E-08 
Clec12a 0.64 1.03E-02 Lingo4 0.516 2.68E-02 Sox7 0.506 4.78E-02 
Clec2d 0.41 7.44E-03 Lix1l -0.292 1.73E-02 Sp100 0.758 9.74E-08 
Clec2f 0.784 1.27E-04 Lmod1 -0.288 3.58E-05 Sp110 0.834 2.32E-06 
Clec2g 0.454 3.36E-02 Loxl2 -0.611 4.97E-06 Sp6 -0.812 3.51E-08 
Clec7a 0.654 6.77E-03 Lpar1 -0.282 2.04E-02 Sparc -0.376 1.42E-02 
Clic4 -0.234 5.33E-04 Lpcat2 0.696 2.39E-03 Spata13 -0.273 5.03E-03 
Clic5 -0.33 4.86E-02 Lpp -0.447 1.72E-05 Spg20 -0.298 2.08E-02 
Clic6 0.484 4.40E-02 Lrmp 0.838 1.18E-04 Sphk1 0.482 2.83E-02 
Clip4 0.62 4.86E-07 Lrp3 -0.393 3.11E-02 Spn 1.354 1.48E-10 
Clmp -0.381 1.81E-04 Lrrc16a 0.283 6.33E-03 Spock1 -1.531 1.69E-13 
Cln3 0.438 2.65E-02 Lrrc45 0.51 1.28E-02 Spock2 -0.386 4.05E-02 
Clnk 0.826 2.68E-04 Lrrc58 -0.264 1.12E-02 Spock3 -0.978 3.89E-09 
Clu 0.263 4.38E-02 Lrrc75b -0.44 3.79E-02 Spred1 -0.282 9.86E-04 
Cmtm4 -0.258 9.83E-03 Lsm2 -0.472 2.12E-02 Sprr2a3 0.713 1.54E-06 
Cnksr2 -0.575 1.78E-02 Ltb 1.193 1.10E-08 Sprr2f 0.501 1.54E-02 
Cnn1 -0.335 2.73E-02 Luc7l3 0.404 3.88E-04 Srcin1 -0.508 4.34E-02 
Cnn3 -0.355 3.88E-03 Lurap1l -0.281 2.43E-02 Srf -0.357 1.26E-03 
Cntrl 0.388 4.72E-04 Ly6c2 1.167 1.20E-08 Srgn 0.72 2.76E-04 
Coa7 -0.446 3.07E-02 Ly6e 0.546 1.39E-07 Srpk1 0.377 2.77E-03 
Col11a1 -0.818 3.82E-05 Ly6g5b 0.8 1.07E-04 Srpx -0.482 3.51E-03 
Col16a1 -0.511 5.67E-04 Ly6k 0.512 2.50E-02 Srrt 0.265 3.98E-02 
Col17a1 1.386 4.31E-27 Ly75 1.026 1.93E-09 Srsf5 0.534 3.67E-04 
Col1a1 -0.44 5.22E-03 Lyn 0.574 1.18E-03 Srxn1 -0.354 1.32E-02 
Col1a2 -0.403 2.49E-03 Lypd6 -1.068 1.00E-08 Ssh2 0.215 2.77E-02 
Col4a1 -0.344 3.70E-03 Lypd6b -0.608 1.41E-02 Ssh3 0.299 4.90E-02 
Col4a2 -0.276 4.41E-02 Lyz2 0.518 6.02E-04 Ssr1 -0.222 2.83E-02 
Col4a5 -0.309 9.73E-04 Mab21l1 0.565 2.73E-02 Ssr3 -0.297 1.13E-02 
Col5a1 -0.403 9.30E-03 Madd 0.277 2.34E-02 St14 0.375 1.43E-02 
Col5a2 -0.455 1.91E-03 Maged1 -0.307 7.65E-04 St3gal1 0.407 5.78E-04 
Col6a1 -0.341 1.91E-02 Maged2 -0.379 1.51E-02 St3gal6 0.458 2.37E-02 
Col6a2 -0.426 1.01E-03 Mal 0.291 1.25E-03 St6gal1 0.512 2.53E-03 
Col6a3 -0.673 6.36E-11 Man2b1 0.262 2.10E-02 St6galnac3 0.832 4.10E-04 
Col7a1 1.888 3.70E-23 Map1a -0.303 1.62E-02 Stab1 0.416 1.47E-03 
Corin -1.194 1.95E-11 Map1b -0.306 3.06E-04 Stap2 0.593 3.74E-03 
Coro1a 1.038 5.38E-11 Map3k1 0.26 1.83E-03 Stat2 0.338 8.89E-03 
Coro1b 0.272 1.76E-02 Map3k14 0.468 7.36E-03 Stat4 0.561 3.07E-02 
Coro7 0.434 5.02E-03 Map4k1 0.811 6.05E-04 Steap4 0.594 1.25E-03 
Cox4i2 -0.581 2.02E-02 Map4k2 0.515 6.19E-04 Stk10 0.522 1.97E-06 
Cp 0.709 3.94E-04 Map6d1 0.559 3.37E-02 Stk25 0.289 4.10E-02 
Cpe -0.342 1.66E-02 Mapk8ip3 0.323 1.10E-02 Stk39 -0.303 2.67E-02 
Cpeb3 -0.331 3.77E-02 Mapt -0.56 2.84E-02 Stt3b -0.262 3.86E-05 




Cpq -0.354 2.26E-02 Marveld1 -0.245 5.88E-03 Sult4a1 -0.488 2.72E-02 
Cpsf1 0.326 2.32E-02 Mc5r -0.981 6.99E-06 Sumo3 -0.278 1.13E-02 
Cpxm1 -0.403 5.38E-03 Mdm4 0.255 1.55E-03 Supt20 0.309 2.34E-02 
Cpxm2 -0.34 1.31E-02 Med11 0.601 8.77E-03 Susd3 0.535 4.78E-02 
Cpz -0.67 5.20E-05 Med12l -0.701 2.11E-04 Sv2b -1.114 1.36E-19 
Cr2 0.576 2.48E-02 Meg3 -0.993 7.93E-09 Svep1 -0.373 1.59E-03 
Cramp1l 0.205 3.63E-02 Megf10 -0.659 7.70E-03 Svil -0.213 4.26E-02 
Creb3l1 -0.471 1.06E-02 Meis1 -0.405 3.83E-12 Svip -0.437 5.38E-03 
Crebzf 0.22 4.45E-02 Mettl17 0.544 2.04E-03 Swap70 0.37 8.34E-03 
Crispld2 -0.33 1.69E-04 Mfap2 -0.582 7.86E-03 Sycp3 -0.531 3.65E-02 
Crlf3 0.389 1.40E-02 Mfng 0.66 8.47E-03 Syk 0.7 1.69E-04 
Crmp1 0.519 2.59E-02 Mgat3 0.376 1.60E-05 Synj1 0.276 4.95E-02 
Crtap -0.333 3.89E-03 Mgst1 -0.333 6.07E-04 Synj2 0.261 3.70E-02 
Csde1 -0.271 1.30E-03 Mgst3 -0.38 1.58E-02 Synj2bp -0.249 1.85E-02 
Csf2rb 0.707 9.96E-05 Mical2 -0.285 3.62E-02 Synm -0.37 9.44E-05 
Csf2rb2 0.592 2.04E-03 Mink1 0.223 9.85E-03 Synpo 0.307 3.08E-02 
Cspg4 -0.243 3.73E-02 Mir3068 0.555 3.47E-02 Synpo2 -0.421 1.42E-06 
Cspp1 0.353 1.85E-02 Mlph 0.656 4.53E-06 Syt16 0.717 1.04E-06 
Csrp1 -0.357 3.72E-03 Mmd -0.409 8.84E-04 Syt8 0.631 2.78E-09 
Ctdp1 0.35 3.65E-03 Mmp12 0.586 2.84E-03 Sytl5 -0.342 5.30E-03 
Ctla2a 0.514 3.11E-02 Mmp2 -0.28 3.16E-03 Tacc1 -0.238 1.58E-02 
Ctla4 0.554 8.09E-03 Mmp25 0.902 1.59E-05 Tacr1 0.654 9.22E-03 
Ctnnal1 -0.279 1.12E-02 Mmrn1 0.826 3.88E-04 Tacstd2 0.31 2.59E-02 
Ctse -0.338 7.73E-04 Mndal 0.438 4.17E-02 Taf4b 0.633 8.38E-04 
Ctsh 0.35 3.11E-03 Mocs1 -0.225 3.25E-02 Tagln -0.31 2.99E-02 
Ctss 0.888 4.59E-07 Moxd1 -0.713 7.73E-04 Taok1 -0.212 3.37E-02 
Ctsw 0.571 2.98E-02 Mpeg1 0.855 3.94E-07 Tap1 0.86 1.63E-07 
Cx3cr1 0.74 1.01E-03 Mrc2 -0.317 4.64E-02 Tap2 0.528 2.64E-04 
Cxcl12 -0.312 6.19E-04 Mrgprf -0.455 6.91E-03 Tbc1d10c 1.052 2.05E-06 
Cxcl16 0.382 3.56E-02 Mrvi1 -0.411 2.04E-08 Tbc1d16 -0.523 1.31E-04 
Cxcr4 0.706 2.14E-03 Ms4a4b 0.525 4.00E-02 Tbc1d32 -0.361 2.86E-02 
Cxcr6 1.318 9.58E-12 Ms4a6c 0.653 2.68E-03 Tbce 0.391 3.72E-02 
Cxx1b -0.518 3.98E-02 Ms4a7 0.581 2.26E-02 Tbx20 -0.477 1.55E-06 
Cyb5a 0.301 4.23E-03 Msh5 0.549 3.96E-02 Tbx4 -0.374 1.77E-02 
Cybb 0.672 3.89E-04 Msi2 -0.274 1.17E-04 Tceal5 -0.468 4.17E-02 
Cyp27a1 0.92 7.35E-10 Msrb3 -0.35 1.12E-05 Tceal8 -0.454 9.73E-04 
Cyp4f15 0.325 3.41E-03 Mtcl1 -0.482 5.25E-03 Tcirg1 0.686 4.71E-05 
Cyp51 0.306 2.12E-02 Mterf4 0.405 1.81E-02 Tdrd9 0.518 3.28E-02 
Cysltr2 0.518 1.30E-02 Mum1l1 -0.504 1.06E-02 Tead1 -0.34 2.14E-04 
Cyth1 0.303 9.76E-03 Myadm -0.256 3.75E-02 Tenm2 -0.403 2.47E-02 
Cyth4 0.545 2.23E-03 Mycbp2 0.235 6.61E-03 Tenm3 -0.535 3.93E-05 
Cytip 1.093 2.02E-07 Myh10 -0.408 8.37E-04 Tespa1 0.65 8.23E-03 
D17H6S56E-5 0.615 7.26E-03 Myh11 -0.225 2.80E-02 Tet1 -0.624 2.74E-04 
D930048N14Rik 0.438 4.82E-02 Myl9 -0.388 2.15E-04 Tfap2a 1.425 6.18E-12 
Daam2 -0.499 1.28E-04 Mylip -0.211 3.55E-02 Tfrc 0.277 4.40E-02 
Dab1 -0.672 3.03E-03 Mylk -0.396 1.11E-07 Tgfb1i1 -0.532 5.41E-08 
Dach1 -0.771 1.17E-06 Myo18a 0.378 7.77E-04 Tgfbi -0.496 3.87E-07 
Dag1 -0.232 3.15E-03 Myo1f 0.928 1.38E-07 Tgfbr1 -0.232 3.85E-02 
Dap -0.259 1.87E-02 Myo1g 0.728 8.42E-04 Tgfbr3 -0.393 2.70E-11 
Dap3 0.367 3.87E-03 Myo5c 0.54 9.99E-05 Tgoln1 -0.281 4.55E-05 
Dcbld2 -0.312 1.37E-02 Myo9b 0.264 1.31E-02 Thbd -0.279 1.22E-02 




Ddx17 0.328 7.38E-05 Myof 0.228 2.83E-02 Them7 -0.689 4.67E-03 
Ddx5 0.285 1.01E-05 Mzb1 0.718 6.27E-04 Themis 0.922 1.33E-05 
Ddx58 0.346 1.34E-02 Naa50 -0.273 5.59E-04 Thsd4 -0.746 5.95E-27 
Dedd2 0.652 1.14E-03 Nacc2 -0.35 2.70E-03 Tia1 0.285 4.78E-02 
Defb1 0.861 1.40E-04 Naip2 0.594 9.51E-03 Tifab 0.527 4.37E-02 
Dennd1c 0.77 3.17E-04 Nalcn -0.815 4.18E-04 Timp2 -0.231 2.89E-03 
Dennd2d 0.327 9.34E-03 Nampt -0.303 2.70E-02 Tjp2 0.224 4.88E-02 
Dennd3 0.54 1.91E-03 Napsa 0.608 1.75E-02 Tjp3 0.318 2.67E-02 
Depdc7 0.557 2.61E-03 Nav1 -0.284 1.20E-02 Tm9sf3 -0.206 4.00E-03 
Deptor -0.262 4.36E-03 Ncald -0.548 4.49E-06 Tmc4 0.29 7.27E-03 
Derl3 0.663 7.16E-03 Ncam1 -0.376 1.04E-04 Tmc6 0.531 3.59E-04 
Des -0.415 7.58E-04 Ncf4 0.554 3.28E-02 Tmem117 -0.512 3.00E-02 
Desi2 -0.263 1.24E-02 Nckap1l 0.614 2.88E-04 Tmem154 0.288 3.80E-02 
Dgka 0.334 2.26E-02 Ncoa1 -0.238 2.03E-02 Tmem2 0.334 4.14E-02 
Dgkd 0.438 2.89E-03 Ncoa3 0.214 5.30E-03 Tmem263 -0.333 1.58E-02 
Dhcr24 0.323 5.47E-03 Nde1 0.371 5.99E-03 Tmem38b -0.317 2.11E-02 
Dhtkd1 -0.491 4.40E-02 Ndn -0.499 3.74E-03 Tmem47 -0.484 5.17E-07 
Diap1 0.179 2.97E-02 Ndufa4 -0.443 1.16E-03 Tmem88b -0.531 4.98E-02 
Dio2 0.589 1.26E-03 Ndufa4l2 -0.538 4.25E-02 Tmprss11e 0.723 1.42E-03 
Diras2 -0.849 1.63E-07 Neat1 0.668 1.08E-10 Tmprss11g 3.496 3.73E-83 
Disp1 -0.452 7.07E-03 Necab1 -0.561 2.26E-02 Tmprss2 0.196 7.82E-03 
Dkk2 -0.375 1.31E-02 Nedd4 -0.213 2.84E-03 Tnc -0.457 2.53E-03 
Dlk2 0.646 9.39E-03 Nedd9 0.376 2.74E-02 Tnf 0.452 4.64E-02 
Dmbt1 0.611 4.87E-03 Nek9 -0.241 6.07E-04 Tnfaip2 0.337 2.02E-02 
Dmd -0.312 5.75E-03 Nell2 -1.435 1.24E-12 Tnfrsf13b 0.511 1.77E-02 
Dmgdh -2.2 8.18E-28 Neo1 -0.296 7.30E-03 Tnfrsf13c 0.682 3.23E-03 
Dmpk -0.301 7.39E-03 Nes -0.547 5.77E-06 Tnfrsf1b 0.505 6.94E-04 
Dmtn -0.834 1.85E-06 Neurl1a -0.391 1.82E-02 Tnfrsf25 0.561 3.25E-02 
Dnah8 0.732 8.74E-04 Neurl3 0.642 4.33E-03 Tnfsf10 0.41 9.48E-03 
Dnajc6 -1.033 3.39E-13 Nfatc1 0.375 3.87E-02 Tnfsf14 0.572 1.37E-02 
Dnajc7 0.335 4.41E-02 Nfatc4 -0.333 1.33E-02 Tnfsf8 0.463 3.01E-02 
Dnase1l3 0.803 4.28E-04 Nfia -0.252 8.34E-03 Tnni2 0.562 2.60E-02 
Dnm2 0.259 3.81E-02 Nfib -0.357 1.26E-06 Tnpo1 -0.168 3.63E-02 
Dock10 0.515 7.39E-03 Nfic -0.305 1.96E-03 Tns1 -0.322 1.01E-03 
Dock2 1.185 4.06E-11 Nfkb1 0.296 8.59E-03 Tns3 0.361 1.57E-03 
Dock3 -0.421 1.31E-02 Nfkbie 0.433 3.52E-02 Tob1 -0.314 5.38E-03 
Dock4 0.393 1.20E-02 Nfkbiz 0.499 1.26E-03 Tox2 -0.67 6.90E-03 
Dock6 0.361 1.13E-02 Nhs -0.418 3.63E-02 Tpcn1 -0.3 5.12E-03 
Dock9 0.183 2.82E-02 Nhsl2 -0.386 5.72E-04 Tpm1 -0.374 3.70E-03 
Dok3 0.613 1.64E-02 Nid1 -0.353 8.59E-03 Tra2a 0.249 4.29E-02 
Dpep1 -0.579 4.85E-03 Nipal1 0.384 2.48E-02 Traf1 0.993 9.67E-06 
Dpysl3 -0.326 2.93E-02 Nkd1 -0.331 1.61E-02 Traf3ip3 1.355 1.77E-10 
Dsc2 0.596 1.07E-04 Nkg7 0.631 9.81E-03 Trf -0.28 4.92E-03 
Dsg2 0.201 1.07E-02 Nlgn3 -0.587 7.22E-03 Trim24 0.355 8.64E-04 
Dsg3 0.501 1.06E-02 Nlrc3 0.765 1.41E-03 Trim30a 0.652 2.27E-04 
Dtna -0.308 1.15E-02 Nlrc4 0.624 1.34E-02 Trim35 -0.249 2.04E-02 
Duox1 0.501 6.25E-04 Nlrc5 1.249 1.04E-17 Trim36 -0.365 2.79E-02 
Duoxa2 0.597 1.07E-02 Nlrp10 1.081 7.03E-07 Trim6 0.499 4.70E-02 
Dusp3 -0.341 2.07E-03 Nlrp3 0.618 1.33E-02 Trim68 0.334 2.84E-02 
Dvl1 0.351 3.57E-02 Nmnat2 -0.771 2.39E-05 Triobp -0.412 1.29E-04 
Dync1li2 -0.192 1.38E-02 Nnt -0.377 2.47E-04 Trnp1 -0.487 3.65E-02 




Dyrk1a -0.175 4.70E-02 Nol7 -0.319 3.21E-02 Trpm2 0.844 3.14E-04 
E130102H24Rik 0.591 2.12E-02 Nos2 0.637 1.18E-02 Trpm6 0.711 1.85E-03 
E330020D12Rik 0.535 6.35E-03 Nostrin 0.625 7.91E-04 Trps1 -0.345 3.11E-03 
Ebpl -0.408 2.43E-02 Notch1 0.208 3.83E-02 Trpv6 0.523 3.07E-02 
Ecm1 -0.34 1.12E-03 Notum -0.656 1.60E-03 Tsc22d1 -0.259 2.46E-03 
Edem2 0.395 2.05E-02 Nptx2 -0.369 4.48E-02 Tspan18 -0.391 3.49E-03 
Edil3 -1.366 1.36E-15 Npy4r -0.544 6.09E-03 Tspan2 -0.439 6.30E-05 
Ednrb -0.783 1.05E-10 Nqo1 -0.532 2.67E-05 Tspan5 -0.292 6.09E-03 
Eed 0.36 4.02E-02 Nr2f2 -0.284 1.12E-02 Tspan6 0.277 2.39E-02 
Efcab1 -1.411 1.50E-11 Nrgn 0.538 1.02E-02 Tspan7 -0.492 8.07E-06 
Efemp1 -0.487 1.74E-03 Nrn1 -1.478 5.27E-19 Tspan9 -0.333 1.36E-03 
Egfl6 -0.698 3.75E-03 Nsg2 -0.842 1.68E-04 Tspyl5 -0.54 2.57E-02 
Egflam -0.461 1.58E-02 Nsmaf 0.268 2.29E-02 Ttc14 0.305 6.83E-03 
Egln3 -0.33 1.91E-02 Nt5dc3 -0.28 4.27E-02 Ttc39a 0.62 7.75E-04 
Ehd2 -0.404 3.87E-03 Ntf3 -0.494 4.06E-02 Ttc7 0.342 1.65E-02 
Ehf 0.22 2.95E-02 Ntn4 -0.401 3.78E-02 Ttll1 -0.481 7.83E-03 
Eif3l -0.304 3.18E-02 Nuak2 0.594 1.08E-02 Ttll10 0.404 3.79E-02 
Elavl1 -0.234 5.78E-03 Nup210 0.661 4.05E-04 Ttll7 -0.291 1.45E-02 
Elavl2 -0.631 8.24E-03 Nxf1 0.389 4.21E-04 Ttn 0.621 1.29E-02 
Elf3 0.33 3.31E-02 Nxf7 -0.467 2.37E-02 Tubb6 -0.365 2.94E-03 
Elf5 -1.282 1.62E-09 Nxpe4 -0.764 1.26E-03 Twsg1 -0.349 3.59E-06 
Elfn1 -0.752 1.16E-03 Oas3 0.575 2.43E-02 Txk 0.556 1.54E-02 
Ell2 0.686 4.11E-07 Obscn 0.546 4.01E-02 Uba7 0.936 4.37E-08 
Ell3 0.616 9.13E-03 Ogdh -0.203 3.07E-02 Ube2d3 -0.247 1.96E-02 
Elmo1 0.42 3.74E-03 Ogt 0.29 3.19E-03 Ube2q2 -0.375 2.18E-03 
Elovl4 -0.474 2.11E-05 Oit1 0.587 4.47E-04 Ube2r2 -0.299 1.54E-02 
Elovl5 -0.279 7.86E-03 Olfml2b -0.516 2.30E-04 Ubxn7 -0.171 4.79E-02 
Emb 0.842 2.11E-05 Olfr60 0.62 2.11E-03 Uchl1 -1.593 2.05E-14 
Emid1 -0.554 3.43E-03 Opcml -0.591 1.69E-03 Uck2 0.369 3.29E-02 
Emilin1 -0.377 1.65E-02 Oplah 0.396 2.39E-02 Ugp2 -0.245 2.54E-02 
Eml1 -0.277 1.15E-02 Oprd1 -0.594 2.21E-02 Ugt2b34 0.563 1.59E-04 
Eml3 0.349 3.26E-02 Optc -0.643 1.19E-04 Ugt2b35 0.972 9.51E-06 
Enah -0.262 2.84E-02 Orai2 0.589 1.17E-02 Unc13d 0.86 3.33E-06 
Eno3 -0.634 1.68E-04 Osbpl3 0.229 8.59E-03 Ushbp1 0.64 3.16E-03 
Enpep -0.53 2.46E-02 Osbpl6 -0.93 3.07E-08 Usp22 -0.27 1.66E-02 
Entpd1 -0.367 1.46E-05 Otud6b -0.274 3.70E-02 Usp24 0.232 3.92E-03 
Epb4.1l3 -0.888 1.73E-09 P2rx1 -0.404 3.16E-03 Usp48 0.224 1.91E-02 
Epha1 0.707 6.89E-10 P2ry10 1 6.21E-06 Utp14b 0.598 3.70E-04 
Ephb6 0.621 7.77E-04 P2ry2 0.455 4.70E-03 Vars 0.394 8.92E-03 
Ephx3 0.733 1.31E-03 Pabpc4l -0.653 8.98E-03 Vav1 0.687 4.20E-03 
Ephx4 0.65 3.69E-03 Pabpn1 0.428 3.48E-03 Vav3 0.575 2.82E-04 
Epsti1 0.485 2.88E-02 Padi1 1.166 8.60E-08 Vcl -0.31 5.59E-04 
Erbb3 0.295 9.26E-03 Padi2 0.524 1.49E-02 Vdr 0.52 4.05E-02 
Ermp1 -0.21 2.86E-02 Padi3 1.02 4.47E-06 Vma21 -0.479 1.46E-03 
Ern2 0.679 6.23E-03 Padi4 1.007 3.86E-12 Vmp1 0.253 4.99E-02 
Esrrg -0.547 1.12E-02 Pafah1b1 -0.208 1.09E-03 Vnn1 0.804 1.63E-04 
Ets1 0.755 7.58E-15 Pag1 0.303 3.02E-02 Vpreb3 0.463 3.00E-02 
Etv3 0.301 8.22E-03 Paip2b -0.282 3.87E-02 Vps33b 0.416 8.86E-03 
Etv5 -0.523 5.80E-04 Pak1 0.402 1.08E-02 Vps35 -0.236 4.58E-02 
Ewsr1 0.193 1.91E-02 Pak3 0.337 3.41E-02 Wbp11 -0.271 2.29E-02 
Extl3 -0.329 7.76E-06 Pak7 -0.309 3.15E-02 Wbscr17 -0.485 4.06E-02 




Eya2 1.028 3.21E-08 Pan2 0.436 5.89E-04 Wfdc1 -0.34 1.98E-02 
F2rl1 0.539 1.08E-02 Pappa2 -0.748 5.91E-04 Whsc1 0.267 2.58E-02 
Fabp4 -0.42 1.60E-03 Parva -0.331 2.25E-03 Wipf3 0.522 2.91E-02 
Fam107b 0.442 8.17E-03 Parvg 1.281 1.39E-09 Wnk3 -0.633 1.85E-03 
Fam114a2 0.275 4.94E-02 Pbx1 -0.244 1.88E-06 Wnt2 0.398 8.47E-03 
Fam118a -0.345 1.23E-02 Pbxip1 -0.289 2.86E-03 Wwtr1 -0.314 5.52E-04 
Fam120c -0.265 1.64E-02 Pcbd1 -0.742 2.04E-03 Xbp1 0.359 8.64E-04 
Fam129a -0.416 1.56E-07 Pcdh17 -0.436 1.73E-02 Xist 0.249 7.09E-03 
Fam162a 0.311 2.54E-02 Pcdh18 -0.404 2.53E-03 Ywhaz -0.275 1.23E-02 
Fam167a 0.568 3.12E-02 Pclo -0.691 1.38E-03 Zadh2 -0.37 5.48E-04 
Fam171a1 -0.341 4.47E-03 Pcolce -0.357 1.54E-02 Zak -0.382 1.26E-08 
Fam189a2 -0.388 1.48E-02 Pcp4l1 -0.51 4.10E-04 Zap70 1.398 3.91E-11 
Fam193b 0.644 7.65E-05 Pcx 0.437 8.40E-03 Zbed3 -0.418 1.20E-02 
Fam199x -0.34 6.99E-04 Pdcd1 0.442 4.03E-02 Zbtb41 -0.224 4.78E-02 
Fam210a -0.386 1.09E-06 Pde11a 0.401 3.31E-02 Zbtb8os 0.511 3.21E-02 
Fam212a 0.518 4.12E-02 Pde3a -0.277 3.98E-02 Zc3h12a 0.723 2.40E-04 
Fam25c 0.383 1.89E-02 Pde4d -0.292 7.20E-03 Zc3h12d 0.987 1.05E-05 
Fam3a 0.47 4.02E-03 Pde5a -0.442 1.73E-07 Zc3h7a 0.479 5.14E-08 
Fam3b 0.646 2.27E-03 Pde7a 0.423 6.88E-03 Zcchc24 -0.383 1.35E-04 
Fam46c 1.025 9.64E-07 Pde7b -0.497 6.73E-07 Zdhhc14 -0.289 2.36E-02 
Fam65b 0.948 3.94E-07 Pdgfc -0.54 3.64E-04 Zdhhc8 -0.287 4.10E-02 
Fam78a 0.797 4.47E-04 Pdgfra -0.336 1.22E-03 Zeb1 -0.33 9.99E-05 
Fam84b -0.259 5.13E-03 Pdgfrl -0.61 5.13E-03 Zeb2 -0.388 7.86E-03 
Faxc -0.451 1.19E-05 Pdk2 -0.353 5.00E-02 Zfc3h1 0.22 3.19E-02 
Fbln5 -0.446 3.09E-03 Pdk4 -0.408 8.00E-03 Zfhx3 -0.288 8.94E-05 
Fbxl12 0.421 4.02E-02 Pdlim3 -0.366 5.39E-03 Zfp207 0.259 8.14E-03 
Fbxl12os 0.644 1.01E-02 Pdlim7 -0.343 1.40E-03 Zfp275 -0.262 4.96E-02 
Fbxl22 -0.512 1.52E-04 Pdzk1ip1 0.407 9.40E-03 Zfp354c -0.369 2.17E-02 
Fbxo3 -0.263 2.26E-03 Pdzrn3 -0.301 9.50E-05 Zfp367 -0.446 4.18E-04 
Fbxo30 -0.379 3.68E-03 Peg10 0.478 1.20E-02 Zfp36l1 -0.206 3.43E-02 
Fcamr 0.6 2.89E-03 Peli2 -0.334 1.58E-03 Zfp423 -0.384 4.63E-03 
Fcgr1 0.536 4.64E-02 Pfkfb2 0.219 7.22E-03 Zfp536 -0.457 5.77E-04 
Fcho1 0.735 2.51E-03 Pfkfb4 0.461 9.97E-03 Zfp692 0.471 3.80E-02 
Fcrl1 0.834 9.05E-05 Pgm5 -0.351 2.07E-06 Zfp704 -0.282 1.70E-02 
Fcrla 0.455 4.07E-02 Phc3 -0.192 1.53E-02 Zfp831 1.134 1.95E-07 
Fdps 0.621 8.81E-04 Phf11d 0.488 3.05E-02 Zfp862-ps -0.289 4.77E-02 
Fer1l4 0.276 2.71E-02 Pi4kb 0.223 2.83E-02 Zgpat 0.392 2.54E-02 
Fermt2 -0.317 5.24E-03 Pid1 -0.415 3.14E-04 Zkscan1 -0.183 4.37E-02 
Fermt3 0.77 7.83E-06 Piezo2 -0.498 4.23E-03 Zkscan8 -0.215 4.14E-02 
Fes 0.661 1.45E-04 Pigr 4.129 1.72E-122 Zmpste24 -0.277 1.94E-02 
Fgd2 0.755 1.26E-03 Pik3ap1 1.21 6.30E-12 Zmynd8 0.238 4.48E-03 
Fgd3 0.546 1.13E-02 Pik3cd 1.157 6.07E-14 Zxdb -0.354 2.29E-02 
Fgd6 0.747 1.26E-06       
Sensitized vs Resolved C3H/HeN 
Genes log P Genes log P Genes log P 
0610040J01Rik 0.442 1.13E-03 Fam189a2 -0.401 2.37E-03 P2ry10 0.835 4.67E-06 
2810474O19Rik 0.256 4.40E-02 Fam3b 0.531 1.30E-03 P3h3 -0.329 2.04E-02 
4932411E22Rik -0.264 1.76E-02 Fam46c 0.975 2.53E-08 Padi1 0.823 7.87E-06 
5830411N06Rik 0.457 7.88E-03 Fam65b 0.753 1.46E-05 Padi2 0.583 8.57E-04 
8430419L09Rik 0.384 3.25E-02 Fam78a 0.515 8.29E-03 Padi3 0.686 4.26E-04 
9330175E14Rik 0.496 2.45E-02 Fam78b -0.425 4.96E-03 Padi4 0.735 3.72E-07 




A630001G21Rik 0.778 3.14E-05 Faxc -0.313 2.07E-03 Parp3 0.263 4.92E-02 
A830010M20Rik 0.448 1.46E-02 Fcamr 0.64 2.01E-04 Parvg 0.89 7.22E-07 
Abhd17b 0.345 1.60E-02 Fcmr 0.47 4.96E-03 Pask -0.528 1.08E-02 
Abi3 0.495 2.56E-02 Fcrl1 0.704 1.18E-05 Pax5 0.36 3.63E-02 
Acap1 0.851 2.07E-06 Fermt3 0.652 3.73E-06 Paxbp1 0.268 4.86E-02 
Acer3 0.361 5.72E-03 Fes 0.414 2.86E-02 Pclo -0.539 3.14E-03 
Acsbg1 0.555 6.94E-03 Fgd6 0.544 1.25E-04 Pcp4l1 -0.298 2.51E-02 
Actc1 -0.528 1.04E-02 Fgr 0.486 3.14E-02 Pde7a 0.296 2.72E-02 
Adam22 -0.254 4.26E-02 Firre 0.44 1.52E-03 Pdk4 -0.381 2.69E-02 
Adarb2 -0.435 4.32E-02 Fkbp1a -0.255 4.71E-02 Peg10 0.396 1.20E-02 
Adcy1 -0.426 2.56E-02 Flt3l 0.478 2.12E-02 Peli2 -0.283 1.46E-03 
Adcy7 0.304 2.23E-02 Flt4 0.721 2.92E-05 Pgm5 -0.175 3.24E-02 
Adcy9 -0.206 4.81E-02 Fmnl1 0.613 1.21E-04 Pid1 -0.334 1.30E-02 
Adgre1 0.479 6.93E-03 Fndc1 -0.323 3.06E-02 Piezo2 -0.4 3.84E-02 
Adgrg5 0.814 9.36E-06 Folr2 -0.442 2.98E-02 Pigr 0.613 1.08E-04 
Adgrl1 -0.277 1.32E-02 Fundc2 -0.308 7.23E-03 Pigt -0.232 1.73E-02 
Adgrl3 -0.392 6.21E-03 Fyb 0.499 1.92E-04 Pik3ap1 0.774 3.86E-06 
Adh1 -0.249 1.07E-03 Fzd2 -0.298 4.46E-02 Pik3cd 0.567 7.42E-06 
Adtrp 0.487 2.44E-02 Fzd3 -0.544 5.46E-07 Pik3r5 0.468 1.08E-02 
Agl -0.282 5.54E-03 Fzd7 -0.263 3.06E-02 Pim1 0.475 4.01E-03 
Ahsa1 0.319 8.68E-03 Gabbr1 0.4 2.66E-03 Pip5k1b -0.676 1.34E-04 
AI504432 1.073 6.17E-10 Gabpb2 0.19 3.95E-02 Pisd-ps1 0.357 3.42E-03 
AI593442 -0.492 1.46E-02 Gabrp 0.683 1.23E-05 Pisd-ps2 0.484 2.30E-02 
AI854703 -0.491 2.76E-02 Galnt4 0.261 4.49E-02 Pkhd1l1 0.404 4.51E-02 
Aim2 1.084 4.16E-10 Gas5 0.326 1.34E-02 Pkp1 0.806 2.43E-07 
Akna 0.718 1.21E-06 Gatm -0.498 8.80E-04 Pla2g7 -0.37 8.10E-04 
Akr1b8 0.502 2.69E-03 Gatsl2 -0.476 5.20E-07 Pla2r1 0.269 1.32E-02 
Aldh3a1 0.574 4.15E-06 Gbp4 0.736 7.22E-07 Plagl1 -0.36 1.89E-02 
Aldh5a1 -0.346 9.30E-03 Gbp9 0.624 9.66E-06 Plcb2 0.579 2.77E-03 
Alpk1 0.287 1.58E-02 Gdf11 -0.453 4.19E-02 Plcg2 0.524 1.71E-04 
Amica1 0.584 1.74E-03 Gfra1 -0.51 6.87E-03 Pld2 0.301 3.20E-02 
Ankrd44 0.357 9.15E-04 Gfra3 -0.439 3.39E-02 Pld4 0.391 3.80E-02 
Anxa8 0.627 7.05E-05 Ggta1 0.417 6.87E-03 Plin3 -0.316 9.16E-04 
Aox3 -0.879 1.24E-08 Gimap3 1.096 2.22E-10 Pls1 1.033 2.39E-09 
Ap3b2 -0.459 4.13E-02 Gimap4 0.611 8.58E-04 Pltp -0.284 4.31E-02 
Apbb1 -0.379 4.16E-02 Gimap6 0.63 2.64E-04 Plxnd1 0.275 2.85E-04 
Apbb2 -0.256 1.13E-02 Gimap7 0.459 3.20E-02 Podnl1 0.466 4.09E-02 
Apobec1 0.602 1.92E-04 Gimap8 1.015 8.15E-12 Pou2af1 0.54 6.01E-04 
Apobec3 0.321 4.12E-03 Glp2r -0.513 2.27E-03 Pou2f2 0.89 7.88E-07 
Apobr 0.729 1.29E-04 Gm12250 0.572 3.97E-03 Ppap2b -0.197 4.49E-02 
Apol7a 0.482 2.62E-02 Gm15708 0.563 6.36E-03 Ppapdc1a -0.761 3.86E-06 
Arhgap15 0.562 7.66E-03 Gm2a -0.312 5.83E-04 Ppic -0.363 2.14E-02 
Arhgap27 0.273 3.29E-02 Gm4759 0.711 1.93E-04 Ppp1r14c 0.517 1.59E-02 
Arhgap30 0.916 6.97E-13 Gm7030 0.427 9.99E-03 Ppp1r16b 0.532 3.14E-03 
Arhgap4 0.653 3.37E-04 Gm9926 0.551 7.23E-03 Ppp1r36 -0.47 3.27E-02 
Arhgap9 0.617 2.62E-04 Gnao1 -0.279 1.87E-02 Prdm6 -0.471 8.01E-04 
Arhgdib 0.41 2.33E-03 Gpc3 -0.405 1.24E-02 Prex1 0.607 1.01E-05 
Art2a-ps 0.42 3.47E-02 Gpnmb 0.585 8.22E-07 Prg2 0.443 2.75E-03 
Arxes2 -0.515 1.90E-02 Gpr137b-ps 0.456 4.06E-03 Prickle2 -0.247 8.86E-03 
Astn2 -0.652 1.59E-04 Gpr37 -0.456 3.87E-02 Prkaca -0.265 2.12E-02 
Atp10d 0.37 4.01E-03 Gpr63 -0.65 2.56E-04 Prkcd 0.349 3.28E-04 




Atp8b4 0.475 3.67E-02 Gprin3 0.545 1.05E-02 Prrc2c 0.154 3.58E-02 
Avpr1a -0.427 2.62E-03 Gpx2 0.65 3.69E-04 Prss35 -0.764 1.65E-07 
AW112010 0.48 1.57E-02 Gpx3 -0.36 5.85E-03 Psd -0.288 4.55E-02 
B2m 0.5 2.23E-02 Grap2 0.783 5.86E-07 Psmb8 0.738 8.68E-08 
B3gnt3 0.533 8.44E-03 Gria3 -0.516 5.36E-03 Psmb9 0.801 1.16E-06 
B4galnt1 0.609 9.31E-05 Grik3 -0.465 3.80E-02 Pstpip1 0.546 9.11E-03 
Baiap2l1 1.129 1.24E-14 Gsdmc2 1.038 2.42E-10 Pstpip2 0.444 5.72E-03 
Bank1 0.497 2.51E-02 Gsdmc3 0.941 1.41E-07 Ptch1 -0.347 1.20E-02 
Baz1a 0.313 1.56E-02 Gsg1l -0.511 1.31E-02 Ptgr1 -0.292 4.02E-02 
BC021614 0.573 5.17E-03 Gsg2 0.585 2.33E-03 Ptgs1 0.264 1.36E-02 
BC026585 -0.646 3.79E-04 Gstm1 -0.213 4.26E-02 Ptn -0.595 1.17E-03 
Bcas1 -0.566 1.90E-04 Gyk 0.432 3.48E-02 Ptpn22 0.871 1.32E-06 
Bcl11b 0.674 2.08E-04 H2-Aa 0.586 3.67E-03 Ptpn6 0.436 1.46E-02 
Bcl3 0.459 2.96E-02 H2-Ab1 0.564 6.68E-03 Ptpn7 0.607 2.90E-03 
Bhmt2 -0.386 6.54E-03 H2-D1 0.562 1.53E-04 Ptprc 0.697 2.08E-04 
Bin2 0.613 1.24E-03 H2-DMa 0.708 1.31E-04 Ptpre 0.509 9.39E-05 
Birc2 0.352 3.26E-03 H2-Ea-ps 0.602 2.82E-03 Ptprs -0.22 2.12E-02 
Birc3 0.634 1.79E-04 H2-Eb1 0.932 3.59E-11 Pygm -0.381 1.62E-02 
Blk 0.526 1.41E-02 H2-Eb2 0.449 2.34E-02 Pyhin1 0.477 3.12E-02 
Blnk 0.539 2.66E-03 H2-K1 0.587 7.73E-05 Rab27a 0.428 9.80E-04 
Bmp5 -0.473 1.82E-03 H2-M2 0.96 3.27E-08 Rab44 0.484 2.78E-02 
Bmp7 -0.252 2.67E-02 H2-M3 0.519 7.55E-03 Rab7 -0.259 8.17E-03 
Btbd11 -0.345 3.52E-02 H2-Ob 0.951 9.36E-08 Rac2 0.605 3.14E-03 
Btk 0.57 6.54E-03 H2-Q4 0.733 6.65E-08 Rasal3 0.931 1.26E-07 
Btla 0.713 1.92E-04 H2-T10 0.483 3.29E-02 Rasgrp1 0.878 8.66E-08 
C030034L19Rik 0.589 2.75E-03 H2-T23 0.462 1.23E-03 Rasl11b -0.405 1.03E-02 
C1qa 0.305 3.92E-02 H2-T24 0.409 2.86E-02 Rassf2 0.373 3.22E-02 
C3 0.32 4.55E-02 H3f3a -0.336 1.50E-02 Rbp4 -0.764 3.01E-07 
C3ar1 0.644 4.12E-05 H60b 0.486 2.72E-02 Reln 0.6 3.71E-04 
C6 0.49 2.02E-02 Hadh -0.391 4.71E-04 Rftn1 0.487 6.87E-03 
C7 -0.379 2.80E-02 Hc 0.864 2.15E-07 Rgl2 0.389 2.62E-03 
C77370 0.549 9.55E-03 Hcls1 0.625 8.49E-04 Rgs14 0.532 8.12E-03 
Cacna1e 0.489 2.93E-02 Helz2 0.29 3.01E-02 Rgs5 -0.388 1.01E-03 
Cacna1h -0.271 3.87E-03 Hgfac 0.606 3.12E-03 Rgs6 -0.484 6.54E-03 
Cacna2d1 -0.223 4.67E-02 Hhip -0.53 2.72E-03 Rhoc -0.324 2.71E-02 
Cadps -0.509 5.55E-03 Hist1h4h -0.531 1.53E-04 Rhoh 0.468 2.86E-02 
Calcrl -0.258 3.29E-02 Hk2 0.556 1.75E-04 Rhou -0.325 5.32E-03 
Calm2 -0.184 1.34E-02 Hmha1 0.653 7.91E-06 Rian -1.045 1.67E-11 
Camk4 0.722 1.73E-04 Hnrnph1 0.195 3.92E-02 Rinl 0.616 2.49E-03 
Capn10 -0.468 1.20E-02 Hs3st3b1 1.079 2.99E-10 Rltpr 0.677 1.52E-04 
Capn13 0.817 3.75E-08 Hspa2 -0.282 1.34E-02 Rnpc3 0.401 2.65E-02 
Capn3 0.462 4.67E-02 Hspg2 -0.245 3.97E-03 Rorb -0.479 1.34E-02 
Car13 0.454 9.22E-03 Htra1 -0.285 2.72E-02 Rorc 0.443 8.85E-04 
Card11 0.484 3.00E-02 Hunk -0.656 4.91E-04 Rpl15 -0.279 3.58E-02 
Casp1 0.901 4.53E-07 Hvcn1 0.464 3.91E-02 Rps6ka1 0.393 1.72E-02 
Casp4 0.61 2.55E-03 Hyal1 0.325 3.44E-02 Rps6kb2 0.409 1.49E-02 
Casp8 0.29 3.01E-02 Icam1 0.434 4.49E-04 Rsph4a 0.425 4.13E-02 
Cbr2 0.466 7.48E-04 Icos 0.691 3.83E-04 Rsrp1 0.364 1.48E-02 
Cbx6 -0.304 1.16E-02 Ifi27 0.401 1.78E-02 Runx3 0.977 6.06E-10 
Ccdc167 0.432 4.38E-02 Ifi47 0.453 4.43E-02 Samd9l 0.415 2.80E-03 
Ccdc3 -0.232 4.85E-02 Ifit3 -0.391 4.65E-02 Samsn1 0.53 1.08E-02 




Cck -0.567 6.89E-03 Igf2bp1 -1.246 4.67E-13 Scin 0.461 4.72E-02 
Ccl24 -0.453 3.80E-02 Igfbp2 -0.32 1.31E-02 Sdc2 -0.317 4.71E-04 
Ccl8 0.457 4.95E-02 Igsf10 -0.513 1.69E-02 Sel1l3 0.44 6.76E-03 
Ccnl2 0.419 4.27E-03 Igtp 0.494 6.83E-03 Selplg 0.53 1.20E-02 
Ccr1 0.443 3.89E-02 Ikbkb 0.283 3.67E-02 Sema4d 0.699 3.86E-06 
Ccr2 0.462 3.41E-02 Ikzf1 0.885 3.25E-08 Sept1 0.7 2.86E-04 
Ccr5 0.639 1.92E-04 Ikzf3 0.342 4.33E-02 Sept3 0.584 3.75E-03 
Ccr6 0.987 1.53E-08 Il10ra 0.656 1.97E-04 Serpina3g 0.688 1.56E-04 
Ccr7 0.476 8.80E-03 Il13ra1 0.323 3.29E-02 Setd7 -0.209 2.37E-02 
Cd101 0.588 1.13E-03 Il16 0.45 4.79E-03 Sf3b1 0.225 3.46E-02 
Cd19 0.384 2.01E-02 Il18 0.782 2.97E-05 Sgk1 0.448 1.01E-02 
Cd2 0.421 2.99E-02 Il18r1 0.931 8.15E-12 Sgsm3 0.394 1.37E-03 
Cd200r3 0.373 2.79E-02 Il18rap 0.859 1.58E-07 Sh2d2a 0.692 3.69E-04 
Cd209b -0.654 2.34E-04 Il1r1 0.278 4.39E-02 Sh2d3c 0.393 2.93E-02 
Cd209f -0.578 5.53E-03 Il1rl2 0.439 2.25E-02 Shisa4 -0.481 1.34E-02 
Cd22 0.908 2.79E-07 Il21r 0.526 1.49E-02 Siglecg 0.582 1.46E-03 
Cd226 0.915 3.56E-07 Il27ra 0.791 2.17E-05 Siglech -0.622 2.05E-03 
Cd247 0.516 1.16E-02 Il2ra 0.446 4.48E-02 Sipa1 0.367 4.59E-02 
Cd24a 0.443 4.79E-03 Il2rg 0.969 1.60E-08 Sit1 0.411 1.31E-02 
Cd274 0.426 1.27E-02 Il33 1.015 8.15E-12 Skint6 0.549 1.17E-03 
Cd300lf 0.466 2.56E-02 Il7 0.8 1.64E-05 Sla 0.796 3.00E-07 
Cd36 -0.43 3.25E-02 Il7r 0.861 1.05E-06 Slamf1 0.536 1.92E-03 
Cd37 0.561 7.23E-03 Impad1 -0.208 1.55E-02 Slamf6 0.676 2.81E-04 
Cd38 0.491 2.75E-03 Inpp5a -0.223 4.03E-02 Slamf7 0.724 1.63E-04 
Cd3d 0.579 1.14E-03 Inpp5d 0.677 7.88E-07 Slbp 0.383 4.96E-03 
Cd3e 1.046 2.99E-10 Iqgap2 -0.393 4.75E-03 Slc12a8 -0.49 1.56E-02 
Cd3g 0.502 7.55E-03 Irf4 1.117 6.70E-12 Slc20a1 0.324 2.96E-02 
Cd4 0.975 2.48E-08 Irf9 0.413 1.05E-02 Slc24a3 -0.285 2.77E-02 
Cd5 0.664 4.26E-04 Irgm1 0.391 1.44E-02 Slc26a2 0.403 9.14E-05 
Cd52 0.577 5.80E-03 Irs1 -0.425 1.73E-04 Slc28a3 0.508 3.47E-03 
Cd53 0.558 6.90E-03 Itga11 -0.413 1.27E-02 Slc38a1 -0.308 2.38E-03 
Cd6 0.717 1.12E-05 Itgae 0.599 3.40E-03 Slc39a11 -0.371 2.71E-02 
Cd7 0.422 1.38E-02 Itgal 1.048 2.24E-10 Slc39a4 1.243 5.07E-13 
Cd72 0.556 8.34E-03 Itgb2 0.602 4.47E-05 Slc47a1 -0.664 5.83E-04 
Cd74 0.761 1.12E-05 Itgb7 0.644 4.71E-04 Slc6a15 -0.753 3.88E-05 
Cd79a 0.691 4.47E-05 Itgb8 -0.491 6.94E-03 Slc7a11 1.038 1.42E-11 
Cd79b 0.575 2.57E-03 Itk 0.693 3.41E-04 Slc7a8 -0.436 3.37E-04 
Cd82 0.297 1.22E-02 Itm2a -0.487 2.79E-07 Slc9a2 -0.349 3.47E-03 
Cd84 0.881 7.22E-07 Itpr2 0.337 7.55E-03 Slfn2 0.424 3.67E-02 
Cd86 0.573 6.30E-03 Itpr3 0.256 5.64E-03 Slfn8 0.544 1.08E-02 
Cd8a 0.404 7.91E-03 Ivns1abp 0.24 3.71E-02 Smoc1 -0.678 3.40E-04 
Cd96 0.99 2.24E-09 Jak3 0.332 4.74E-02 Smpd3 -0.466 9.08E-03 
Cdc14a 0.355 2.82E-02 Jchain 1.231 9.93E-14 Soga1 -0.318 2.35E-03 
Cdkn2a 0.542 4.79E-03 Kazald1 -0.492 2.34E-02 Sort1 -0.326 1.92E-04 
Cdo1 0.661 1.74E-05 Kcnb2 -0.593 3.94E-03 Sox9 -0.464 3.91E-02 
Cds1 -0.233 9.89E-03 Kcnc1 0.586 4.70E-03 Sp100 0.491 4.43E-03 
Cecr2 -0.659 1.58E-05 Kcnj10 0.489 1.36E-02 Sp110 0.51 3.38E-03 
Celsr1 0.652 3.41E-04 Kcnk2 -0.674 1.46E-04 Sp6 -0.8 3.82E-08 
Cercam -0.311 4.92E-02 Kcnk3 -0.443 1.35E-02 Sparc -0.353 1.31E-02 
Cerk 0.344 5.84E-03 Kcnk5 0.386 2.83E-02 Spib 0.669 2.53E-04 
Ces2f 0.633 1.65E-03 Kctd12b 0.664 3.23E-06 Spn 0.772 3.52E-05 




Chd7 0.339 2.15E-02 Kif5c -0.473 1.18E-02 Spock3 -0.506 4.24E-03 
Chst2 -0.645 7.22E-07 Kl -0.43 4.87E-02 Sprr2a3 0.421 4.86E-02 
Ciita 0.537 6.40E-03 Klhl14 -0.5 2.67E-03 Srcin1 -0.517 1.57E-02 
Cilp2 -0.378 4.20E-02 Klhl6 0.69 3.69E-04 Srgn 0.564 2.81E-03 
Ckb -0.335 8.03E-03 Krt14 0.46 1.77E-03 Srp54a -0.44 4.25E-02 
Clca2 1.216 8.34E-13 Krt20 -0.471 3.25E-08 Srpk1 0.33 5.70E-03 
Clca3a1 1.039 2.39E-09 Krt4 0.538 9.55E-03 Srpk3 0.498 2.56E-02 
Clca3a2 1.435 4.32E-17 Kynu 0.41 2.62E-02 St3gal1 0.309 1.16E-02 
Cldn1 -0.435 1.57E-02 Lamc1 -0.225 2.80E-03 St3gal6 0.467 6.09E-03 
Clec2d 0.508 6.53E-05 Laptm5 0.573 1.90E-04 St6galnac3 0.676 5.74E-04 
Clec2f 0.601 1.46E-04 Lat 1.051 1.91E-09 St8sia1 0.401 4.32E-02 
Clec2g 0.358 3.47E-02 Lat2 0.463 4.55E-02 St8sia4 0.463 1.40E-02 
Clec7a 0.454 3.96E-02 Lax1 0.939 1.50E-07 Stab1 0.341 1.38E-02 
Clec9a 0.475 3.14E-02 Lck 0.482 2.35E-02 Stap2 0.48 1.11E-02 
Clip4 0.68 5.79E-10 Lcp2 0.908 5.80E-08 Stat1 0.425 2.33E-03 
Clu 0.384 2.19E-04 Ldb3 -0.303 6.54E-03 Stat2 0.247 3.39E-02 
Cmah 0.641 1.90E-04 Ldlr 0.327 2.24E-02 Stk10 0.322 3.76E-03 
Cmtm4 -0.279 3.50E-03 Ldlrad3 -0.738 1.52E-09 Stx1a 0.576 4.16E-03 
Cnnm1 -0.486 2.08E-02 Lef1 -0.376 3.84E-02 Susd3 0.493 2.75E-02 
Col11a1 -0.55 7.55E-03 Leng8 0.399 2.10E-03 Sv2b -0.609 2.12E-05 
Col16a1 -0.57 2.92E-05 Lgi2 0.473 3.06E-02 Svep1 -0.299 8.12E-03 
Col17a1 0.838 7.68E-10 Limch1 -0.415 6.89E-03 Syk 0.515 2.35E-03 
Col18a1 -0.367 9.50E-03 Limd2 0.505 1.04E-03 Sync 0.61 9.71E-04 
Col1a1 -0.468 1.36E-03 Lin28b -0.622 8.09E-05 Synj1 0.286 3.20E-02 
Col1a2 -0.431 1.75E-03 Lipm 0.366 3.92E-02 Syt16 0.527 8.98E-04 
Col4a1 -0.254 1.12E-02 Lix1l -0.25 4.71E-02 Tacr1 0.777 3.33E-05 
Col4a5 -0.256 2.35E-02 Lmo1 -0.468 1.24E-03 Tap1 0.617 5.45E-06 
Col4a6 -0.355 4.52E-03 Loxl2 -0.393 2.14E-03 Tap2 0.359 7.41E-03 
Col5a1 -0.374 9.89E-03 Lpcat2 0.562 5.64E-03 Tbc1d10c 0.476 3.53E-02 
Col5a2 -0.322 3.39E-02 Lpxn 0.506 2.12E-02 Tbc1d16 -0.579 5.13E-07 
Col6a1 -0.308 4.50E-02 Lrmp 0.716 1.92E-04 Tbca -0.303 4.55E-02 
Col6a2 -0.369 7.23E-03 Lrp3 -0.401 1.06E-02 Tbx20 -0.238 2.80E-02 
Col6a3 -0.537 3.38E-10 Lrp8 0.483 3.28E-02 Tead3 -0.241 2.96E-02 
Col7a1 1.099 9.13E-11 Lrrc18 0.526 1.30E-02 Tenm3 -0.383 6.55E-03 
Corin -0.965 1.01E-10 Ltb 0.826 1.54E-06 Terf2ip -0.259 4.02E-02 
Coro1a 0.67 2.45E-05 Ltbp2 0.451 2.47E-02 Tespa1 0.563 6.11E-03 
Cp 0.52 5.09E-03 Ly6c2 0.747 5.69E-06 Tfap2a 0.64 1.26E-03 
Cpz -0.438 2.97E-02 Ly6e 0.427 2.08E-04 Tfcp2l1 -0.352 2.10E-02 
Cr2 0.52 1.69E-02 Ly75 0.645 1.50E-05 Tgfbi -0.274 2.23E-02 
Creb3l1 -0.625 5.71E-06 Lyn 0.492 4.75E-03 Tgfbr3 -0.198 1.10E-02 
Crispld1 -0.468 3.87E-02 Lypd6 -0.794 7.52E-06 Thbs2 -0.322 5.06E-03 
Crmp1 0.451 1.98E-02 Lyz2 0.434 1.05E-02 Them7 -0.506 2.26E-02 
Csf2rb2 0.379 4.88E-02 Map4k1 0.769 4.33E-05 Themis 0.746 8.94E-06 
Ctla4 0.461 4.73E-03 Med12l -0.531 3.13E-03 Thsd4 -0.449 5.11E-11 
Ctse -0.317 9.77E-03 Meg3 -1.033 8.34E-13 Tia1 0.311 4.52E-03 
Ctss 0.543 1.08E-02 Meis1 -0.189 2.56E-02 Tln2 -0.27 3.64E-02 
Ctsw 0.473 3.86E-02 Mgst1 -0.235 4.92E-02 Tlr12 -0.456 3.32E-02 
Cx3cr1 0.686 3.41E-04 Micall2 -0.339 3.92E-02 Tlr13 0.472 1.88E-02 
Cxcl13 0.538 4.34E-03 Mir3064 0.501 1.36E-02 Tlr3 0.372 9.96E-03 
Cxcr4 0.472 3.94E-02 Mlph 0.376 2.10E-02 Tmem119 -0.356 1.48E-02 
Cxcr6 0.891 1.11E-07 Mmd -0.286 9.40E-03 Tmem159 -0.285 7.55E-03 




Cyb5a 0.251 2.12E-02 Mmp2 -0.409 1.94E-07 Tmem35 -0.406 4.05E-02 
Cyp27a1 0.474 1.12E-03 Mmrn1 0.66 8.58E-04 Tmem38a -0.428 8.44E-03 
Cysltr2 0.398 2.76E-02 Mndal 0.604 1.63E-04 Tmprss11e 0.647 1.00E-04 
Cyth4 0.424 1.01E-02 Moxd1 -0.555 3.55E-03 Tmprss11g 0.511 1.26E-03 
Cytip 0.811 1.09E-05 Mpeg1 0.573 8.80E-04 Tmprss4 0.483 1.72E-02 
D17H6S56E-5 0.592 2.86E-04 Mrc2 -0.411 1.92E-04 Tnc -0.378 1.32E-03 
Dab1 -0.597 2.70E-03 Mrps2 -0.33 2.47E-02 Tnfaip3 0.436 1.32E-02 
Dach1 -0.541 6.63E-04 Ms4a1 0.5 1.08E-02 Tnfrsf13c 0.591 1.46E-03 
Dcaf5 -0.242 1.76E-02 Ms4a4b 0.494 1.30E-02 Tnfrsf1b 0.391 2.39E-03 
Ddx17 0.278 1.51E-03 Ms4a6b 0.712 5.31E-05 Tnfrsf25 0.509 2.05E-02 
Ddx5 0.226 2.74E-02 Ms4a6c 0.529 9.08E-03 Tnfsf10 0.335 3.09E-02 
Ddx58 0.331 2.44E-02 Msi2 -0.194 2.30E-02 Tnfsf14 0.422 4.28E-02 
Dennd1c 0.556 3.29E-03 Mt2 -0.481 5.72E-03 Tns3 0.284 1.54E-02 
Dennd4a 0.34 1.14E-02 Mtcl1 -0.433 6.38E-03 Tob1 -0.252 4.53E-02 
Depdc7 0.441 1.40E-02 Musk -0.499 2.47E-02 Traf1 0.741 1.01E-04 
Derl3 0.499 2.10E-02 Mycbp2 0.213 3.91E-02 Traf3ip3 0.689 4.04E-04 
Dio2 0.638 1.90E-04 Myh10 -0.243 4.42E-02 Treml2 0.315 3.16E-02 
Diras2 -0.406 4.54E-02 Myo1e 0.289 1.14E-02 Trf -0.246 4.19E-02 
Dlk1 -0.634 1.62E-03 Myo1f 0.541 2.79E-03 Trim24 0.318 2.70E-03 
Dmgdh -1.06 1.76E-10 Myo1g 0.508 9.96E-03 Trim30a 0.421 1.34E-02 
Dmtn -0.476 2.12E-02 Myo5c 0.423 2.14E-03 Trim59 0.461 2.69E-02 
Dnajc6 -0.741 1.80E-07 Myo9b 0.215 2.83E-02 Trim7 0.464 5.64E-03 
Dnase1l3 0.512 2.00E-02 Mzb1 0.71 8.59E-06 Tsc22d1 -0.236 4.43E-03 
Dock11 0.512 9.52E-03 Nadk 0.18 3.47E-02 Tspan5 -0.296 2.80E-02 
Dock2 0.801 1.18E-06 Naglu -0.455 1.08E-02 Tspan7 -0.407 1.61E-04 
Dram1 0.447 4.35E-02 Naip2 0.449 3.41E-02 Ttc14 0.273 1.08E-02 
Dsc2 0.521 7.21E-04 Nalcn -0.567 2.18E-03 Ttr -0.973 2.72E-11 
Duox2 0.46 3.84E-02 Nampt -0.242 4.45E-02 Uba7 0.517 5.95E-04 
Duoxa2 0.543 2.38E-03 Ncald -0.311 2.60E-02 Ubash3a 0.41 2.28E-02 
Dvl1 0.329 2.05E-02 Ncam1 -0.242 4.66E-02 Ube2e2 -0.393 2.07E-02 
Ecm1 -0.257 3.27E-02 Ncf1 0.381 2.44E-02 Ube2h -0.245 3.74E-02 
Edar -0.459 2.34E-02 Ncf4 0.569 6.40E-03 Uchl1 -0.757 1.49E-05 
Edil3 -0.725 6.17E-05 Nckap1l 0.813 9.27E-09 Ugt2b34 0.37 2.54E-02 
Ednrb -0.462 6.04E-03 Nckap5 -0.327 6.02E-03 Ugt2b35 0.524 1.57E-02 
Eef2k -0.199 2.81E-02 Ncs1 -0.385 3.58E-02 Unc93b1 0.391 7.23E-03 
Efcab1 -0.82 8.97E-07 Ndufv3 -0.305 3.03E-02 Upk1a -0.3 2.72E-03 
Egfl6 -0.456 4.55E-02 Neat1 0.423 4.76E-03 Upk2 -0.312 1.10E-02 
Ehf 0.254 2.84E-03 Necab1 -0.502 2.30E-02 Upk3a -0.356 9.96E-03 
Eid2 -0.446 1.78E-02 Nell2 -1.024 2.39E-09 Utp14b 0.529 4.26E-04 
Elf5 -0.815 9.68E-06 Nes -0.464 4.49E-04 Vav1 0.592 3.40E-03 
Elfn1 -0.568 6.41E-03 Nfib -0.208 4.54E-02 Vav3 0.519 4.30E-04 
Ell2 0.498 1.90E-04 Nfic -0.248 2.61E-02 Vcl -0.191 2.85E-02 
Emb 0.532 8.88E-03 Nfkbid 0.516 1.31E-02 Vmp1 0.277 3.81E-02 
Emid1 -0.749 8.97E-07 Nfkbiz 0.563 1.18E-05 Vnn1 0.756 1.81E-05 
Eno3 -0.425 9.89E-03 Ngb -0.435 2.48E-02 Vpreb3 0.344 4.86E-02 
Enpep -0.479 3.10E-02 Nipal1 0.347 2.20E-02 Was 0.6 3.26E-03 
Epb4.1l1 -0.225 1.46E-02 Nkg7 0.444 3.92E-02 Wasf3 -0.401 3.20E-02 
Epb4.1l3 -0.869 3.59E-11 Nlrc3 0.468 3.99E-02 Wbp11 -0.23 2.93E-02 
Epb4.1l4a 0.432 1.07E-02 Nlrc5 0.858 3.13E-11 Wdfy4 0.759 2.40E-09 
Epha1 0.385 1.01E-03 Nlrp10 0.455 4.49E-02 Wfdc15b -0.353 3.41E-02 
Ephx4 0.678 1.56E-05 Nmnat2 -0.515 7.84E-03 Xbp1 0.395 7.85E-05 




Erap1 0.339 2.60E-03 Nphp4 -0.479 3.49E-02 Xist 0.213 1.76E-02 
Ereg 0.523 1.54E-02 Nrbp2 0.291 3.19E-02 Zak -0.172 4.80E-02 
Ero1lb 0.363 4.81E-02 Nrn1 -1.103 1.27E-13 Zap70 0.886 7.55E-07 
Ets1 0.585 3.25E-08 Nsg2 -0.61 1.09E-03 Zc3h12a 0.475 1.48E-02 
Eya2 0.736 1.33E-05 Nup210 0.507 6.66E-03 Zc3h12d 0.628 1.82E-03 
F2rl1 0.597 1.03E-03 Nxf1 0.253 4.86E-02 Zc3h7a 0.306 2.66E-03 
Fads1 0.23 2.77E-02 Nxpe4 -0.526 1.48E-02 Zdhhc14 -0.275 3.75E-02 
Fam107b 0.454 3.07E-03 Olfml2b -0.331 1.72E-02 Zfp395 -0.313 3.39E-02 
Fam111a 0.553 2.72E-03 Olfr60 0.447 8.33E-03 Zfp536 -0.384 5.71E-03 
Fam155a -0.357 7.11E-03 Oprd1 -0.534 1.29E-02 Zfp809 0.391 4.91E-04 
Fam171a1 -0.379 6.89E-03 Optc -0.508 1.96E-04 Zfp831 0.724 1.63E-04 
Fam174b -0.239 2.23E-02 Osbpl6 -0.679 2.59E-05 Zfp931 0.451 2.83E-02 
 
Table S6. 
Top 25 enriched pathways predicted by IPA software. -lp = -log10(Padjusted). z = z-score. R = ratio, 
a ratio of the number of genes from the list that maps to the pathway divided by thee total 
number of genes that map to the same pathway. 
Resolved vs Adult Naïve (2 weeks convalescent) 
Pathway -lp R z Molecules 
Antigen Presentation 
Pathway 7.34 0.18 N/A B2M,NLRC5,HLA-A,HLA-DQA1,PSMB8,HLA-DQB1,CD74 
Oxidative 




Signaling 3.9 0.07 N/A B2M,H2-T10,HLA-A,H2-M5,HLA-DQA1,HLA-DQB1 
OX40 Signaling 
Pathway 3.73 0.07 N/A B2M,H2-T10,HLA-A,H2-M5,HLA-DQA1,HLA-DQB1 
Th1 and Th2 Activation 
Pathway 3.52 0.04 N/A 
IL33,TGFB1,HLA-A,PIK3R1,ICOS,HLA-DQA1,IL27RA,HLA-
DQB1 
Th2 Pathway 3.34 0.05 N/A IL33,TGFB1,HLA-A,PIK3R1,ICOS,HLA-DQA1,HLA-DQB1 
T Helper Cell 
Differentiation 3.27 0.07 N/A TGFB1,HLA-A,ICOS,HLA-DQA1,HLA-DQB1 
Cdc42 Signaling 3.06 0.04 N/A B2M,H2-T10,PPP1R12A,HLA-A,H2-M5,HLA-DQA1,HLA-DQB1 
Graft-versus-Host 
Disease Signaling 3.02 0.08 N/A IL33,HLA-A,HLA-DQA1,HLA-DQB1 
Mitochondrial 
Dysfunction 3 0.04 N/A 
MT-CO1,MT-ND1,MT-ND5,MT-ND4,MT-CO2,MT-ND2,MT-
ND4L 
Altered T Cell and B 
Cell Signaling in 
Rheumatoid Arthritis 
2.86 0.06 N/A IL33,TGFB1,HLA-A,HLA-DQA1,HLA-DQB1 
Th1 Pathway 2.83 0.04 0.00 HLA-A,PIK3R1,ICOS,HLA-DQA1,IL27RA,HLA-DQB1 
ERK/MAPK Signaling 2.57 0.03 0.82 ELF3,H3F3A/H3F3B,YWHAH,PPP1R12A,PIK3R1,PRKACA,EIF4E 
B Cell Development 2.37 0.08 N/A HLA-A,HLA-DQA1,HLA-DQB1 
iCOS-iCOSL Signaling 





Maturation 2.06 0.03 1.63 IL33,B2M,HLA-A,PIK3R1,HLA-DQA1,HLA-DQB1 
Autoimmune Thyroid 
Disease Signaling 2.02 0.06 N/A HLA-A,HLA-DQA1,HLA-DQB1 
IL-4 Signaling 1.95 0.04 N/A HLA-A,PIK3R1,HLA-DQA1,HLA-DQB1 
Insulin Receptor 
Signaling 1.95 0.03 0.45 PPP1R12A,SGK1,PIK3R1,PRKACA,EIF4E 
mTOR Signaling 1.93 0.03 N/A RPS19,RHEB,PIK3R1,RPS18,RPS27L,EIF4E 
Histamine Degradation 1.9 0.11 N/A ALDH2,Aldh3b2 
Glucocorticoid Receptor 
Signaling 1.85 0.02 N/A 
KRT77,YWHAH,SGK1,TGFB1,PIK3R1,PRKACA,CD163,POL
R2L 
STAT3 Pathway 1.84 0.04 0.00 TGFB1,TGFA,SOCS2,IL27RA 
Oxidative Ethanol 
Degradation III 1.81 0.10 N/A ALDH2,Aldh3b2 
Nur77 Signaling in T 
Lymphocytes 1.78 0.05 N/A HLA-A,HLA-DQA1,HLA-DQB1 
Sensitized vs Adult Naïve (2 weeks convalescent) 
Pathways -lp R z Molecules 
B Cell 
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CD28 Signaling in 
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PI3K Signaling in 








8.34 0.31 N/A BLNK,IL2RG,CD19,CD3E,CD79A,IGHG1,TAP1,IL7R,PTPRC,LCK,Igha,ZAP70,IGHM,Ighg2b,TAP2 
T Helper Cell 




Th1 and Th2 
Activation 
Pathway 
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Sensitized vs Resolved mice (2 weeks convalescent) 




12.4 0.34 N/A B2M,PSMB9,HLA-A,HLA-DQA1,PSMB8,CD74,HLA-
DQB1,TAP1,NLRC5,HLA-DMB,HLA-DOB,HLA-E,HLA-DRB5 
B Cell 















Signaling in T 
Helper Cells 




Hepatic Fibrosis / 
Hepatic Stellate 
Cell Activation 




Th1 and Th2 
Activation 
Pathway 




CD28 Signaling in 




T Helper Cell 
Differentiation 





















Signaling 6.73 0.14 N/A 
B2M,H2-T22,HLA-A,H2-M5,HLA-DMB,HLA-DQA1,HLA-
DOB,IGHG1,HLA-DQB1,Ighg2b,HLA-DRB5,HLA-E 
PKCθ Signaling in 
T Lymphocytes 












5.53 0.12 N/A B2M,H2-T22,CD3E,HLA-A,H2-M5,HLA-DMB,HLA-DQA1,HLA-
DOB,HLA-DQB1,HLA-DRB5,HLA-E 




5.22 0.17 N/A IL33,HLA-A,HLA-DMB,HLA-DQA1,HLA-DOB,HLA-DQB1,HLA-
DRB5,HLA-E 
Cdc42 Signaling 4.96 0.08 0.00 
B2M,ITGB1,H2-T22,CD3E,HLA-A,HLA-DQA1,MYLK,HLA-
DQB1,MYL9,H2-M5,HLA-DMB,HLA-DOB,HLA-E,HLA-DRB5 
Role of NFAT in 
Regulation of the 
Immune Response 







4.8 0.13 N/A B2M,ITGB1,ITGA11,FLNA,HLA-A,INSR,ACTG1,ITGAL,ITGB7 
Oxidative 
Phosphorylation 
4.77 0.10 -3.32 ATP5PF,MT-CO1,MT-ND1,MT-ATP6,Cox6c,MT-CYB,MT-CO3,MT-
CO2,MT-ND3,NDUFAB1,ATP5MC3 
Altered T Cell and 
B Cell Signaling in 
Rheumatoid 
Arthritis 






Pathway 4.71 0.11 3.16 
IL7R,IL2RG,Igha,PIK3R5,IGHM,PIK3CD,IGHG1,STAT1,Ighg2c,Ighg
2b 
IL-4 Signaling 4.55 0.11 N/A 
IL2RG,PTPN6,HLA-A,HLA-DMB,PIK3R5,HLA-DQA1,HLA-
DOB,PIK3CD,HLA-DQB1,HLA-DRB5 
Resolved vs Adult Naïve mice (4-week convalescent) 
Pathways -lp R Z Molecules 
Ceramide 
Degradation 2.27 0.17 N/A ACER2 
Cellular Effects of 
Sildenafil (Viagra) 





2.14 0.13 N/A ACER2 
Calcium Transport I 2.05 0.10 N/A ATP2B4 
Cdc42 Signaling 2.01 0.01 N/A HLA-A,MYLK 




of Target Cells 
1.54 0.03 N/A HLA-A 




1.48 0.03 N/A HLA-A 
Neuroprotective 
Role of THOP1 in 
Alzheimer's Disease 




1.38 0.02 N/A HLA-A 
Graft-versus-Host 
Disease Signaling 
1.37 0.02 N/A HLA-A 
Protein Kinase A 
Signaling 
1.32 0.01 N/A PDE5A,MYLK 




Pathways  -lp R Z Molecules 
iCOS-iCOSL 
Signaling in T 
Helper Cells 









CD28 Signaling in 
T Helper Cells 









Role of NFAT in 
Regulation of the 
Immune Response 










PKCθ Signaling in 








PI3K Signaling in B 
































Endothelial Cells in 
Rheumatoid 
Arthritis 










T Cell Receptor 







Protein Kinase A 
Signaling 












B Cell Receptor 

























































































































Virus Entry via 
Endocytic Pathways 











Sensitized vs Resolved mice (4-week convalescent) 
Pathways  -lp R Z Molecules 
iCOS-iCOSL 
Signaling in T 
Helper Cells 













11.40 0.32 N/A B2M,PSMB9,NLRC5,HLA-A,HLA-DRA,HLA-DQA1,CIITA,HLA-DOB,PSMB8,CD74,TAP1,HLA-DRB5 
CD28 Signaling in 





Development 10.60 0.33 N/A 
IL7R,PTPRC,CD19,SPN,CD79B,HLA-DRA,HLA-
DQA1,HLA-DOB,CD79A,HLA-DQB1,HLA-DRB5 
Role of NFAT in 
Regulation of the 
Immune Response 





T Cell Receptor 






8.37 0.19 2.65 CD3G,LCK,CAMK4,CD3E,ITPR2,CD4,HLA-DRA,HLA-DQA1,HLA-DOB,PRKCH,HLA-DQB1,HLA-DRB5 
Hepatic Fibrosis / 
Hepatic Stellate 
Cell Activation 




PKCθ Signaling in 









Altered T Cell and 
B Cell Signaling in 
Rheumatoid 
Arthritis 




PI3K Signaling in B 
Lymphocytes 6.60 0.11 2.50 
BLNK,CD19,CAMK4,CD79B,ITPR2,PIK3R1,CD79A,INPP
5D,NFATC1,BLK,PTPRC,PLCG2,PIK3CD,CR2 








T Helper Cell 
Differentiation 5.86 0.14 N/A 
IL2RG,IL23R,HLA-DRA,ICOS,HLA-DQA1,HLA-
DOB,HLA-DQB1,STAT1,HLA-DRB5,IL18R1 
Virus Entry via 




Nur77 Signaling in 
T Lymphocytes 5.76 0.16 N/A 
CD3G,CAMK4,CD3E,HLA-DRA,HLA-DQA1,HLA-
DOB,HLA-DQB1,HLA-DRB5,NFATC1 
B Cell Receptor 




















in Cytotoxic T 
Lymphocytes 
5.00 0.11 N/A B2M,CD3G,LCK,CD3E,GRAP2,HLA-A,PIK3R1,PIK3CD,CD8A,PTPN22 
OX40 Signaling 




in B Lymphocytes 4.83 0.17 1.13 BLNK,CD79B,PLCG2,PIK3R1,CD79A,PIK3CD,INPP5D 
C3H/HeN Adult Naïve mice 24 hpi vs PBS 






















Altered T Cell 









Th1 and Th2 
Activation 
Pathway 
12.5 0.27 N/A 
CD247,CCR3,SOCS3,SOCS1,CCR5,TNFRSF4,IL12RB1,HAVCR2,HLA-
DQB1, IL6, SPI1, CD28, CD274, IL2RB, KLRC1, IL4R, IL2RG, DLL1, 
IL12RB2, TLR9, IRF1, PIK3R3, IL33, IRS1, IL10RA, VAV1, PIK3CD, 
ICAM1, KLRD1, HLA-A, HLA-DQA1, PIK3R5, NFIL3, IL2, HLA-DMA, 
HLA-DRA, HLA-DMB, PIK3R2, STAT1, CCR1, IFNG, TNFSF11, IKZF1, 
TSLP, STAT4, ITGB2, CD80, IL10RB, JAK3 











T Helper Cell 





















Type I Diabetes 
Mellitus 
Signaling 







Maturation 10.2 0.24 4.73 
IL1A,PLCB2,ICAM1,HLA-A,NFKBIE,PIK3R5,HLA-DQA1, NOTUM, 
LTB, HLA-DQB1, IL6, FCGR2B, FCGR1A, MAPK11, PLCH1, PLCD3, 
HLA-DMA, HLA-DRA, HLA-DMB, PIK3R2, TNFRSF1B, STAT1, 
PLCD4, FCGR3A/FCGR3B, TNFRSF11B, FCGR2A, MYD88, TYROBP, 
NFKB2, CREB5, TLR9, STAT4, PIK3R3, IL33, NFKBID, CD80, IL1RN, 
PLCG2, IRS1, FCER1G, IL1B, STAT2, PIK3CD, IRF8, TNF, CCR7 
HMGB1 








9.27 0.42 N/A 
IFNG, IL1A, HLA-A, HLA-DQA1, HLA-DQB1, IL6, FAS, IL33, CD28, 
CD80, HLA-DMA, IL2, IL1RN, HLA-DMB, HLA-DRA, FCER1G, IL1B, 







































Th2 Pathway 8.68 0.25 1.569 
CD247,CCR3,SOCS3,CCR5,ICAM1,TNFRSF4,IL12RB1,HLA-
A,PIK3R5,HLA-DQA1,HLA-DQB1,SPI1,CD28,HLA-DMA,IL2,HLA-
DRA, HLA-DMB, PIK3R2, IL2RB, CCR1, IFNG, IL4R, DLL1, IL2RG, 
IKZF1, IL12RB2, TLR9, TSLP, IL33, PIK3R3, STAT4, ITGB2, CD80, 
IRS1, VAV1, PIK3CD, JAK3 
Atherosclerosis 












































Signaling in T 
Helper Cells 











C3H/HeN Adult Naïve mice 6 hpi vs PBS 
Pathways  -lp R z Molecules 
Acute Phase 




















Coagulation System 11.5 0.43 0.78 KNG1,F12,PLAUR,F2,FGG,SERPINF2,BDKRB2,PLG,F5,SERPINA1,FGB,SERPINE1,FGA,BDKRB1,PLAT 
FXR/RXR 

















Production of Nitric 
Oxide and Reactive 
Oxygen Species in 
Macrophages 










IL-17A Signaling in 
Fibroblasts 6.9 0.31 N/A 
NFKBIA,CCL2,NFKBIE,LCN2,CEBPD,CEBPB,NFKB2,NFKBIZ,IL17
RA,NFKB1,MAPK11 








Type I Diabetes 




EIF2 Signaling 6.6 0.13 -0.22 
RPS23,RPL39,RPLP2,RPL35A,RPS7,PPP1CC,RPL35,RPL18A,RPL13, 
NKX6-2, Rpl39l, PIK3R2, RPS12, PPP1CA, RPL32, RPS8, RPL17, 
EIF3J, RPL12, RPL37A, FAU, RPL9, RPS6, 
EIF4A1,RPL5,RPL37,RPL13A,RPL41 
IL-12 Signaling and 
Production in 
Macrophages 

















iNOS Signaling 5.68 0.24 2.83 NFKBIA,MYD88,NFKBIE,IRAK3,LBP,HMGA1,NFKB2,NOS2,NFKB1,MAPK11,IRF1 
Toll-like Receptor 
Signaling 5.48 0.18 2.33 
IL1A,MYD88,TNFAIP3,IRAK3,NFKB2,NFKB1,MAPK11,IL33,TLR2,
UBD,NFKBIA,IL1RN,LBP,TNF 




Endothelial Cells in 
Rheumatoid 
Arthritis 





Altered T Cell and 
B Cell Signaling in 
Rheumatoid 
Arthritis 




T Helper Cell 
Differentiation 4.96 0.18 N/A 
IL2RG,IL4R,IL5,IL12RB1,HLA-
A,FOXP3,IL12RB2,RORC,CD28,IL2,IL10RA,TNFRSF1B,TNF 








TNFR2 Signaling 4.58 0.27 1.63 NFKBIA,NFKBIE,TNFAIP3,NFKB2,TNFRSF1B,NFKB1,BIRC3,TNF 




C3H/HeN Adult Naïve mice 3.5 hpi vs PBS 
Pathways  -lp R z Molecules 
Granulocyte Adhesion and Diapedesis 8.49 0.06 N/A CXCL10,VCAM1,ICAM1,CCL2,IL1RN,Ccl2,CCL17,CCL20,CXCL2,TNF 
Agranulocyte Adhesion and Diapedesis 8.22 0.05 N/A CXCL10,VCAM1,ICAM1,CCL2,IL1RN,Ccl2,CCL17,CCL20,CXCL2,TNF 
Role of 
Hypercytokinemia/hyperchemokinemia 
in the Pathogenesis of Influenza 
6.03 0.12 N/A CXCL10,CCL2,IL1RN,IL6,TNF 
Atherosclerosis Signaling 6.01 0.06 N/A VCAM1,ICAM1,CCL2,IL1RN,IL6,TNF,TNFRSF12A 
HMGB1 Signaling 5.87 0.05 2.65 VCAM1,ICAM1,CCL2,IL6,MAPK11,TNF,PLAT 
IL-17A Signaling in Gastric Cells 5.49 0.16 N/A CXCL10,CCL20,MAPK11,TNF 
IL-10 Signaling 5.04 0.07 N/A IL1RN,CD14,IL6,MAPK11,TNF 
IL-17A Signaling in Fibroblasts 4.88 0.11 N/A CCL2,IL6,NFKBIZ,MAPK11 
Toll-like Receptor Signaling 4.85 0.07 1 IL1RN,CD14,TNFAIP3,MAPK11,TNF 
TREM1 Signaling 4.83 0.07 2.24 ICAM1,CCL2,CD83,IL6,TNF 
Glucocorticoid Receptor Signaling 4.6 0.03 N/A VCAM1,ICAM1,CCL2,IL1RN,PRKACA,IL6,MAPK11,TNF 
Communication between Innate and 
Adaptive Immune Cells 4.46 0.06 N/A CXCL10,IL1RN,CD83,IL6,TNF 
Hepatic Cholestasis 4.28 0.04 N/A IL1RN,PRKACA,CD14,IL6,INSR,TNF 
Differential Regulation of Cytokine 
Production in Macrophages and T Helper 
Cells by IL-17A and IL-17F 
4.27 0.17 N/A CCL2,IL6,TNF 
Hepatic Fibrosis / Hepatic Stellate Cell 
Activation 3.94 0.03 N/A VCAM1,ICAM1,CCL2,CD14,IL6,TNF 
Dendritic Cell Maturation 3.86 0.03 2.45 ICAM1,IL1RN,CD83,IL6,MAPK11,TNF 
LXR/RXR Activation 3.83 0.04 -2.24 CCL2,IL1RN,CD14,IL6,TNF 
PXR/RXR Activation 3.81 0.06 N/A PRKACA,IL6,INSR,TNF 
IL-6 Signaling 3.73 0.04 2 IL1RN,CD14,IL6,MAPK11,TNF 
Role of MAPK Signaling in the 
Pathogenesis of Influenza 3.64 0.06 N/A CXCL10,CCL2,MAPK11,TNF 
IL-15 Signaling 3.55 0.05 N/A VCAM1,IL6,MAPK11,TNF 
IL-17 Signaling 3.37 0.05 N/A CXCL10,CCL2,IL6,MAPK11 
Role of IL-17F in Allergic Inflammatory 
Airway Diseases 3.09 0.07 N/A CXCL10,CCL2,IL6 
iNOS Signaling 3.09 0.07 N/A CD14,HMGA1,MAPK11 
IL-9 Signaling 3.07 0.07 N/A CISH,BCL3,TNF 
C3H/HeN Resolved mice 24 hpi vs PBS 
Pathways  -lp R z Molecules 
Th1 and Th2 
Activation Pathway 11.3 0.2 N/A 
CD247,CCR3,CCR5,TNFRSF4,IL12RB1,HLA-A, KLRD1, HAVCR2, 
HLA-DQA1, HLA-DQB1, SPI1, CD28, NFIL3, HLA-DMA, IL2, 






CD28 Signaling in T 
Helper Cells 10.8 0.23 1.79 
CD247, HLA-A, HLA-DQA1, HLA-DQB1, CTLA4, PTPRC, CD28, 
LCK, HLA-DMA, IL2, HLA-DRA, HLA-DMB, PIK3R2, ITK, 
PTPN6, ITPR2, TLR9, PIK3R3, NFKBID, WAS, CARD11, GRAP2, 
SYK, IRS1, FCER1G, PIK3R6, PIK3CD, VAV1, LCP2, HLA-DRB5 
Graft-versus-Host 




Altered T Cell and B 
Cell Signaling in 
Rheumatoid Arthritis 
10.3 0.27 N/A 
IL1A, SPP1, HLA-A, HLA-DQA1, TLR8, LTB, HLA-DQB1, TLR9, 
IL33, CD28, HLA-DMA, IL1RN, IL2, TNFSF13, HLA-DMB, TLR1, 
HLA-DRA, FCER1G, CCL21, Tlr13, IL1B, TNFRSF13B, HLA-
DRB5, FASLG 
iCOS-iCOSL 
Signaling in T Helper 
Cells 
10.1 0.23 3.27 
CD247, HLA-A, HLA-DQA1, HLA-DQB1, PTPRC, CD28, LCK, 
HLA-DMA, IL2, HLA-DMB, HLA-DRA, PIK3R2, IL2RB, ITK, 
IL2RG, ITPR2, TLR9, INPP5D, PIK3R3, NFKBID, GRAP2, IRS1, 
FCER1G, PIK3R6, PIK3CD, VAV1, LCP2, HLA-DRB5 

















Role of NFAT in 
Regulation of the 
Immune Response 
8.78 0.18 4.27 
CD247, RAF1, PLCB2, HLA-A, HLA-DQA1, HLA-DQB1, FCGR1A, 
H2BFM, CD28, LCK, HLA-DMA, HLA-DRA, HLA-DMB, PIK3R2, 
FCGR3A/FCGR3B, ITK, GNG4, FCGR2A, ITPR2, TLR9, GNG10, 
PIK3R3, BTK, NFKBID, PLCG2, SYK, IRS1, LYN, FCER1G, 
PIK3R6, PIK3CD, LCP2,HLA-DRB5 
Granulocyte Adhesion 






between Innate and 
Adaptive Immune 
Cells 
7.61 0.22 N/A 
IL1A, HLA-A, TLR8, CCL5, TLR9, Ccl9, IL33, CD28, IL1RN, IL2, 
TNFSF13, TLR1, HLA-DRA, FCER1G, Tlr13, IL1B, TNFRSF13B, 
HLA-F, HLA-DRB5, CCR7, HLA-E 
Natural Killer Cell 





IL-4 Signaling 7.32 0.23 N/A 
PTPN6,IL2RG,IRF4,HLA-A,HLA-DQA1, HMGA1, HLA-DQB1, 
TLR9, INPP5D, PIK3R3, HLA-DMA, IRS1, HLA-DMB, HLA-DRA, 
RPS6KB2, PIK3R6, PIK3CD, PIK3R2, JAK3, HLA-DRB5 
PKCθ Signaling in T 
Lymphocytes 7.32 0.19 3.67 
CD247, HLA-A, HLA-DQA1, HLA-DQB1, TLR9, PIK3R3, CD28, 
MAP3K12, NFKBID, LCK, IL2, GRAP2, CARD11, HLA-DMA, 
PLCG2, IRS1, HLA-DRA, HLA-DMB, PIK3R6, FCER1G, VAV1, 




T Helper Cell 





Pathway 7.29 0.34 N/A 
PSMB9,HLA-A,HLA-DQA1,CIITA,PSMB8,CD74,HLA-DQB1,HLA-
DMA,HLA-DRA,HLA-DMB,HLA-F,HLA-E,HLA-DRB5 
Type I Diabetes 










Dendritic Cells and 
Natural Killer Cells 
6.61 0.21 N/A 
IL2RG, TYROBP, HLA-A, KLRD1, LTB, TLR9, CD28, CSF2RB, 
PRF1, IL2, HLA-DRA, CD226, TNFRSF1B, HLA-F, HLA-DRB5, 




6.21 0.14 N/A 
CD247, IL1A, HLA-A, Rnu6, RNU2-1, FCGR1A, PTPRC, CD28, 
LCK, IL2, EFTUD2, PIK3R2, HLA-F, FCGR3A/FCGR3B, LSM4, 
SNRNP40, PTPN6, FCGR2A, TLR9, INPP5D, RNU1-4, IL33, 
PIK3R3, IL1RN, IRS1, PLCG2, LYN, FCER1G, PIK3R6, IL1B, 
PIK3CD, HLA-E 
Phagosome 








Bacteria and Viruses 











Role of Macrophages, 
Fibroblasts and 
Endothelial Cells in 
Rheumatoid Arthritis 






IL-2 Signaling 5.17 0.22 1.94 RAF1,CSNK2A1,IL2RG,TLR9,PIK3R3,LCK,IL2,IRS1,SYK,PIK3R6,PIK3CD,PIK3R2,JAK3,IL2RB 
C3H/HeN Resolved mice 6 hpi vs PBS 



























































Signaling 14.9 0.43 5.303 
Naip1 (includes others), TREM1, ICAM1, LAT2, TLR8, CD83, IL6, JAK2, 
FCGR2B, NFKB1, Tlr12, CXCL3, CCL2, TLR1, CASP1, NLRP3, MYD88, 
TYROBP, ITGA5, STAT3, NFKB2, TLR2, TLR4, NOD2, CD40, NLRP12, 
TLR6, Tlr13, CD86, IL1B, TNF, ITGAX 
Altered T Cell 



































Th1 and Th2 
Activation 
Pathway 



























10.9 0.33 N/A 
IL1A, HLA-A, TLR8, CD83, IL6, CCL5, Tlr12, CXCL10, CD28, IL36G, 
CCL3L3, IL2, TLR1, HLA-F, Ccl9, TLR2, IL33, TLR4, CCL4, CD40, 
CD80, IL1RN, TNFSF13, TLR6, FCER1G, Tlr13, CD86, IL1B, TNF, CCR7, 
HLA-E 
TNFR2 
Signaling 10.7 0.57 2.32 
MAP3K14, NAIP, Naip1 (includes others), NFKBIE, TNFAIP3, IKBKE, 
NFKB2, NFKB1, NFKBID, FOS, JUN, NFKBIA, NFKBIB, TNFRSF1B, 
TNF, BIRC3, TRAF1 
NF-κB 







































10.2 0.30 3.4 
CD247, SOCS1, SOCS3, HLA-A, NFKBIE, JAK2, NFKB1, MAPK11, FAS, 
CD28, NFKBIA, IL2, NOS2, HLA-F, NFKBIB, TNFRSF1B, IL1RAP, 
MAP3K14, MAP2K7, MYD88, IKBKE, NFKB2, IL1R1, IRF1, NFKBID, 
RIPK1,CD80,FCER1G,CD86,IL1B,CYCS,TNF,HLA-E 
EIF2 
Signaling 10.2 0.23 -0.32 
RAF1, RPS23, RPLP2, RPL39, RPL35A, HSPA5, MYC, RPS7, RPL13, 
RPS13, NKX6-2, ATF4, PPP1CA, RPL32, ATF3, RPL3, RPS8, RPL12, 
RPL37A, RPL9, RPS6, IRS1, PPP1R15A, PIK3R6, PIK3CD, RPL13A, 
RPL41, PIK3R5, KLB, RPL27A, RPL35, PPP1CC, RPL18A, UBA52, 
Rpl39l, PIK3R2, RPS12, RPL31, RPS24, RPL17, RPL30, EIF3J, TRIB3, 
RPS21, FAU, EIF4A1, RPS27A, RPL5, RPL37, EIF1AX 
iNOS 
Signaling 9.96 0.44 4.12 
MYD88,NFKBIE,IKBKE,NFKB2,HMGA1,JAK2,IRAK3,NFKB1,MAPK11
,IRF1,FOS,TLR4,NFKBID,JUN,NFKBIA,CD14,LBP,NFKBIB,NOS2,JAK3 













C3H/HeN Resolved mice 3.5 hpi vs PBS 
Pathways  -lp R z Molecules 
TNFR2 Signaling 5.66 0.10 N/A NFKBIA,TNFAIP3,BIRC3 
IL-17A Signaling in Fibroblasts 5.41 0.09 N/A NFKBID,NFKBIA,NFKBIZ 
iNOS Signaling 5.11 0.07 N/A NFKBIA,CD14,IRF1 
TNFR1 Signaling 4.96 0.06 N/A NFKBIA,TNFAIP3,BIRC3 
Toll-like Receptor Signaling 4.42 0.04 N/A NFKBIA,CD14,TNFAIP3 
MIF-mediated Glucocorticoid Regulation 3.41 0.06 N/A NFKBIA,CD14 
TWEAK Signaling 3.38 0.06 N/A NFKBIA,BIRC3 
Role of PKR in Interferon Induction and Antiviral 
Response 3.24 0.05 N/A NFKBIA,IRF1 
MIF Regulation of Innate Immunity 3.22 0.05 N/A NFKBIA,CD14 
Role of Osteoblasts, Osteoclasts and Chondrocytes 
in Rheumatoid Arthritis 2.96 0.01 N/A NFKBIA,CSF1,BIRC3 
Induction of Apoptosis by HIV1 2.89 0.03 N/A NFKBIA,BIRC3 
Lymphotoxin Œ≤ Receptor Signaling 2.79 0.03 N/A NFKBID,NFKBIA 
Role of IL-17A in Arthritis 2.79 0.03 N/A NFKBIA,CCL20 
IL-10 Signaling 2.78 0.03 N/A NFKBIA,CD14 
IL-17A Signaling in Airway Cells 2.67 0.03 N/A NFKBIA,CCL20 
CD40 Signaling 2.66 0.03 N/A NFKBIA,TNFAIP3 
Macropinocytosis Signaling 2.63 0.02 N/A CSF1,CD14 
LPS-stimulated MAPK Signaling 2.58 0.02 N/A NFKBIA,CD14 
Apoptosis Signaling 2.55 0.02 N/A NFKBIA,BIRC3 
Death Receptor Signaling 2.52 0.02 N/A NFKBIA,BIRC3 
RANK Signaling in Osteoclasts 2.44 0.02 N/A NFKBIA,BIRC3 
Type I Diabetes Mellitus Signaling 2.37 0.02 N/A NFKBIA,IRF1 
IL-6 Signaling 2.25 0.02 N/A NFKBIA,CD14 
IL-12 Signaling and Production in Macrophages 2.13 0.01 N/A REL,IRF1 
Hepatic Cholestasis 2.06 0.01 N/A NFKBIA,CD14 
C3H/HeN Sensitized mice 24 hpi vs PBS 













Altered T Cell 




20.4 0.47 N/A 
IL1A, IL12A, HLA-A, TLR8, IL22, HLA-DQB1, IL6, NFKB1, FAS, 
CD28, IL36G, CXCL13, IL2, HLA-DMA, HLA-DRA, TLR1, HLA-
DMB, IL23A, MAP3K14, IFNG, TNFSF11, SPP1, RELB, IL36A, 
























Maturation 17.4 0.31 6.26 
PLCB2, HLA-DQB1, IL6, FCGR1A, CD1D, NFKBIB, IL23A, 
TNFRSF11B, MAP3K14, IL36A, PLCL2, NFKB2, CREB5, TLR9, IL33, 
PIK3R3, TLR2, NFKBID, CD40, IL1RN, PLCG2, PIK3R6, CD86, 
PIK3CD, STAT2, IRF8, TNF, CCR7, IL1A, ICAM1, IL12A, HLA-A, 
PDIA3, NFKBIE, NOTUM, PIK3R5, CD83, FCGR2B, NFKB1, 
MAPK11, IL36G, HLA-DMA, HLA-DRA, HLA-DMB, LY75, PIK3R2, 
TNFRSF1B, STAT1, FCGR3A/FCGR3B, TYROBP, 
FCGR2A,MYD88,RELB,STAT4,PLCB4,CD80,FCER1G,IL1B,CSF2 












Th1 and Th2 
Activation 
Pathway 
15.6 0.30 N/A 
CD247,SOCS1,CCR3,SOCS3,CCR5,TNFRSF4,IL12RB1,HAVCR2,HLA
-DQB1, IL6, SPI1, CD28, CD274, KLRC1, IL2RB, IL2RG, IL4R, 
PTGDR2, IL12RB2, STAT3, TLR9, IRF1, PIK3R3, IL33, CD40, 
PIK3R6, IL10RA, CD86, VAV1, PIK3CD, ICAM1, IL12A, HLA-A, 
KLRD1, PIK3R5, NFKB1, NFIL3, IL2, HLA-DMA, HLA-DRA, HLA-
DMB, PIK3R2, STAT1, CCR1, IFNG, TNFSF11, CXCR4, IKZF1, TSLP, 
STAT4, ITGB2, CD80, ICOS, IL2RA, JAK3 
T Helper Cell 

























and Natural Killer 
Cells 
13.4 0.38 N/A 
IL12A, HLA-A, KLRD1, TNFSF10, CD83, IL6, NFKB1, FAS, CD28, 
PRF1, IL2, HLA-DRA, ACTG2, HLA-F, TNFRSF1B, ACTC1, IL2RB, 
IFNG, CD209, IL2RG, TYROBP, CD69, NFKB2, TLR9, ITGAL, 





13.4 0.37 N/A 
IL1A, IL12A, HLA-A, TLR8, CD83, CCL5, IL6, CXCL10, CD28, 
IL36G, CCL3L3, IL2, HLA-DRA, TLR1, HLA-F, IFNG, IL36A, TLR9, 
Ccl9, TLR2, IL33, CCL4, CD40, CD80, IL1RN, TNFSF13, TLR6, 



























Type I Diabetes 
Mellitus 
Signaling 





































Th2 Pathway 11.7 0.29 2.48 
CD247, CCR3, SOCS3, CCR5, ICAM1, TNFRSF4, IL12A, IL12RB1, 
HLA-A, PIK3R5, HLA-DQB1, NFKB1, SPI1, CD28, IL2, HLA-DMA, 
HLA-DRA, HLA-DMB, PIK3R2, IL2RB, CCR1, IFNG, IL4R, PTGDR2, 
IL2RG, CXCR4, IKZF1, IL12RB2, TLR9, TSLP, STAT4, PIK3R3, IL33, 




























in T Helper Cells 9.89 0.28 3.66 
CD247, ARPC1B, HLA-A, NFKBIE, ARPC5, PIK3R5, HLA-DQB1, 
NFKB1, CTLA4, PTPRC, CD28, LCK, IL2, HLA-DMA, HLA-DRA, 
HLA-DMB, PIK3R2, NFKBIB, PTPN6, RAC1, NFKB2, MALT1, TLR9, 
PIK3R3, NFKBID, CD80, CARD11, WAS, SYK, ZAP70, FCER1G, 
PIK3R6, CD86, VAV1, PIK3CD, LCP2, ARPC4 
Toll-like Receptor 










C3H/HeN Sensitized mice 6 hpi vs PBS 








































































Altered T Cell 











Maturation 14.9 0.31 5.53 
MAP2K4, HLA-DOA, LTB, IL6, FCGR1A, PLCD3, CD1D, ATF4, 
NFKBIB, TNFRSF11B, MAP3K14, IL36A, NFKB2, PIK3R3, TLR2, 
IL33, NFKBID, CD40, IL1RN, PLCG2, IRS1, PIK3R6, CD86, PIK3CD, 
STAT2, TNF, CCR7, IL1A, ICAM1, LEP, HLA-A, NFKBIE, PIK3R5, 
NOTUM, CD83, JAK2, IGHG1, FCGR2B, NFKB1, MAPK11, IL36G, 
NFKBIA, LY75, PIK3R2, TNFRSF1B, FCGR3A/FCGR3B, TYROBP, 
FCGR2A, MYD88, RELB, IL15, IKBKE, STAT4, TLR4, CD80, IL12B, 
LTA, FCER1G, IL1B, CSF2 
Hepatic 







































Th1 and Th2 
Activation 
Pathway 


















Type I Diabetes 
Mellitus 
Signaling 

























































































C3H/HeN Sensitized mice 3.5 hpi vs PBS 












































Signaling 16.7 0.25 4.36 
TREM1,ICAM1,NLRP3,MYD88,CD83,IL6,NFKB2,STAT3,NFKB1,FC
GR2B,TLR2,CXCL3,NOD2,CCL2,CD40,CD86,IL1B,CSF2,TNF 




































iNOS Signaling 14 0.32 3.46 NFKBIA,JUN,MYD88,NFKBIE,CD14,IKBKE,NFKB2,IRAK3,LBP,NFKBIB,NOS2,NFKB1,MAPK11,IRF1 
Altered T Cell 




13.9 0.2 N/A MAP3K14,IL1A,RELB,IL6,NFKB2,NFKB1,FAS,IL17A,TLR2,IL36G,CD40,IL1RN,CSF1,LTA,CD86,IL1B,CSF2,TNF 
TNFR2 Signaling 13.7 0.41 2.33 MAP3K14,NFKBIA,JUN,NFKBIE,LTA,TNFAIP3,IKBKE,NFKB2,NFKBIB,NFKB1,BIRC3,TNF 
IL-17A Signaling 
in Airway Cells 12.7 0.21 1.94 
CXCL3,NFKBIA,NFKBIE,PIK3R5,CCL20,IKBKE,STAT3,NFKB2,IL6,
NFKBIB,IL17RA,CCL11,NFKB1,MAPK11,CXCL6,IL17A 
CD40 Signaling 12.6 0.21 1.81 MAP3K14,ICAM1,NFKBIE,PIK3R5,TNFAIP3,IKBKE,NFKB2,STAT3,NFKB1,MAPK11,JUN,NFKBIA,CD40,LTA,PTGS2,NFKBIB 
Role of IL-17A in 
Arthritis 12.4 0.22 N/A 
CXCL3,NFKBIA,CCL2,NFKBIE,PIK3R5,CCL20,PTGS2,NFKB2,NFK
BIB,NOS2,IL17RA,NFKB1,MAPK11,CXCL6,IL17A 
Type I Diabetes 
Mellitus 
Signaling 
12.3 0.16 3 SOCS1,SOCS3,MAP3K14,MYD88,NFKBIE,IKBKE,NFKB2,NFKB1,MAPK11,FAS,IRF1,NFKBIA,LTA,CD86,IL1B,NFKBIB,NOS2,TNF 
Atherosclerosis 
Signaling 12.2 0.15 N/A 
IL1A,SELE,VCAM1,ICAM1,MSR1,IL6,NFKB2,NFKB1,CCL11,IL36G,
CCL2,SELP,CD40,CSF1,IL1RN,IL1B,S100A8,TNF,MMP9 











IL-17 Signaling 10.8 0.18 N/A MAP3K14,PIK3R5,IL6,CEBPB,NFKB1,CCL11,IL17RA,MAPK11,IL17A,CXCL10,JUN,CCL2,PTGS2,IL17F,NOS2 
IL-12 Signaling 
and Production in 
Macrophages 
10.2 0.12 N/A MYD88,PIK3R5,IKBKE,CEBPB,NFKB2,NFKB1,MAPK11,SPI1,IRF1,TLR2,JUN,CD40,MAP3K8,S100A8,NFKBIB,REL,NOS2,TNF 
C3H/HeOuJ Juvenile Naïve mice 24 hpi vs PBS 






























Hepatic Fibrosis / 
Hepatic Stellate 
Cell Activation 



































































Altered T Cell 










Role of Pattern 
Recognition 
Receptors in 



































and Natural Killer 
Cells 





















Type I Diabetes 
Mellitus 
Signaling 







































Th1 and Th2 
Activation 
Pathway 















T Helper Cell 

























C3H/HeOuJ Juvenile Naïve mice 3.5 hpi vs PBS 
Pathways  -lp R z Molecules 
IL-17A Signaling in Fibroblasts 6.31 0.114 N/A FOS,CCL2,CEBPD,NFKBIZ 
IL-17A Signaling in Gastric Cells 4.89 0.12 N/A CXCL10,FOS,CCL20 
ErbB Signaling 3.11 0.03 N/A FOS,HBEGF,AREG 
TNFR2 Signaling 2.89 0.07 N/A FOS,TNFAIP3 
HMGB1 Signaling 2.73 0.02 N/A FOS,CCL2,PLAT 
Role of Hypercytokinemia/hyperchemokinemia in the 
Pathogenesis of Influenza 2.55 0.05 N/A CXCL10,CCL2 
Role of IL-17F in Allergic Inflammatory Airway 
Diseases 2.53 0.05 N/A CXCL10,CCL2 
TNFR1 Signaling 2.44 0.04 N/A FOS,TNFAIP3 
Granulocyte Adhesion and Diapedesis 2.38 0.02 N/A CXCL10,CCL2,CCL20 
Agranulocyte Adhesion and Diapedesis 2.3 0.02 N/A CXCL10,CCL2,CCL20 
Role of IL-17A in Arthritis 2.17 0.03 N/A CCL2,CCL20 
Chemokine Signaling 2.12 0.03 N/A FOS,CCL2 
Role of MAPK Signaling in the Pathogenesis of 




Toll-like Receptor Signaling 2.09 0.03 N/A FOS,TNFAIP3 
TREM1 Signaling 2.08 0.03 N/A CCL2,CD83 
CD40 Signaling 2.04 0.03 N/A FOS,TNFAIP3 
IL-17 Signaling 1.97 0.02 N/A CXCL10,CCL2 
Neuregulin Signaling 1.94 0.02 N/A HBEGF,AREG 
Communication between Innate and Adaptive Immune 
Cells 1.93 0.02 N/A CXCL10,CD83 
Pathogenesis of Multiple Sclerosis 1.79 0.11 N/A CXCL10 
Corticotropin Releasing Hormone Signaling 1.75 0.02 N/A FOS,NR4A1 
HGF Signaling 1.72 0.02 N/A FOS,ELF3 
Role of Macrophages, Fibroblasts and Endothelial 
Cells in Rheumatoid Arthritis 1.72 0.01 N/A FOS,CCL2,CEBPD 
Renin-Angiotensin Signaling 1.69 0.02 N/A FOS,CCL2 
Role of Tissue Factor in Cancer 1.68 0.02 N/A EGR1,HBEGF 
C3H/HeOuJ Juvenile Naïve mice 6 hpi vs PBS 






































































Altered T Cell 



























Hepatic Fibrosis / 
Hepatic Stellate 
Cell Activation 






















Signaling 10.7 0.27 3.21 
PPARA,MAP3K14,IL1A,MYD88,TNFAIP3,IRAK3,NFKB2,NFKB1,MA
PK11,IL33,TLR2,FOS,IL36G,JUN,NFKBIA,IL1RN,IL1B,CD14,LBP,TNF 
TNFR2 Signaling 10.3 0.45 2.71 FOS,MAP3K14,NFKBIA,JUN,NFKBIE,TNFAIP3,IKBKE,NFKB2,NFKBIB,TNFRSF1B,NFKB1,TNF,BIRC3 










10 0.24 N/A IL1A,IL10,CD83,CCL5,IL6,Ccl9,Tlr12,IL33,TLR2,CXCL10,IL36G,CCL4,CD80,CCL3L3,IL1RN,FCER1G,Tlr13,IL1B,CSF2,TNF,CCR7 



























iNOS Signaling 8.71 0.32 3.46 FOS,NFKBIA,JUN,MYD88,NFKBIE,CD14,IKBKE,NFKB2,IRAK3,LBP,HMGA1,NFKBIB,NFKB1,MAPK11 
C57BL/6J Juvenile Naïve mice 24 hpi vs PBS 
Pathways  -lp R z Molecules 
Cell Cycle Control of 
Chromosomal Replication 11.3 0.34 N/A 
MCM5,MCM3,LIG1,MCM6,CDC45,MCM2,CDT1,CDC6,TOP2
A,POLD1,MCM4,MCM7,RPA2 
Granulocyte Adhesion and 




Cell Cycle: G2/M DNA 
Damage Checkpoint 
Regulation 












IL-10 Signaling 5.95 0.16 N/A IL33,IL1R2,CCR1,HMOX1,SOCS3,CCR5,FCGR2A,IL1RN,IL10RA,IL1B,FCGR2B 
Communication between 
Innate and Adaptive 
Immune Cells 





5.36 0.13 3.46 PLD4,HMOX1,FCGR2A,SYK,LYN,HCK,VAV1,FCGR1A,FCGR3A/FCGR3B,FGR,INPP5D,LCP2 
Atherosclerosis Signaling 5.33 0.11 N/A CCR3,MSR1,MMP3,CXCR4,CCR2,SELPLG,IL33,PLBD1,ITGB2,LYZ,IL1RN,IL1B,S100A8,CLU 








Natural Killer Cell 
Signaling 4.83 0.11 N/A 
PTPN6,FCGR2A,KLRD1,TYROBP,TLR9,INPP5D,LCK,SYK,F
CER1G,VAV1,PIK3CD,FCGR3A/FCGR3B,LCP2 
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 
4.73 0.12 N/A IL33,SPP1,IL1RN,HLA-DMB,TLR1,FCER1G,TLR8,LTB,Tlr13,IL1B,TLR9 
Th1 and Th2 Activation 
Pathway 4.64 0.09 N/A 
CCR1,CCR3,SOCS3,IL2RG,CCR5,KLRD1,CXCR4,TLR9,SPI1,
IL33,ITGB2,HLA-DMB,IL10RA,PIK3CD,VAV1,IL2RB 




ATM Signaling 4.44 0.13 0.33 CDC25C,SMC2,FANCD2,H2AFX,CCNB2,HIST1H4J,BRCA1,CDK1,CHEK1,CCNB1 
Pathogenesis of Multiple 
Sclerosis 4.32 0.44 N/A CCR1,CXCL10,CCR5,CCL5 
Role of Pattern 
Recognition Receptors in 
Recognition of Bacteria 
and Viruses 
4.29 0.09 2.65 OAS1,OAS2,TLR8,CCL5,TLR9,CLEC7A,IRF7,SYK,TLR1,IL1B,PIK3CD,CLEC6A,C3AR1 
Role of 
Hypercytokinemia/hyperch
emokinemia in the 
Pathogenesis of Influenza 
4 0.16 N/A IL33,CCR1,CXCL10,CCR5,IL1RN,IL1B,CCL5 









Role of IL-17A in Psoriasis 3.6 0.31 N/A S100A9,CCL20,S100A8,CXCL6 
Interferon Signaling 3.56 0.17 2.24 IFITM3,IFIT3,OAS1,IRF9,PSMB8,ISG15 
Hereditary Breast Cancer 
Signaling 3.53 0.08 N/A 
UBD,FANCB,CDC25C,FANCD2,H2AFX,E2F1,PIK3CD,TLR9,
BRCA1,CDK1,CHEK1,CCNB1 
iCOS-iCOSL Signaling in 
T Helper Cells 3.52 0.09 2.53 
PTPRC,IL2RG,LCK,HLA-
DMB,FCER1G,VAV1,PIK3CD,TLR9,INPP5D,LCP2,IL2RB 
Role of NFAT in 
Regulation of the Immune 
Response 
3.52 0.08 3.21 PLCB2,FCGR2A,TLR9,FCGR2B,FCGR1A,H2BFM,LCK,SYK,HLA-DMB,LYN,FCER1G,PIK3CD,FCGR3A/FCGR3B,LCP2 
C57BL/6J Juvenile Naïve mice 3.5 hpi vs PBS 
Pathways  -lp R z Molecules 
Granulocyte Adhesion and 
















IL-17A Signaling in 




Role of Macrophages, 
Fibroblasts and Endothelial 
Cells in Rheumatoid 
Arthritis 





Acute Phase Response 











TREM1 Signaling 13.7 0.23 3.64 TREM1,ICAM1,NLRP3,IL10,MYD88,CD83,IL6,NFKB2,NFKB1,Tlr12,TLR2,CXCL3,NOD2,CCL2,IL1B,CSF2,TNF 




Role of Pattern 
Recognition Receptors in 
Recognition of Bacteria 
and Viruses 










Differential Regulation of 
Cytokine Production in 
Intestinal Epithelial Cells 
by IL-17A and IL-17F 
11.5 0.44 N/A IL1A,CCL4,CCL2,IL10,LCN2,IL1B,CSF3,CSF2,TNF,IL17A 
Toll-like Receptor 




Innate and Adaptive 
Immune Cells 
11.3 0.18 N/A IL1A,IL10,CD83,IL6,Tlr12,Ccl9,IL33,TLR2,CXCL10,CCL4,CD80,CCL3L3,IL1RN,IL1B,CSF2,TNF 
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 
11.2 0.18 N/A IL1A,IL10,RELB,IL6,NFKB2,NFKB1,FAS,Tlr12,IL17A,IL33,TLR2,CD80,IL1RN,IL1B,CSF2,TNF 
Differential Regulation of 
Cytokine Production in 
Macrophages and T Helper 
Cells by IL-17A and IL-
17F 
11.1 0.5 N/A CCL4,CCL2,IL10,IL1B,IL6,CSF3,CSF2,TNF,IL17A 




iNOS Signaling 10.9 0.27 3.16 FOS,NFKBIA,JUN,MYD88,NFKBIE,CD14,HMGA1,NFKB2,NFKBIB,NFKB1,MAPK11,IRF1 
TNFR2 Signaling 10.3 0.35 2.12 FOS,NFKBIA,JUN,NFKBIE,TNFAIP3,NFKB2,NFKBIB,NFKB1,BIRC3,TNF 
Activation of IRF by 
Cytosolic Pattern 
Recognition Receptors 
10.2 0.21 0.83 IRF7,NFKBIA,JUN,IL10,NFKBIE,IRF9,NFKB2,IL6,NFKBIB,IFIT2,NFKB1,TNF,ISG15 
PPAR Signaling 9.91 0.16 -3.87 
IL1A,PPARD,NFKBIE,NFKB2,NFKB1,IL33,IL1R2,FOS,JUN,N
FKBIA,IL1RN,IL1B,PTGS2,NFKBIB,TNF 
Role of IL-17A in Arthritis 9.71 0.19 N/A CXCL3,NFKBIA,CCL2,NFKBIE,CCL20,PTGS2,NFKB2,NFKBIB,IL17RA,NFKB1,MAPK11,CXCL6,IL17A 
Role of 
Hypercytokinemia/hyperch
emokinemia in the 
Pathogenesis of Influenza 
9.69 0.26 N/A IL33,CCR1,CXCL10,IL1A,CCL4,CCL2,IL1RN,IL1B,IL6,TNF,IL17A 
Role of Osteoblasts, 













C57BL/6J Juvenile Naïve mice 6 hpi vs PBS 
Pathways  -lp R z Molecules 
Granulocyte Adhesion 























Role of Macrophages, 
Fibroblasts and 
Endothelial Cells in 
Rheumatoid Arthritis 




























Bacteria and Viruses 












































IL-17A Signaling in 




Th1 and Th2 







between Innate and 
Adaptive Immune 
Cells 
10.7 0.30 N/A 
IL1A, HLA-A, TLR8, CD83, IL6, CCL5, Tlr12, CXCL10, IL36G, 
CCL3L3, TLR1, TLR9, Ccl9, TLR2, IL33, CCL4, CD40, CD80, 
IL1RN, TLR6, FCER1G, Tlr13, CD86, IL1B, CSF2, TNF, CCR7 
Altered T Cell and B 
Cell Signaling in 
Rheumatoid Arthritis 
10.6 0.3 N/A 
MAP3K14, IL1A, HLA-A, RELB, TLR8, LTB, NFKB2, IL6, NFKB1, 
TLR9, FAS, Tlr12, IL17A, IL33, TLR2, IL36G, CD80, CD40, IL1RN, 
TLR6, TLR1, FCER1G, Tlr13, IL1B, CD86, CSF2, TNF 
Hepatic Fibrosis / 
Hepatic Stellate Cell 
Activation 

























iNOS Signaling 9.79 0.41 3.87 MYD88,NFKBIE,IKBKE,HMGA1,IRAK3,NFKB2,NFKB1,MAPK11,IRF1,FOS,JUN,NFKBIA,CD14,LBP,NFKBIB,STAT1,NOS2,JAK3 
Role of IL-17A in 












Production of Nitric 
Oxide and Reactive 
Oxygen Species in 
Macrophages 






TNFR2 Signaling 8.9 0.48 2.31 MAP3K14,NAIP,NFKBIE,TNFAIP3,IKBKE,NFKB2,NFKB1,FOS,JUN,NFKBIA,NFKBIB,TNFRSF1B,BIRC3,TNF 
 
Table S7. 
TNFα signaling pathways downstream gene expression changes.  
mouse time pointα pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C57BL/6J 
3.5 hpi vs PBS TNFR1 7.83 0.204 2.333 2 





Expected Location Type(s) 
BIRC3 baculoviral IAP repeat 
containing 3 
1.557 1.46E-23 Down Cytoplasm enzyme 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.878 2.42E-25 Up Nucleus transcription 
regulator 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.488 3.59E-29 Up Nucleus transcription 
regulator 
NFKB1 nuclear factor kappa B 
subunit 1 
1.181 3.45E-14 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
1.48 6.15E-23 Up Nucleus transcription 
regulator 
NFKBIA NFKB inhibitor alpha 1.542 1.56E-33 Up Cytoplasm transcription 
regulator 
NFKBIB NFKB inhibitor beta 1.091 2.26E-08 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 1.776 1.14E-19 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 2.336 1.17E-17 Up Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 3.724 4.26E-97   Nucleus enzyme 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C57BL/6J 









Expected Location Type(s) 
BIRC3 baculoviral IAP repeat 
containing 3 
1.557 1.46E-23 Down Cytoplasm enzyme 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.878 2.42E-25 Up Nucleus transcription 
regulator 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.488 3.59E-29 Up Nucleus transcription 
regulator 
NFKB1 nuclear factor kappa B 
subunit 1 
1.181 3.45E-14 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
1.48 6.15E-23 Up Nucleus transcription 
regulator 
NFKBIA NFKB inhibitor alpha 1.542 1.56E-33 Up Cytoplasm transcription 
regulator 
NFKBIB NFKB inhibitor beta 1.091 2.26E-08 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 1.776 1.14E-19 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 2.336 1.17E-17   Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 3.724 4.26E-97   Nucleus enzyme 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C57BL/6J 
6 hpi vs PBS TNFR1 7.98 0.347 2.5 2 





Expected Location Type(s) 
BIRC3 baculoviral IAP repeat 
containing 3 
1.899 1.63E-47 Down Cytoplasm enzyme 
CASP8 caspase 8 1.035 1.03E-09 Up Nucleus peptidase 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.462 6.70E-14 Up Nucleus transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.4 2.12E-28 Up Cytoplasm kinase 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.143 4.25E-17 Up Nucleus transcription 
regulator 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.375 2.12E-14 Up Cytoplasm kinase 
NAIP NLR family apoptosis 
inhibitory protein 
1.092 6.49E-08 Down Cytoplasm other 
NFKB1 nuclear factor kappa B 
subunit 1 
1.761 6.64E-70 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
2.118 2.30E-67 Up Nucleus transcription 
regulator 
NFKBIA NFKB inhibitor alpha 1.24 1.25E-23 Up Cytoplasm transcription 
regulator 
NFKBIB NFKB inhibitor beta 1.585 2.23E-13 Up Nucleus transcription 
regulator 





PAK3 p21 (RAC1) activated kinase 
3 
-1.077 2.40E-08 Up Cytoplasm kinase 
PAK6 p21 (RAC1) activated kinase 
6 
1.117 9.13E-09 Up Cytoplasm kinase 
TNF tumor necrosis factor 2.891 1.14E-21 Up Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 3.041 7.76E-66   Nucleus enzyme 
TNFRSF1A TNF receptor superfamily 
member 1A 




       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C57BL/6J 
6 hpi vs PBS TNFR2 8.9 0.483 2.309 2 





Expected Location Type(s) 
BIRC3 baculoviral IAP repeat 
containing 3 
1.899 1.63E-47 Down Cytoplasm enzyme 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.462 6.70E-14 Up Nucleus transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.4 2.12E-28 Up Cytoplasm kinase 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.143 4.25E-17 Up Nucleus transcription 
regulator 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.375 2.12E-14 Up Cytoplasm kinase 
NAIP NLR family apoptosis 
inhibitory protein 
1.092 6.49E-08 Down Cytoplasm other 
NFKB1 nuclear factor kappa B 
subunit 1 
1.761 6.64E-70 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
2.118 2.30E-67 Up Nucleus transcription 
regulator 
NFKBIA NFKB inhibitor alpha 1.24 1.25E-23 Up Cytoplasm transcription 
regulator 
NFKBIB NFKB inhibitor beta 1.585 2.23E-13 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 2.063 2.69E-22 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 2.891 1.14E-21   Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 3.041 7.76E-66   Nucleus enzyme 
TNFRSF1B TNF receptor superfamily 
member 1B 




       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C3H/HeOuJ 
3.5 hpi vs PBS TNFR1 2.44 0.0408 NA 2 









FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
1.178 2.81E-06 Up Nucleus transcription 
regulator 
TNFAIP3 TNF alpha induced protein 3 1.205 3.56E-06   Nucleus enzyme 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C3H/HeOuJ 
3.5 hpi vs PBS TNFR2 2.89 0.069 NA 2 





Expected Location Type(s) 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
1.178 2.81E-06 Up Nucleus transcription 
regulator 
TNFAIP3 TNF alpha induced protein 3 1.205 3.56E-06   Nucleus enzyme 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C3H/HeOuJ 
6 hpi vs PBS TNFR1 7.08 0.265 2.887 2 





Expected Location Type(s) 
BIRC3 baculoviral IAP repeat 
containing 3 
1.877 5.51E-26 Down Cytoplasm enzyme 
CASP8 caspase 8 1.097 3.04E-08 Up Nucleus peptidase 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.884 2.00E-20 Up Nucleus transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.176 1.11E-09 Up Cytoplasm kinase 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.307 1.96E-19 Up Nucleus transcription 
regulator 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.116 4.60E-06 Up Cytoplasm kinase 
NFKB1 nuclear factor kappa B 
subunit 1 
1.757 9.54E-20 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
1.769 1.48E-18 Up Nucleus transcription 
regulator 
NFKBIA NFKB inhibitor alpha 1.374 9.38E-21 Up Cytoplasm transcription 
regulator 
NFKBIB NFKB inhibitor beta 1.344 1.21E-08 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 1.726 1.35E-09 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 2.38 2.00E-09 Up Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 3.235 9.50E-22   Nucleus enzyme 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C3H/HeOuJ 









Expected Location Type(s) 
BIRC3 baculoviral IAP repeat 
containing 3 
1.877 5.51E-26 Down Cytoplasm enzyme 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.884 2.00E-20 Up Nucleus transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.176 1.11E-09 Up Cytoplasm kinase 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.307 1.96E-19 Up Nucleus transcription 
regulator 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.116 4.60E-06 Up Cytoplasm kinase 
NFKB1 nuclear factor kappa B 
subunit 1 
1.757 9.54E-20 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
1.769 1.48E-18 Up Nucleus transcription 
regulator 
NFKBIA NFKB inhibitor alpha 1.374 9.38E-21 Up Cytoplasm transcription 
regulator 
NFKBIB NFKB inhibitor beta 1.344 1.21E-08 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 1.726 1.35E-09 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 2.38 2.00E-09   Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 3.235 9.50E-22   Nucleus enzyme 
TNFRSF1B TNF receptor superfamily 
member 1B 




       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C3H/HeOuJ 
24 hpi vs PBS TNFR1 8.39 0.449 2.837 2 





Expected Location Type(s) 
APAF1 apoptotic peptidase 
activating factor 1 
1.03 2.72E-06 Up Cytoplasm other 
BIRC3 baculoviral IAP repeat 
containing 3 
1.87 3.84E-17 Down Cytoplasm enzyme 
CASP7 caspase 7 1.458 7.34E-08 Up Cytoplasm peptidase 
CASP8 caspase 8 1.605 3.03E-17 Up Nucleus peptidase 
CYCS cytochrome c, somatic 1.757 1.11E-25 Up Cytoplasm transporter 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.03 6.49E-06 Up Cytoplasm kinase 
MAP4K2 mitogen-activated protein 
kinase kinase kinase kinase 2 
6.325 9.33E-20 Up Cytoplasm kinase 
NAIP NLR family apoptosis 
inhibitory protein 
1.988 1.09E-19 Down Cytoplasm other 
Naip1 (includes 
others) 
NLR family, apoptosis 
inhibitory protein 1 
1.921 3.78E-10 Down Cytoplasm other 
NFKB1 nuclear factor kappa B 
subunit 1 





NFKB2 nuclear factor kappa B 
subunit 2 
2.171 1.49E-17 Up Nucleus transcription 
regulator 
NFKBIB NFKB inhibitor beta 1.613 1.71E-06 Up Nucleus transcription 
regulator 
NFKBID NFKB inhibitor delta 2.519 1.60E-08 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 1.91 3.96E-13 Up Nucleus transcription 
regulator 
PAK1 p21 (RAC1) activated kinase 
1 
1.052 4.92E-06 Up Cytoplasm kinase 
TNF tumor necrosis factor 3.178 2.51E-14 Up Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 2.909 5.75E-15   Nucleus enzyme 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
Juvenile Naive 
C3H/HeOuJ 
24 hpi vs PBS TNFR1 9.97 0.621 2.5 2 





Expected Location Type(s) 
BIRC3 baculoviral IAP repeat 
containing 3 
2.167 1.38E-66 Down Cytoplasm enzyme 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.215 1.21E-38 Up Nucleus transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.959 1.88E-52 Up Cytoplasm kinase 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.362 1.61E-20 Up Nucleus transcription 
regulator 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.409 8.14E-10 Up Cytoplasm kinase 
NAIP NLR family apoptosis 
inhibitory protein 
1.616 1.11E-11 Down Cytoplasm other 
Naip1 (includes 
others) 
NLR family, apoptosis 
inhibitory protein 1 
1.462 3.40E-06 Down Cytoplasm other 
NFKB1 nuclear factor kappa B 
subunit 1 
1.638 1.52E-31 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
2.163 2.16E-51 Up Nucleus transcription 
regulator 
NFKBIA NFKB inhibitor alpha 1.144 1.56E-27 Up Cytoplasm transcription 
regulator 
NFKBIB NFKB inhibitor beta 1.949 1.55E-22 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 2.476 1.78E-29 Up Nucleus transcription 
regulator 
TBK1 TANK binding kinase 1 1.145 1.53E-11 Up Cytoplasm kinase 
TNF tumor necrosis factor 4.254 1.80E-33   Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 3.877 1.53E-125   Nucleus enzyme 
TNFRSF1B TNF receptor superfamily 
member 1B 




TRAF1 TNF receptor associated 
factor 1 




TRAF2 TNF receptor associated 
factor 2 
1.039 2.44E-14 Up Cytoplasm enzyme 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Adult Naive 
3.5 hpi vs PBS TNFR1 1.75 0.0408 NA 1.5 





Expected Location Type(s) 
TNFAIP3 TNF alpha induced protein 3 1.032 7.40E-08   Nucleus enzyme 
TNF tumor necrosis factor 0.659 5.63E-03 Up Extracellular 
Space 
cytokine 
       
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Adult Naive 
3.5 hpi vs PBS TNFR2 2.19 0.069 NA 1.5 
TNFAIP3 TNF alpha induced protein 3 1.032 7.40E-08   Nucleus enzyme 
TNF tumor necrosis factor 0.659 5.63E-03   Extracellular 
Space 
cytokine 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Adult Naive 
6 hpi vs PBS TNFR1 3.64 0.18 2.121 2 





Expected Location Type(s) 
MAP4K2 mitogen-activated protein 
kinase kinase kinase kinase 2 
5.592 2.12E-26 Up Cytoplasm kinase 
TNFAIP3 TNF alpha induced protein 3 2.454 1.71E-26   Nucleus enzyme 
NFKBIE NFKB inhibitor epsilon 1.828 1.04E-17 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
1.758 2.29E-15 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.742 2.42E-26 Down Cytoplasm enzyme 
TNF tumor necrosis factor 1.396 1.29E-02 Up Extracellular 
Space 
cytokine 
NFKB1 nuclear factor kappa B 
subunit 1 
1.185 9.49E-09 Up Nucleus transcription 
regulator 
CYCS cytochrome c, somatic 1.075 5.28E-19 Up Cytoplasm transporter 
NFKBIA NFKB inhibitor alpha 1.023 1.43E-04 Up Cytoplasm transcription 
regulator 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Adult Naive 
6 hpi vs PBS TNFR2 4.58 0.267 1.633 2 









TNFAIP3 TNF alpha induced protein 3 2.454 1.71E-26   Nucleus enzyme 
NFKBIE NFKB inhibitor epsilon 1.828 1.04E-17 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
1.758 2.29E-15 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.742 2.42E-26 Down Cytoplasm enzyme 
TNF tumor necrosis factor 1.396 1.29E-02   Extracellular 
Space 
cytokine 
NFKB1 nuclear factor kappa B 
subunit 1 
1.185 9.49E-09 Up Nucleus transcription 
regulator 
TNFRSF1B TNF receptor superfamily 
member 1B 




NFKBIA NFKB inhibitor alpha 1.023 1.43E-04 Up Cytoplasm transcription 
regulator 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Adult Naive 
24 hpi vs PBS TNFR1 3.7 0.26 1.732 2 





Expected Location Type(s) 
MAP4K2 mitogen-activated protein 
kinase kinase kinase kinase 2 
6.036 9.74E-24 Up Cytoplasm kinase 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.012 1.60E-05 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 1.923 1.34E-06 Up Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 1.818 1.18E-11   Nucleus enzyme 
CYCS cytochrome c, somatic 1.706 2.51E-55 Up Cytoplasm transporter 
Naip1 (includes 
others) 
NLR family, apoptosis 
inhibitory protein 1 
1.612 1.21E-07 Down Cytoplasm other 
NAIP NLR family apoptosis 
inhibitory protein 
1.567 3.62E-13 Down Cytoplasm other 
NFKBIE NFKB inhibitor epsilon 1.541 6.87E-12 Up Nucleus transcription 
regulator 
NFKBID NFKB inhibitor delta 1.402 4.61E-04 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.366 1.23E-18 Down Cytoplasm enzyme 
NFKB2 nuclear factor kappa B 
subunit 2 
1.353 8.29E-12 Up Nucleus transcription 
regulator 
CASP3 caspase 3 1.23 3.17E-09 Up Cytoplasm peptidase 
CASP8 caspase 8 1.041 1.49E-07 Up Nucleus peptidase 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Adult Naive 
24 hpi vs PBS TNFR2 3.94 0.333 0.707 2 









FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.012 1.60E-05 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 1.923 1.34E-06   Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 1.818 1.18E-11   Nucleus enzyme 
Naip1 (includes 
others) 
NLR family, apoptosis 
inhibitory protein 1 
1.612 1.21E-07 Down Cytoplasm other 
NAIP NLR family apoptosis 
inhibitory protein 
1.567 3.62E-13 Down Cytoplasm other 
NFKBIE NFKB inhibitor epsilon 1.541 6.87E-12 Up Nucleus transcription 
regulator 
TNFRSF1B TNF receptor superfamily 
member 1B 




NFKBID NFKB inhibitor delta 1.402 4.61E-04 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.366 1.23E-18 Down Cytoplasm enzyme 
NFKB2 nuclear factor kappa B 
subunit 2 
1.353 8.29E-12 Up Nucleus transcription 
regulator 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Resolved 
3.5 hpi vs PBS TNFR1 4.96 0.0612 NA 1.5 





Expected Location Type(s) 
TNFAIP3 TNF alpha induced protein 3 0.73 6.61E-06   Nucleus enzyme 
BIRC3 baculoviral IAP repeat 
containing 3 
0.603 2.70E-03 Down Cytoplasm enzyme 
NFKBIA NFKB inhibitor alpha 0.6 2.96E-03 Up Cytoplasm transcription 
regulator 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Resolved 
3.5 hpi vs PBS TNFR2 5.66 0.103 NA 1.5 





Expected Location Type(s) 
TNFAIP3 TNF alpha induced protein 3 0.73 6.61E-06   Nucleus enzyme 
BIRC3 baculoviral IAP repeat 
containing 3 
0.603 2.70E-03 Down Cytoplasm enzyme 
NFKBIA NFKB inhibitor alpha 0.6 2.96E-03 Up Cytoplasm transcription 
regulator 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Resolved 
6 hpi vs PBS TNFR1 7.29 0.36 2.668 2 









MAP4K2 mitogen-activated protein 
kinase kinase kinase kinase 2 
6.155 1.37E-25 Up Cytoplasm kinase 
TNFAIP3 TNF alpha induced protein 3 4.19 5.46E-109   Nucleus enzyme 
NFKBID NFKB inhibitor delta 3.95 5.56E-27 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
2.786 1.92E-82 Down Cytoplasm enzyme 
NFKB2 nuclear factor kappa B 
subunit 2 
2.677 5.45E-58 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 2.509 2.30E-35 Up Nucleus transcription 
regulator 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
2.368 1.86E-04 Up Nucleus transcription 
regulator 
NFKB1 nuclear factor kappa B 
subunit 1 
2.301 8.89E-62 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 2.123 1.61E-12 Up Extracellular 
Space 
cytokine 
NFKBIB NFKB inhibitor beta 1.61 1.34E-16 Up Nucleus transcription 
regulator 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.51 1.59E-19 Up Cytoplasm kinase 
NFKBIA NFKB inhibitor alpha 1.462 1.49E-25 Up Cytoplasm transcription 
regulator 
CYCS cytochrome c, somatic 1.397 3.31E-35 Up Cytoplasm transporter 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.254 1.09E-09 Up Cytoplasm kinase 
Naip1 (includes 
others) 
NLR family, apoptosis 
inhibitory protein 1 
1.146 3.41E-04 Down Cytoplasm other 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.144 1.76E-08 Up Nucleus transcription 
regulator 
NAIP NLR family apoptosis 
inhibitory protein 
1.093 1.27E-07 Down Cytoplasm other 
RIPK1 receptor interacting 
serine/threonine kinase 1 
1.014 4.38E-24 Up Plasma 
Membrane 
kinase 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Resolved 
6 hpi vs PBS TNFR2 10.7 0.567 2.324 2 





Expected Location Type(s) 
TNFAIP3 TNF alpha induced protein 3 4.19 5.46E-109   Nucleus enzyme 
NFKBID NFKB inhibitor delta 3.95 5.56E-27 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
2.786 1.92E-82 Down Cytoplasm enzyme 
NFKB2 nuclear factor kappa B 
subunit 2 
2.677 5.45E-58 Up Nucleus transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 2.509 2.30E-35 Up Nucleus transcription 
regulator 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 





NFKB1 nuclear factor kappa B 
subunit 1 
2.301 8.89E-62 Up Nucleus transcription 
regulator 
TNF tumor necrosis factor 2.123 1.61E-12   Extracellular 
Space 
cytokine 
TNFRSF1B TNF receptor superfamily 
member 1B 




NFKBIB NFKB inhibitor beta 1.61 1.34E-16 Up Nucleus transcription 
regulator 
TRAF1 TNF receptor associated 
factor 1 
1.578 7.90E-16 Up Cytoplasm other 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.51 1.59E-19 Up Cytoplasm kinase 
NFKBIA NFKB inhibitor alpha 1.462 1.49E-25 Up Cytoplasm transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.254 1.09E-09 Up Cytoplasm kinase 
Naip1 (includes 
others) 
NLR family, apoptosis 
inhibitory protein 1 
1.146 3.41E-04 Down Cytoplasm other 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
1.144 1.76E-08 Up Nucleus transcription 
regulator 
NAIP NLR family apoptosis 
inhibitory protein 
1.093 1.27E-07 Down Cytoplasm other 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Sensitized 
3.5 hpi vs PBS TNFR1 9.28 0.224 2.53 1.5 





Expected Location Type(s) 
TNFAIP3 TNF alpha induced protein 3 2.262 9.90E-23   Nucleus enzyme 
TNF tumor necrosis factor 1.703 2.73E-12 Up Extracellular 
Space 
cytokine 
NFKB2 nuclear factor kappa B 
subunit 2 
1.296 4.75E-11 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.295 1.09E-08 Down Cytoplasm enzyme 
NFKBIA NFKB inhibitor alpha 1.221 1.64E-13 Up Cytoplasm transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 1.163 1.30E-07 Up Nucleus transcription 
regulator 
NFKBIB NFKB inhibitor beta 0.917 6.74E-05 Up Nucleus transcription 
regulator 
NFKB1 nuclear factor kappa B 
subunit 1 
0.89 1.17E-06 Up Nucleus transcription 
regulator 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
0.876 1.81E-08 Up Nucleus transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
0.827 6.46E-05 Up Cytoplasm kinase 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
0.6 6.57E-03 Up Cytoplasm kinase 




mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Sensitized 
3.5 hpi vs PBS TNFR2 13.7 0.414 2.333 1.5 





Expected Location Type(s) 
TNFAIP3 TNF alpha induced protein 3 2.262 9.90E-23   Nucleus enzyme 
TNF tumor necrosis factor 1.703 2.73E-12   Extracellular 
Space 
cytokine 
NFKB2 nuclear factor kappa B 
subunit 2 
1.296 4.75E-11 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.295 1.09E-08 Down Cytoplasm enzyme 
NFKBIA NFKB inhibitor alpha 1.221 1.64E-13 Up Cytoplasm transcription 
regulator 
NFKBIE NFKB inhibitor epsilon 1.163 1.30E-07 Up Nucleus transcription 
regulator 
NFKBIB NFKB inhibitor beta 0.917 6.74E-05 Up Nucleus transcription 
regulator 
NFKB1 nuclear factor kappa B 
subunit 1 
0.89 1.17E-06 Up Nucleus transcription 
regulator 
JUN Jun proto-oncogene, AP-1 
transcription factor subunit 
0.876 1.81E-08 Up Nucleus transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
0.827 6.46E-05 Up Cytoplasm kinase 
LTA lymphotoxin alpha 0.789 9.75E-03   Extracellular 
Space 
cytokine 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
0.6 6.57E-03 Up Cytoplasm kinase 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Sensitized 
6 hpi vs PBS TNFR1 3.98 0.3 3.207 2 





Expected Location Type(s) 
MAP4K2 mitogen-activated protein 
kinase kinase kinase kinase 2 
5.812 2.74E-20 Up Cytoplasm kinase 
TNF tumor necrosis factor 2.824 1.16E-17 Up Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 2.758 5.09E-39   Nucleus enzyme 
NFKBID NFKB inhibitor delta 2.474 5.34E-09 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
2.472 2.90E-37 Up Nucleus transcription 
regulator 
NFKB1 nuclear factor kappa B 
subunit 1 
2.047 6.38E-29 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.945 1.21E-30 Down Cytoplasm enzyme 




NFKBIE NFKB inhibitor epsilon 1.704 9.75E-13 Up Nucleus transcription 
regulator 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.397 3.85E-11 Up Cytoplasm kinase 
NFKBIB NFKB inhibitor beta 1.339 1.05E-06 Up Nucleus transcription 
regulator 
CASP8 caspase 8 1.319 1.09E-16 Up Nucleus peptidase 
NFKBIA NFKB inhibitor alpha 1.063 1.41E-13 Up Cytoplasm transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.034 2.73E-08 Up Cytoplasm kinase 
MAP2K4 mitogen-activated protein 
kinase kinase 4 
1.017 9.28E-09 Up Cytoplasm kinase 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Sensitized 
6 hpi vs PBS TNFR2 7.27 0.5 2.887 2 





Expected Location Type(s) 
TNF tumor necrosis factor 2.824 1.16E-17   Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 2.758 5.09E-39   Nucleus enzyme 
NFKBID NFKB inhibitor delta 2.474 5.34E-09 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
2.472 2.90E-37 Up Nucleus transcription 
regulator 
NFKB1 nuclear factor kappa B 
subunit 1 
2.047 6.38E-29 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.945 1.21E-30 Down Cytoplasm enzyme 
TNFRSF1B TNF receptor superfamily 
member 1B 




NFKBIE NFKB inhibitor epsilon 1.704 9.75E-13 Up Nucleus transcription 
regulator 
LTA lymphotoxin alpha 1.401 1.21E-02   Extracellular 
Space 
cytokine 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.397 3.85E-11 Up Cytoplasm kinase 
TRAF1 TNF receptor associated 
factor 1 
1.344 7.17E-06 Up Cytoplasm other 
NFKBIB NFKB inhibitor beta 1.339 1.05E-06 Up Nucleus transcription 
regulator 
NFKBIA NFKB inhibitor alpha 1.063 1.41E-13 Up Cytoplasm transcription 
regulator 
IKBKE inhibitor of nuclear factor 
kappa B kinase subunit 
epsilon 
1.034 2.73E-08 Up Cytoplasm kinase 
MAP2K4 mitogen-activated protein 
kinase kinase 4 
1.017 9.28E-09 Up Cytoplasm kinase 




mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Sensitized 
24 hpi vs PBS TNFR1 5.47 0.32 1.807 2 





Expected Location Type(s) 
MAP4K2 mitogen-activated protein 
kinase kinase kinase kinase 2 
6.325 9.33E-20 Up Cytoplasm kinase 
TNF tumor necrosis factor 3.178 2.51E-14 Up Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 2.909 5.75E-15   Nucleus enzyme 
NFKBID NFKB inhibitor delta 2.519 1.60E-08 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
2.171 1.49E-17 Up Nucleus transcription 
regulator 
NAIP NLR family apoptosis 
inhibitory protein 
1.988 1.09E-19 Down Cytoplasm other 
Naip1 (includes 
others) 
NLR family, apoptosis 
inhibitory protein 1 
1.921 3.78E-10 Down Cytoplasm other 
NFKBIE NFKB inhibitor epsilon 1.91 3.96E-13 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.87 3.84E-17 Down Cytoplasm enzyme 
CYCS cytochrome c, somatic 1.757 1.11E-25 Up Cytoplasm transporter 
NFKBIB NFKB inhibitor beta 1.613 1.71E-06 Up Nucleus transcription 
regulator 
CASP8 caspase 8 1.605 3.03E-17 Up Nucleus peptidase 
CASP7 caspase 7 1.458 7.34E-08 Up Cytoplasm peptidase 
NFKB1 nuclear factor kappa B 
subunit 1 
1.182 1.24E-07 Up Nucleus transcription 
regulator 
PAK1 p21 (RAC1) activated kinase 
1 
1.052 4.92E-06 Up Cytoplasm kinase 
APAF1 apoptotic peptidase 
activating factor 1 
1.03 2.72E-06 Up Cytoplasm other 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
1.03 6.49E-06 Up Cytoplasm kinase 
       
mouse time point pathway  -log(p-
value) 
Ratio z-score gene fold 
change cut off 
C3H/HeN 
Resolved 
24 hpi vs PBS TNFR2 6.27 0.433 1.508 2 





Expected Location Type(s) 
TNF tumor necrosis factor 3.178 2.51E-14   Extracellular 
Space 
cytokine 
TNFAIP3 TNF alpha induced protein 3 2.909 5.75E-15   Nucleus enzyme 
NFKBID NFKB inhibitor delta 2.519 1.60E-08 Up Nucleus transcription 
regulator 
NFKB2 nuclear factor kappa B 
subunit 2 
2.171 1.49E-17 Up Nucleus transcription 
regulator 
TNFRSF1B TNF receptor superfamily 
member 1B 







NAIP NLR family apoptosis 
inhibitory protein 
1.988 1.09E-19 Down Cytoplasm other 
Naip1 (includes 
others) 
NLR family, apoptosis 
inhibitory protein 1 
1.921 3.78E-10 Down Cytoplasm other 
NFKBIE NFKB inhibitor epsilon 1.91 3.96E-13 Up Nucleus transcription 
regulator 
BIRC3 baculoviral IAP repeat 
containing 3 
1.87 3.84E-17 Down Cytoplasm enzyme 
NFKBIB NFKB inhibitor beta 1.613 1.71E-06 Up Nucleus transcription 
regulator 
TRAF1 TNF receptor associated 
factor 1 
1.362 2.08E-06 Up Cytoplasm other 
NFKB1 nuclear factor kappa B 
subunit 1 
1.182 1.24E-07 Up Nucleus transcription 
regulator 
MAP3K14 mitogen-activated protein 
kinase kinase kinase 14 
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